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This dissertation focuses on the biochemical and genetic characterization of the protein-protein 
interaction in the budding yeast Saccharomyces cerevisiae between the cytosolic translation initiation 
guanine nucleotide exchange factor eIF2B and the endoplasmic reticulum (ER) membrane-embedded very-
long-chain fatty acid (VLCFA) synthesis beta-keto-reductase enzyme YBR159W (IFA38). The dissertation 
is divided between the physical characterization of the interaction and examination of the functional 
consequences the ybr159wΔ deletion has on the yeast cell’s physiology. I first look at how the interaction is 
occurring in yeast. I utilize yeast 2-hybrid analysis to show that eIF2B subunits GCD6 and GCD7 interact 
with YBR159W. My experiments show that eIF2B does not interact with other VLCFA synthesis enzymes 
and that YBR159W does not interact directly with the other canonical components of the eIF2B complex. 
Compared to a wild type strain, a ybr159wΔ null yeast strain has a reduced growth rate and the hallmarks of 
a reduced translation activity including reduced 
35
S-methionine incorporation and low levels of 
polyribosomes. It is unknown if the reduced translation rate is a direct or indirect consequence of the 
ybr159wΔ mutation. The total cellular abundance of eIF2B complex is reduced in a ybr159wΔ null strain 
but the stoichiometry of the eIF2B complex and its enzymatic activity appears equivalent to wild-type. 
Deletion of YBR159W or other VLCFA synthesis enzymes significantly alters sphingolipid production in 
yeast. Deletion of the eIF2B subunit GCN3 does not cause a significant change in sphingolipid production 
in yeast. In the second section, I examine what effect YBR159W has on the localization of the cytoplasmic 
eIF2B complex. In yeast, eIF2B forms one or two large foci known as eIF2B bodies. I discover that 
YBR159W is important for either the formation or maintenance of the eIF2B body. In ybr159wΔ null yeast, 
eIF2B forms many smaller foci throughout the cell. Other VLCFA synthesis enzyme mutants display this 
same phenotype. I also find that a fraction of the eIF2B complex associates with lipid membranes. This 
lipid association is not dependent on the presence of YBR159W and is not mediated by rough ER bound 
ribosomes. Further experiments are required to determine the mechanistic and functional role of YBR159W 
interacting with eIF2B.  
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CHAPTER I 
 
INTRODUCTION 
 
Abstract 
 
Advances in our understanding of protein synthesis have revealed a wide array of factors 
necessary for the regulation of translation in the cell. Mass spectrometry techniques have led to the 
identification of new factors associated with translation. I hypothesize that as yet uncharacterized 
regulatory mechanisms exist for the synthesis of proteins. My laboratory discovered a novel protein-protein 
interaction in yeast between the eukaryotic translation initiation factor eIF2B and the ketoacyl-reductase 
involved in very-long-chain fatty acid synthesis YBR159W. I hypothesize that YBR159W serves as a novel 
regulator of eIF2B and translation initiation. If so, it stands to reason that a ybr159wΔ yeast strain would 
show changes in eIF2B activity and protein synthesis. In the past, translation has often taken a backseat to 
transcription in models of the regulation of gene expression. As new techniques are developed, I expect 
more and more factors will be found that aid in the regulation of gene expression through regulation of 
translation. 
 
Background 
 
An Understanding of the Mechanisms of Protein Translation 
 Translation is the fundamental biological process of turning genomic information on messenger 
RNA (mRNA) into polypeptides, or proteins. Translation is carried out by the ribosome, an organelle 
composed of multiple ribosomal RNAs (rRNA) and proteins (Klinge et al. 2012; Wilson and Doudna Cate 
2012). In eukaryotes, the ribosome is composed of the large 60S ribosomal subunit and the small 40S 
ribosomal subunit, each named for its sedimentation coefficient (Claude 1937; Claude 1938; Claude 1940; 
Palade 1955). The 60S ribosomal subunit contains the 5S, 5.8S, and 28S/25S rRNA molecules and 46 
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ribosomal proteins (Gongadze 2011; Nazar 1984; Noller 1991; Poll et al. 2009). The largest rRNA 
molecule in humans is 28S while it is only 25S in yeast. The 40S ribosomal subunit is made up of the 18S 
rRNA and 33 proteins (Gerbasi et al. 2004; Karbstein 2011). The 40S and 60S ribosomal subunits bind 
together when active to form the 80S ribosome. Aminoacyl transfer RNA (tRNA) is a short segment of 
RNA bound with a specific charged amino acid (Ibba and Soll 2000; Sonenberg 2000). The tRNA contains 
a three nucleotide anti-codon loop that base-pairs with a codon on mRNA in the 80S ribosome. The 
ribosome then catalyzes the formation of a peptide bond between the charged amino acid and the growing 
polypeptide chain. For most mRNAs, the start codon that signals the beginning point for translation is the 
codon sequence AUG (Hinnebusch 2011). The AUG start codon encodes the amino acid methionine and 
base pairs with a special tRNA bound with methionine, the initiator tRNA (meti-tRNA) (Kolitz and Lorsch 
2010). Finally, translation is regulated by a number of proteins called translation factors that interact with 
the ribosome, RNAs, and each other (Sonenberg 2000; Warner 1999). 
Translation is divided into three steps; initiation, elongation, and termination (Sonenberg 2000). 
Translation initiation is the primary mechanism of regulating protein synthesis (Pestova et al. 2001; Preiss 
and M 2003). The scanning model, as proposed by Marilyn Kozak details our current understanding of 
translation initiation in eukaryotes (Kozak 1987; Kozak and Shatkin 1978). The model details how a large 
group of translation initiation factors (eIFs) work in concert to position the ribosome and initiator tRNA on 
the AUG start codon of mRNA (Kozak 1980). The mechanism of translation initiation will be discussed in 
detail in the proceeding section.  
After the initiation phase the elongation phase begins, elongation requires eukaryotic elongation 
factor 1 (eEF1) to catalyze the delivery of charged amino acid-tRNAs to the ribosome. Elongation factor 
eEF2 is a translocase that moves the ribosome along the mRNA one codon at a time (Sasikumar et al. 
2012). In bacteria, the homologues of eEF1 are two factors, EF-Tu and EF-T. The bacterial homologue of 
eEF2 is EF-G (Agirrezabala and Frank 2009). These factors: eEF1/EF-Tu, EF-T and eEF2/EF-G help the 
ribosome elongate the growing polypeptide until a stop codon is reached; at which point the termination 
phase is triggered and release factors interact to promote polypeptide release and ribosome dissociation. 
Fungi are unique among eukaryotes for possessing a third elongation factor, EF-3. EF-3 is necessary for 
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stimulating the binding of eEF1, GTP, and charged amino acid-tRNA with the ribosome (Belfield and Tuite 
1993). 
For termination of translation, the three stop codons UAA, UAG, and UGA are recognized by 
release factors or RFs. In eukaryotes, eRF1 recognizes all three stop codons. eRF1 interacts with the A-site 
of the ribosome where it releases the polypeptide from the ribosome. eRF3 interacts with eRF1 and helps 
facilitate peptide release. Following peptide release, the ribosomal subunits dissociate from the mRNA 
(Jackson et al. 2012). In prokaryotes, RF1 and RF2 are homologues of eRF1 and each recognize different 
stop codons (Scolnick et al. 1968). Depending on the stop codon, one of the RFs will interact with the A-
site and facilitate polypeptide release. Release factor RF3 then removes the bond RF from the A-site. 
Ribosome recycling factors (RRFs) and elongation factor eEF-G then dissociate the ribosomal subunits 
from the mRNA (Petry et al. 2008). Neither the elongation nor the termination phases of translation are 
strongly regulated, it is at the initiation phase where protein synthesis is controlled. 
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Figure 1-1 Eukaryotic translation initiation. Image taken from Preiss and Hertz. Bioessays. 2003, 
25(12): 1201-1211. 
 
5 
 
Translation Initiation is the Fundamental Regulatory Step in Protein Synthesis 
Eukaryotic translation initiation is a complex process requiring a large number of different factors. 
Figure 1-1 diagrams the major steps in translation initiation (Fig. 1-1) (Preiss and M 2003). Initial steps in 
the process include the activation of the mRNA and formation of the 43S preinitiation complex. Activation 
of mRNA involves the eIF4F complex situated at the 5’ end of the mRNA binding with poly(A)-binding 
protein (PABP) situated at the 3’ end of the mRNA to form a closed-loop structure (Sachs and Varani 
2000). The eIF4F complex is composed of the cap-binding protein eIF4E, the scaffold protein eIF4G, and 
the RNA-helicase eIF4A (Gingras et al. 1999; McKendrick et al. 1999). eIF4G interacts with PABP, eIF4E, 
eIF4A, eIF4B, and eventually eIF3 (Keiper et al. 1999). The 43S preinitiation complex is composed of 
eIF1, eIF1A, eIF5, eIF3, and the 40S ribosomal subunit (Asano et al. 2001; Hinnebusch 2006; Merrick W. 
C.). The ternary complex composed of eIF2 bound with GTP and the initiator tRNA also binds to the 43S 
preinitiation complex (Kimball 1999). The activated mRNA and 43S preinitiation complex join together 
via interactions between eIF4G and eIF3 (Lamphear et al. 1995). Additional interactions between eIF5 and 
eIF4G and between eIF4B and eIF3 may also play an important role in mRNA and preinitiation complex 
binding (Asano et al. 2001; Methot et al. 1996; Vries et al. 1997). eIF4A then unwinds the 5’ end of the 
mRNA to facilitate the 40S subunit to scan along the mRNA in search of the AUG start codon (Rogers et 
al. 2002). The translation start site is recognized by the complementary base-pairing of the anti-codon loop 
of the initiator tRNA with the start codon, eIF1 ensures the proper sequence and context of the start codon 
(Hinnebusch 2011). Upon start codon recognition, several events occur. Initially, eIF1 is displaced by the 
codon-anticodon base-pairing and dissociates from the initiation complex (Mitchell and Lorsch 2008). eIF1 
acts as an inhibitor of the GTPase-activating protein (GAP) eIF5. Now uninhibited, eIF5 induces eIF2 to 
hydrolyze the GTP bound to itself, this causes eIF2 to dissociate from the initiation complex (Das and 
Maitra 2001). Next, eIF5B bound with GTP binds to the initiation complex (Dever et al. 2001). eIF5B 
mediates the dissociation of eIF1A and eIF3 from the initiation complex. The 60S ribosome can then join 
with the initiation complex. After GTP hydrolysis, eIF5B also dissociates from the now complete 
translation complex (Dever et al. 2001). The ribosome is now poised and ready to begin elongating the 
polypeptide chain.  
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Translation initiation in prokaryotes is considerably different from eukaryotes. In prokaryotes, the 
positioning of the ribosome for elongation is primarily mediated by an RNA-RNA interaction between the  
16s rRNA of the small subunit and a 5-16 base RNA element localized just upstream of the start codon. 
There appears to be no small subunit scanning along the 5’-UTR to locate the start codon like is postulated 
in the Kozak model for translation initiation. There are only three initiation factors: IF1, IF2, and IF3. IF3 
is responsible for binding to the small, 30S subunit and keeping it separated from the large, 50S subunit and 
localizing to the start codon. IF1, IF2, initiator tRNA, and the mRNA bind to the 30S subunit and IF3 to 
form the 30S initiation complex. IF1 and IF2 along with the prokaryote-only Shine-Delgarno sequence on 
the 5’ Untranslated Region (UTR) of the mRNA facilitate recognition of the AUG start codon. IF3 then 
dissociates from the initiation complex and allows the 50S ribosome to join. IF1 and IF2 then dissociate 
from the ribosome and elongation can begin (Simonetti et al. 2009). 
 
Internal Ribosome Entry Sites: Alternative Methods of Translation Initiation 
 The eukaryotic initiation pathway described above is termed cap-dependent initiation because it 
relies on the 5’ cap structure on the mRNA acting as an anchor point for many of the initiation factors to 
bind. The cap structure is composed of eIF4E bound to modified guanine residues at the 5’ end of the 
mRNA. An alternative method has been discovered that does not require a 5’ mRNA cap. A class of 
mRNA contains what is known as an Internal Ribosome Entry Site (IRES) that initiates independent of the 
5’ end of the mRNA. An IRES is located in the 5’ UTR of the mRNA and was first discovered in viral 
transcripts (Jang et al. 1988; Pelletier and Sonenberg 1988). A circular mRNA construct confirmed that no 
cap structure is needed for translation from an IRES (Chen and Sarnow 1995). While most IRESs are viral 
in nature, IRESs have also been shown to be purposefully translated by eukaryotic cells under certain stress 
conditions when cap-dependent translation is downregulated. The sequence of an IRES is highly variable 
and the mode of ribosome recruitment varies considerably as well. Translation initiation factors are still 
needed for many IRESs but the exact set of factors varies and no single initiation factor is required for all 
IRESs. For those IRESs that require initiation factors; eIF2, eIF3, and eIF4G are the most common 
constituents. Some IRESs do not require any initiation factors at all for translation (Pisarev et al. 2005). A 
special class of factors called IRES Transacting Factors (ITAF) help facilitate translation of some IRESs 
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(Thompson 2012). ITAFs are distinguished from initiation factors because they are not thought to be 
involved in canonical, cap-dependent translation initiation. Following cap-independent initiation, the 
elongation and termination phases occur normally. Though IRES translated genes have proven to play a 
significant role in the cell, the vast majority of proteins are translated by the cap-dependent mechanism. 
The efficiency of translation of an IRES is highly variable. Viral IRESs tend to be very efficiently 
translated, certain ones being more efficiently expressed than from cap-dependent translation. Under 
normal conditions, cellular IRESs tend to be less efficient than cap-dependent translation. During stress, 
cellular IRESs translation rate can often be higher than cap-dependent mechanisms because cap-dependent 
translation is often specifically downregulated during stress (Komar and Hatzoglou 2011). 
 
The Role of eIF2B in Translation Initiation 
The binding of GTP- and initiator tRNA-bound eIF2 to the 43S preinitiation complex is one of the 
key steps in cap-dependent translation initiation. The S. cerevisiae eIF2 is composed of three subunits: 
SUI2 (α), SUI3 (β), and GCD11 (γ). The α subunit is the target of a number of kinases that regulate protein 
translation. The β subunit is thought to be important for initiator tRNA binding and the γ subunit is 
responsible for binding GDP/GTP for the complex (Schmitt et al. 2010). After start codon recognition, the 
GAP eIF5 induces the hydrolysis of the GTP bound to eIF2 to GDP. eIF2 then dissociates from the 
translation complex. To undergo another round of translation initiation, eIF2 must be recharged. eIF2 is 
unable to efficiently displace the GDP it has bound. This displacement is the job of initiation factor eIF2B.  
Initiation factor eIF2B is the guanine-nucleotide exchange factor (GEF) for eIF2 (Preiss and M 
2003). This GTP exchange event is one of the key steps in regulating translation initiation (Kimball 1999; 
Merrick W. C.). Though called GTP exchange, the catalytic activity of eIF2B is primarily to displace GDP 
from eIF2; eIF2B does not necessarily facilitate the rebinding of GTP on eIF2, which is something eIF2 
can do on its own due to the much higher concentration of GTP in the cell versus GDP (Mohammad-
Qureshi et al. 2008; Pilz et al. 1997). eIF2 is the only known target for the GEF exchange function of eIF2B 
(Pavitt 2005). eIF2B is unique among other GEFs in being composed of multiple subunits. There are 5 
subunits of eIF2B in eukaryotes named α-ε. In yeast, the 5 subunits are GCN3 (α), GCD7 (β), GCD1 (γ), 
GCD2 (δ), and GCD6 (ε) (Bushman et al. 1993; Cigan et al. 1993). Table 1-1 illustrates the different 
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nomenclature in humans and yeast for each eIF2B subunit as well as their sequence identity and functions 
(Table 1-1). The eIF2B complex is a large complex (almost 300 kD in yeast) (Pavitt 2005). Unlike many 
other translation complexes, no structure for the entire complex has been determined. The α subunit and the 
catalytic domains of the ε subunits of yeast and human eIF2B have crystal structures determined (Boesen et 
al. 2004; Hiyama et al. 2009; Wei et al. 2010).  
In yeast, the first eIF2B subunit to be characterized was GCD1 (originally called TRA3) in a 
screen of genes affecting amino acid biosynthesis (Wolfner et al. 1975). Other members of the eIF2B 
complex were also determined to affect amino acid biosynthesis in a similar fashion. The gene names of the 
subunits all derive from this connection to the amino acid general control pathway. The four GCD genes 
stand for General Control Derepressible, indicating mutation of them leads to constitutively upregulated 
amino acid biosynthesis. The single GCN gene, GCN3, stands for General Control Non-derepressible and 
indicates that amino acid biosynthesis cannot be induced in a Gcn3
-
 mutant. From here it was eventually 
determined that GCD1 played a role in protein synthesis itself (Hill and Struhl 1988). The various eIF2B 
genes weren’t identified as being part of the GEF for eIF2 until later (Cigan et al. 1993).  
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Table 1-1 Nomenclature, Sequence Similarity, and Function of eIF2B Subunit Genes. Sequence identity is 
between each yeast and human subunit. In the function column; Y = Yeast, M = Mammalian, D = 
Drosophila. Adapted from Pavitt. Biochem Soc Trans. 2005 Dec (Pt 6): 1487-1492. 
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In yeast, all subunits except the α subunit GCN3 are essential (Giaever et al. 2002). In humans, all 
subunits are essential. GCN3 is known to be an important regulator of stress responses (Hannig and 
Hinnebusch 1988). The GCN3 subunit is similar in sequence to the δ and β subunits GCD2 and GCD7 
(Paddon et al. 1989; Pavitt et al. 1997). GCD2 and GCD7 are thought to form a subcomplex with GCN3 
important for the regulatory function of GCN3 (Yang and Hinnebusch 1996). The eIF2B ε subunit GCD6 
performs the enzymatic functions of eIF2B, binding to eIF2γ to exchange GDP with GTP. GCD6 is capable 
of performing GEF exchange on its own, albeit at a slower rate than the holoenzyme. GCD1 increases the 
efficiency of eIF2B GEF exchange. In fact, the subcomplex formed by GCD1 and GCD6 actually has an in 
vitro GEF exchange rate higher than that of the eIF2B holoenzyme (Pavitt et al. 1998).  
The C-terminal domain of the eIF2B catalytic subunit GCD6 contains a minimal enzymatic 
domain capable of binding eIF2 and displacing GDP (Gomez et al. 2002). This region is rich in aromatic 
and acidic residues and is similar in sequence to the C-terminal domain of the GAP eIF5. eIF5 is 
responsible for the hydrolysis of GTP bound to eIF2 during translation initiation. Mutations in the shared 
C-terminal domain of eIF2Bε or eIF5 reduce their affinities for eIF2. This domain has shown to bind to 
eIF2 via the N-terminal domain of the β subunit of eIF2. Mutations in this region of eIF2β reduce the 
affinity of eIF2 for not only eIF2B and eIF5 but also eIF3 (Asano et al. 1999). The N-terminal domain of 
eIF2β forms lysine rich blocks thought important for its interactions with these initiation factors (Asano et 
al. 1999). Residues Thr552 and Ser576 on eIF2Bε were determined to play an important role in guanine 
nucleotide exchange. A mutation in Glu569 is lethal and in vitro assays show eIF2Bε with this mutation is 
unable to perform enzymatic activity (Boesen et al. 2004). The atomic structure of eIF2Bε reveals the 
catalytic domain of the protein forms four stacked pairs of α-helixes similar to HEAT repeat domains. The 
residues Thr552, Ser576, and Glu569 are clustered at the surface of one end of the structure (Boesen et al. 
2004). The surface is extensively charged and thought to be important for binding to eIF2β. The binding to 
eIF2β then puts the eIF2Bε active site in close proximity to eIF2γ for GTP exchange (Pavitt 2005). The 
eIF2B complex itself does not appear to actually bind guanine nucleotide as part of its exchange activity 
(Reid et al. 2012). 
The eIF2B regulatory subunit GCN3 functions via interactions with the phosphorylated form of 
the α subunit of eIF2. eIF2α is phosphorylated at serine 51 by a number of protein kinases during cellular 
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stresses. In yeast, the best characterized eIF2α ser51 kinase is GCN2, which is activated during amino acid 
starvation. Higher eukaryotic eIF2α ser51 is phosphorylated by GCN2 as well as Protein Kinase R (PKR), 
PKR-like Endoplasmic Reticulum Kinase (PERK), and Heme-Regulated Inhibitor of translation (HRI) 
(Pavitt 2005). PKR is associated with the cell antiviral response and is activated by double-stranded RNA 
(Schneider and Mohr 2003). PERK is an ER membrane protein that responds to unfolded protein in the ER 
lumen to activate the unfolded protein response (Shi et al. 1998). HRI senses the availability of heme in 
cells and is activated in its absence. Homologues of HRI, HRI1 and HRI2, have been described to regulate 
eIF2α phosphorylation in Schizosaccharomyces pombe during oxidative stress (Zhan et al. 2004; Zhan et al. 
2002). Phosphorylated eIF2α binds to eIF2Bα, this binding event inactivates the eIF2B complex (Rowlands 
et al. 1988). In yeast, while eIF2Bα/GCN3 is thought to be the primary interactor with phosphorylated 
eIF2α, it appears the interaction takes place on the eIF2B subcomplex composed of GCN3, GCD2, and 
GCD7 at a separate location from the enzyme activity of eIF2B (Vazquez de Aldana et al. 1993; Yang and 
Hinnebusch 1996). Point mutations in GCD2 and GCD7 can rescue the translation inhibiting effects of 
phospho-eIF2α in a similar manner to mutations in GCN3 (Pavitt et al. 1998; Yang and Hinnebusch 1996). 
The effects of the inhibition of eIF2B activity by binding to phosphorylated eIF2α is to downregulate 
translation of most cellular mRNAs and upregulate translation of stress response mRNAs. In yeast, 
upregulation is carried out by translation of the stress response transcription factor GCN4. In mammals, the 
gene Activating Transcription Factor 4 (ATF4) is upregulated in a similar manner to GCN4 in yeast 
(Vattem and Wek 2004). Figure 1-2 illustrates yeast and human interactions with eIF2B (Fig. 1-2) (Pavitt 
2005). 
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Figure 1-2 Interaction and regulation of eIF2B subunits in yeast and 
humans. Image taken from Pavitt. Biochem Soc Trans. 2005 Dec (Pt 6): 
1487-1492. 
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In mammals, direct phosphorylation of eIF2Bε is also utilized to regulate translation initiation. 
Several protein kinases have been shown to carry out the phosphorylation including casein kinases 1 and 2 
(CK1 and CK2), duel-specificity tyrosine phosphorylated and regulated kinase (DYRK), and glycogen 
synthase kinase 3 (GSK3) (Wang et al. 2001; Woods et al. 2001). GSK3 is thought to have the largest role 
in eIF2B regulation and is insulin regulated (Kim and Kimmel 2000). An additional phosphorylation site on 
eIF2Bε has been shown to regulate translation during amino acid starvation in humans. This regulation is 
independent of the classical amino acid starvation pathway via the eIF2α kinase GCN2 (Wang and Proud 
2008). eIF2Bε phosphorylation is downregulated during resistance exercise in humans (Glover et al. 2008). 
In yeast, eIF2B is directly regulated by fusel alcohols. Fusel alcohols are breakdown products of amino 
acid catabolism and are thought to signal nitrogen scarcity (Ashe et al. 2001; Taylor et al. 2010). Fusel 
alcohols bind to eIF2B and inhibit its activity. 
In humans, eIF2B is linked with a number of diseases. One of the first to be characterized was 
Leukoencephalopathy with vanishing white matter (VWM) (Bugiani et al. 2010; van der Knaap et al. 
1997). The cause of the disease is mutations in any of the 5 subunits of eIF2B. Over one hundred mutations 
that cause the disease have been identified in the 5 eIF2B subunits (Richardson et al. 2004). Figure 1-3 
summarizes a number of these mutation sites on eIF2B subunits (Fig. 1-3).  
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Figure 1-3 Sites of Mutations Linked to VWM. Closed down 
arrows represent mutations found in patients with VWM. 
Open down arrows represent mutations found in patients 
with severe, early-onset VWM. Image taken from Pavitt. 
Biochem Soc Trans. 2005 Dec (Pt 6): 1487-1492. 
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The disease is characterized by disruption of two brain cell types, oligodendrocytes and astrocytes (van der 
Knaap et al. 2006). There is a great reduction of myelin in the white matter regions of the brain (Pavitt and 
Proud 2009). The primary symptom of VWM is cerebellar ataxia (loss of motor control); under normal 
conditions the disease progresses slowly and is eventually fatal. During stress events such as infection or 
head trauma the progressive loss of motor function speeds up rapidly. Lymphoblasts and fibroblasts derived 
from affected patients show that the mutations in eIF2B typically reduce its activity from 20% to 70% 
(Horzinski et al. 2010; Li et al. 2004; van Kollenburg et al. 2006). There appears to be some correlation 
between the severity of the disease and the level of eIF2B inactivation, though this is rather inconsistent 
(Liu et al. 2011; van der Lei et al. 2010). Overall protein synthesis levels in affected cells are not reduced, 
leading to the hypothesis that it is not lower protein levels that are causing the disease but inability to 
adequately respond to cellular stresses (van Kollenburg et al. 2006). For example, during heat stress (as can 
occur as a response to infection) the cell’s response is to reduce protein translation, this is partially done 
through the regulation of eIF2B activity (Clemens 2001). The eIF2B mutations in the disease could be 
affecting the cell’s ability to respond to stress. Evidence shows upregulation of the unfolded protein 
response (UPR) in eIF2B mutant cells (Horzinski et al. 2010). The UPR is a cellular pathway that responds 
to unfolded proteins in the endoplasmic reticulum (ER) (Welihinda et al. 1999). Unfolded protein in the ER 
would indicate an inability to slow down protein translation in response to a cellular stress. 
 
Localization of eIF2B in Yeast: the eIF2B Body 
 It has been found that a portion of eIF2B in yeast resides in distinct punctate structures or foci 
termed eIF2B bodies (Fig. 1-4) (Campbell et al. 2005). The eIF2B bodies appear as 1 to 2 bright areas per 
cell under a fluorescent microscope. The bodies can be single points or thin lines about a third the diameter 
of the cell. These foci contain both eIF2B and eIF2. During logarithmic growth, as much as 50% of total 
eIF2B and eIF2 reside in the foci; the rest of eIF2B and eIF2 are diffusely localized to the cytoplasm. Using 
Fluorescence Recovery After Photobleaching (FRAP), it was found that the presence of eIF2B in the 
bodies is relatively stable with little movement between the bodies and the cytoplasm but that eIF2 cycles 
in and out of the bodies fairly rapidly. It was shown that the rate of cycling of eIF2 in the bodies remains 
high during logarithmic growth and decreases during several different stresses that decrease the GEF 
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activity of eIF2B. This has led to the conclusion that eIF2B bodies are sites for eIF2B GEF exchange and 
that eIF2 cycles into the body to exchange its GDP with GTP (Campbell and Ashe 2006; Campbell et al. 
2005). Fusel alcohols, an endpoint metabolite of amino acid catabolism, have been shown to inhibit 
translation initiation via interactions with eIF2B (Ashe et al. 2001). It has been found that treatment of cells 
with fusel alcohol causes eIF2B bodies to become immobile in the cell (Taylor et al. 2010). Under normal 
conditions eIF2B bodies are fairly mobile and can be seen to lightly vibrate and migrate throughout the 
cell; fusel alcohol treatment decreases the frequency of motion of the bodies and their subsequent 
movement throughout the cell is cut in half. It is not known what mechanism causes the body’s loss of 
movement. One possibility is that they become tethered to some cellular structure and lose their freedom of 
motion. The fact that fusel alcohol also decreases the GEF activity of eIF2B lends itself to the theory that 
the free movement of the bodies is important for translation initiation (Taylor et al. 2010). So far, eIF2B 
bodies have not been found in any other organism besides Saccharomyces cerevisiae. 
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Figure 1-4 Live cell fluorescence microscopy of yeast eIF2B 
bodies. All strains are genomically tagged with GFP. The α and γ 
subunits of eIF2 as well as γ and ε subunits of eIF2B are found to 
localize to punctate foci in the cell. These foci have been named 
eIF2B bodies. eIF4E and eIF3b are included as cytoplasmic 
controls. In addition, eIF4E is a component of stress induced P-
bodies. This shows that eIF2B bodies are distinct from P-bodies. 
eIF2B bodies contain subunits of both eIF2 and eIF2B. Images 
were taken during logarithmic growth. Image taken from 
Campbell et al. J Cell Biol. 2005 Sep 12;170(6):925-34. 
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The General Control Pathway: Sensing Amino Acid Availability in Yeast 
In yeast, regulation of eIF2B activity via eIF2α phosphorylation activates the primary stress 
response pathway known as the general control pathway (Hinnebusch 1994). This pathway is activated 
during a number of cellular stresses including amino acid starvation, membrane stress, heat stress, oxidative 
stress, and heat shock. The pathway was first described for amino acid starvation and it is the best 
characterized method of translation control (Hinnebusch and Fink 1983). The pathway begins with 
activation of the protein kinase GCN2 by uncharged tRNAs (de Haro et al. 1996). In the cell, tRNA exists 
predominately in its amino acid charged form and a very small change in the concentration of charged to 
uncharged tRNA can activate GCN2 (Qiu et al. 2001). The only kinase target of GCN2 is the previously 
described serine 51 on eIF2α (de Haro et al. 1996). Phosphorylated eIF2 then binds to GCN3 on eIF2B at a 
site separate from GEF exchange and is thought to inhibit eIF2B GEF activity by sequestration 
(Hinnebusch 1993; Sarre 1989). Cells express an excess of eIF2 in comparison to eIF2B and 
phosphorylation of a small percentage of eIF2 can sequester a much larger percentage of total eIF2B and 
have a significant effect on the number of active eIF2B complexes. The reduction in GEF exchange reduces 
the rate of formation of ternary complex, composed of eIF2 bound with GTP and initiator tRNA. This 
reduction in ternary complex formation has a unique effect on the translation of the stress response 
transcription factor GCN4. The GCN4 gene is unusual in that protein expression is completely controlled at 
the level of translation. GCN4 mRNA is present in cells under all conditions and does not seem to be 
precisely regulated (Mueller and Hinnebusch 1986). Upstream of the GCN4open reading frame (ORF) are 
4 smaller upstream ORFs (uORF), each only encoding a 3-5 amino acid product (Mueller and Hinnebusch 
1986). Though there are 4 of these uORFs the first and last ones are sufficient for full wild-type regulation 
of GCN4 protein translation(Mueller and Hinnebusch 1986). Translation initiation and elongation occur at 
the first uORF in a cap-dependent manner (Hinnebusch et al. 1988). Sequences surrounding the first uORF 
prevent normal dissociation of the ribosome after termination (Grant and Hinnebusch 1994). Instead, a 
special form of cap-independent translation called translation reinitiation allows the 40S subunit to stay 
associated with the mRNA and continue scanning (Powell 2010). The scanning 40S ribosome lacks ternary 
complex and must rebind it to detect an AUG start codon. The 40S ribosome will pause and initiate 
translation at the first AUG start codon it encounters after rebinding ternary complex (Hinnebusch 2005). 
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Under normal growth conditions the ribosome rebinds ternary complex quickly and the first AUG codon 
encountered is the fourth uORF before the actual GCN4 ORF. The fourth uORF does not promote 
translation reinitiation and GCN4 protein is not made (Grant and Hinnebusch 1994). During amino acid 
starvation, the reduction in ternary complex formation delays its rejoining with the scanning 40S ribosome. 
This delay is enough that the 40S ribosome can bypass the fourth uORF and reinitiation translation at the 
GCN4 ORF and allow for GCN4 protein to be synthesized. Expression of GCN4 protein is sensitive enough 
to perturbations in ternary complex formation that it has become an important readout to detect changes in 
activity of a variety of translation initiation factors, including eIF2B (Hinnebusch 2005). 
 
An Overview of Fatty Acid Synthesis 
 Lipids are an essential class of biological molecule in cells. They form the basis of cellular 
membranes and thus enable the compartmentalization that allows cells to maintain homeostasis in a 
changing environment. Lipids serve as important signaling molecules both intra- and inter-cellularly 
(English 1996; Hannun and Bell 1989; Mineo and Shaul 2012; van Meer 1993). Excluding sterols, the 
fundamental building block of a lipid is the fatty acid. A fatty acid is comprised of an acyl chain of 
hydrocarbons with a carboxyl head group. The carboxyl group reacts with other molecules to form the 
more complex lipid species such as phospholipids, triglycerides and sphingolipids. Cells can gain new fatty 
acids from their environment, such as lipid particles in the blood stream, or can synthesize them from 
precursors.  
The fundamentals of lipid synthesis were discovered by Earl Stadtman and Horace Barker in the 
late 1940’s (Barker et al. 1945; Stadtman and Barker 1949; Stadtman and Barker 1949; Stadtman and 
Barker 1949; Stadtman and Barker 1949; Stadtman and Barker 1949; Stadtman and Barker 1950). Lipid 
synthesis in cells begins with an acetyl group conjugated to coenzyme A (CoA) being carboxylated to 
malonyl-CoA by the enzyme acetyl-CoA carboxylase. Malonyl-CoA is activated for further reactions by 
exchanging the CoA group with acyl carrier protein (ACP). This reaction is carried out by malonyl-
CoA:ACP transacylase. Malonyl-ACP is condensed with acetyl-ACP by 3-ketoacyl synthetase. Acetyl-
ACP is generated from acetyl-CoA by acetyl-CoA:ACP transacylase. The 3-keto group on the newly 
elongated acyl chain is reduced to 3-hydroxyacyl-ACP by 3-ketoacyl reductase using NADPH as a 
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cofactor. The hydroxyl group in the 3 position is then dehydrated to produce enoyl-ACP by 3-hydroxyacyl 
dehydratase. The double bond in enoyl-ACP is then reduced to form acyl-ACP by enoyl reductase. The 
acyl-ACP is analogous to acetyl-ACP in the original reaction and can now undergo a new round of 
elongation with another molecule of malonyl-ACP. The elongation, reduction, dehydration, and reduction 
reactions are usually grouped as a 4 step cycle in fatty acid synthesis. Two carbons are added to the chain 
length of a growing fatty acid with each cycle of elongation. Figure 1-6 displays the pathway and 
intermediates in fatty acid synthesis (Fig. 1-6). The enzyme thio esterase releases a fully elongated fatty 
acid from ACP (Wakil et al. 1983). 
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Figure 1-5 Schematic of fatty acid elongation. Shown are the four major cyclic 
steps and intermediates. The two carbons that elongate the acyl chain are 
shown in red. 
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In eukaryotes, the enzymes responsible for fatty acid synthesis reside on a large, multi-enzyme 
complex called fatty acid synthase (FAS) (Maier et al. 2010). In humans, FAS is composed of a single 
polypeptide that forms a homodimer (Semenkovich 1997). In yeast, FAS is composed of two separate 
genes: FAS1 and FAS2. Six copies of each protein are incorporated into a single FAS complex to form a 
heterododecamer (Schweizer et al. 1978). An overview of the composition of the yeast and human FAS 
complex is presented in Table 1-2 in the next section. In both cases, the final FAS complex is roughly half 
a million Daltons in size. Despite the hydrophobic nature of its products, FAS is a soluble, cytoplasmic 
complex. FAS migrates close to the endoplasmic reticulum (ER) after synthesis of a fatty acid and transfers 
its fatty acid product to the membrane bilayer of the ER. Further enzymes in the membrane then 
incorporate the fatty acid into various lipid products. Mammalian FAS and yeast FAS have strikingly 
different structures. Dimeric mammalian FAS is X-shaped and features extensions resembling arms and 
legs extending from a central body, enzyme active sites are facing outward in the cleft formed between 
each arm and leg and the acyl chain passes between each site during the cycle (Maier et al. 2006). 
Dodecameric yeast FAS is barrel-shaped and contains 2 large hydrophobic pockets in its center. The inner 
surface of each pocket contains 3 sets of active sites of the various enzymes required for fatty acid 
synthesis and 3 anchor points for a growing acyl chain connected to ACP (Jenni et al. 2007). It is thought 
that as each step in the synthesis is carried out the acyl product is passed to another active site for another 
reaction while still connected to the same ACP anchor site. Elongation in yeast FAS would be continuous 
and only terminate after the synthesized fatty acid becomes too long to fit into the inner pocket of the 
complex. This mechanism usually limits synthesized fatty acids to 16-18 carbons in length that form the 
majority of yeast fatty acids (Ejsing et al. 2009; Schweizer et al. 1978). Interestingly, the fatty acid synthase 
enzymes in prokaryotes are each discreet proteins rather than the enormous single complex characteristic of 
eukaryotic fatty acid synthase (White et al. 2005). 
 
Very-Long-Chain Fatty Acids and the Elongase Complex 
 In yeast, the typical products of FAS are palmitoleic (C16) and oleic (C18) acid (Ejsing et al. 2009). 
These two fatty acids make up the majority of the fatty acids in the cell. Certain lipid species contain longer 
chain fatty acids and for these a separate elongation complex called the elongase complex is required 
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(Cassagne et al. 1978; Jakobsson et al. 2006; Leonard et al. 2004; Welch and Burlingame 1973). The 
elongase complex uses CoA-bound fatty acids instead of the ACP-bound fatty acids of the FAS complex. 
Table 1-2 summarizes the components of the yeast and human elongase and FAS complexes (Table 1-2). 
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Table 1-2 Genes of FAS and the Elongase Complex in Yeast and Humans. Shown are the genes in each 
complex and what enzymatic functions they possess. Acetyl/malonyl CoA:ACP transaclyase is not needed 
by the elongase complex. HSD17B12 and SC2 are also known as KAR and TER respectively. The gene 
responsible for 3-hydroxyacyl dehydratase activity has not been determined for the human elongase 
complex. 
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In yeast, the elongase complex resides in the ER membrane where it elongates fatty acids received 
from the cytoplasmic FAS complex to fatty acids greater than 20 carbons in length (Han et al. 2002). Fatty 
acids greater than 20 carbons are known as very-long-chain fatty acids (VLCFA). The predominant 
VLCFA in yeast is 26 carbons long and makes up 1-5% of all fatty acids in yeast (Ejsing et al. 2009; 
Rezanka 1989). The elongase complex uses the same 4 steps (elongation, reduction, dehydration, and 
reduction) used by FAS to generate VLCFAs. Unlike eukaryotic FAS, each enzyme is encoded by a 
separate gene in a similar manner to the prokaryotic FAS complex. In addition, the elongase complex is a 
complex in name only, each member seems to operate independent of the others and no single elongase 
supermolecule has been identified. Each enzyme performs its specific reaction then passes off the product 
to another member of the complex by simple diffusion in the lipid bilayer (Leonard et al. 2004). In yeast, 
the elongase complex is composed of 5 proteins (Table 1-2). The first step, elongation, is performed by 
both FEN1 and SUR4 (Oh et al. 1997; Rossler et al. 2003). Each protein contains a fully functional 
elongation enzyme and each protein acts independently. Rather than being completely complementary with 
each other, FEN1 and SUR4 prefer different fatty acid precursors (Denic and Weissman 2007). FEN1 has a 
high affinity for C20 fatty acids and is important for the conversion of C20 to C22 (Oh et al. 1997). SUR4 has 
a broader range of precursor fatty acid sizes but is required for the conversion of C24 fatty acids to the final 
C26 fatty acids (Oh et al. 1997). Deletion of either gene singly has few noticeable effects on cells but 
deletion of both is synthetically lethal (Revardel et al. 1995; Silve et al. 1996). In humans, six separate 
genes (ELOVL 1-6) are responsible for the first elongation step in VLCFA synthesis (Jakobsson et al. 
2006). The first reduction step and second step overall in VLCFA elongation is carried out by 
IFA38/YBR159W (from here on referred to as YBR159W) (Rossler et al. 2003). The homolog of 
YBR159W in humans is HSD17B12 or KAR (See proceeding section on YBR159W and HSD17B12 for 
more detail) (Moon and Horton 2003). The third step in VLCFA synthesis, dehydration, is carried out by 
PHS1 (Denic and Weissman 2007; Schuldiner et al. 2005). Deletion of PHS1 is lethal in yeast (Giaever et 
al. 2002). A human homolog of PHS1 is not known. The second reduction reaction and fourth and final 
step overall in VLCFA synthesis is carried out by TSC13. Deletion of TSC13 is also lethal in yeast (Giaever 
et al. 2002). SC2 or TER is the human homolog of TSC13 (Moon and Horton 2003). 
. 
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The Utilization of Very-Long-Chain Fatty Acids 
Utilization of VLCFAs varies considerably between species. In plants, VLCFAs form an essential 
component of seed coatings (Cassagne et al. 1994). For mammals they are used as signaling molecules as 
well as structural components in membranes (Calder and Yaqoob 2009). In mammals, the VLCFA 
component of sphingolipids has been linked to fertility of spermatozoa (Sandhoff et al. 2005). VLCFA 
length in mammals is extremely variable, being anywhere from 28 to 36 carbons in length (Kihara 2012).  
In yeast, nearly all VLCFAs are incorporated into sphingolipids (Dickson et al. 2006). Yeast 
contain 3 classes of sphingolipid: Inositolphosphoceramide (IPC), mannosylinositolphosphoceramide 
(MIPC), and mannose-(inositol-P)2-ceramide (M(IP)2C) (Dickson et al. 2006). IPC is the most abundant 
sphingolipid (Ejsing et al. 2009). Figure 1-7 shows the structure of an IPC molecule and its components 
(Fig. 1-7). A sphingolipid is a class of lipid that is composed of a head group and a ceramide molecule. The 
head group is one of three types and determines the class of the sphingolipid. Ceramide in turn is composed 
of a sphingosine molecule and a fatty acid. In yeast, there are 2 primary classes of sphingosine, also known 
as a long-chain base: phytoshingosine and dihydrosphingosine (Dickson et al. 2006). In yeast, the fatty acid 
component of ceramide is most commonly a C26 VLCFA (Ejsing et al. 2009; Rezanka 1989). The 
formation of ceramide is catalyzed by the ceramide synthase complex, in yeast composed of LAC1/LAG1 
and LIP1 (Kageyama-Yahara and Riezman 2006). Sphingosine is generated from palmitic acid and the 
amino acid serine by serine palmitoyltransferase, composed of LCB1 and LCB2 in yeast (Gable et al. 2002).  
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Figure 1-6 Structure of a inositol phospho-ceramide. The head group is shaded blue. The sphingoid base is 
shaded green. The VLCFA is shaded yellow. The ceramide portion of the sphingolipid is composed of the 
yellow and green shaded regions. 
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Sphingolipids in yeast are predominately used in a structural role. The extreme length of the 
VLCFA component of sphingolipids reduces physical stress on highly curved membrane formations 
(Schneiter et al. 2004; Schneiter et al. 1996). The VLCFAs themselves have been shown to be important 
for this stress reduction, a yeast mutant unable to generate sphingolipids but able to incorporate VLCFAs 
into phospholipids is able to resist many of the symptoms that indicate membrane stress (Gaigg et al. 2006). 
VLCFA-containing sphingolipids are also important for lipid raft formation (Gaigg et al. 2006). 
Interestingly, it has been found that sphingolipids containing VLCFAs are not essential in yeast but that 
both VLCFAs and sphingolipids individually are essential, indicating that they play multiple necessary and 
independent functions in the cell (Cerantola et al. 2007). In mammals, sphingolipids and ceramides have 
been linked to a number of essential biological functions. In addition to the previously mentioned role in 
the fertility of spermatozoa, sphingolipids are also involved in cell proliferation, inflammation, autophagy, 
and cell differentiation (Bedia et al. 2011; Perrotta et al. 2005; Pettus et al. 2004; Spiegel 1993). Ceramide 
has been shown to be involved in signaling cascades during apoptosis (Kolesnick et al. 1994).  
 
The 3-Ketoacyl Reductase YBR159W and HSD17B12 
Like other members in the elongase complex YBR159W is an integral membrane protein in the 
ER membrane (Han et al. 2002). It uses NADPH as a cofactor in its 3-ketoacyl reductase activity 
(Beaudoin et al. 2002; Han et al. 2002). A ybr159wΔ deletion leads to temperature sensitivity and extreme 
slow growth (Breslow et al. 2008; Han et al. 2002). The ybr159wΔ mutant fails to grow in the presence of 
the FAS inhibitor cerulenin and exogenous fatty acids (Omura 1976; Rossler et al. 2003). It is believed that 
the viability of the deletion mutant is due to the residual activity of the gene AYR1 compensating for some 
of the 3-ketoacyl reductase activity of YBR159W (Han et al. 2002). AYR1 is a 1-acyl dihydroxyacetone 
phosphate reductase involved in phosphatidic acid biosynthesis (Athenstaedt and Daum 2000). The AYR1 
and YBR159W amino acid sequences share 42% similarity and 23% identity. A ybr159wΔ, ayr1Δ double 
mutant is synthetic lethal (Han et al. 2002). KetoAcyl Reductase (KAR), also known as 17β hydroxysteroid 
dehydrogenase type 12 (HSD17B12) is the human homolog of YBR159W (Moon and Horton 2003). The 
amino acid sequences of YBR159W and HSD17B12 share 53% similarity and 32% identity. In addition to 
its role in VLCFA synthesis, HSD17B12 is responsible for the last step in the synthesis of estradiol from 
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estrogen (Luu-The et al. 2006). The role of HSD17B12 in estrogen production has led to it being an 
important marker for a variety of sex-hormone-related-organ cancers (Audet-Walsh et al. 2012; Plourde et 
al. 2009; Song et al. 2006; Szajnik et al. 2012). 
 
Rationale for Dissertation Research 
 
 Recently, using tandem affinity purification and mass spectrometry, a novel protein-protein 
interaction has been discovered in yeast between all five subunits of eukaryotic initiation factor eIF2B and 
the 3-ketoacyl reductase YBR159W (Link et al. in preparation). This interaction shows a previously 
unknown link between protein translation and the VLCFA synthesis pathway. I hypothesize that the 
interaction with YBR159W represents a new mode of regulation of eIF2B in translation initiation. 
Furthermore, I hypothesize that this interaction represents only one of many forms of regulation of protein 
synthesis that have so far gone uncharacterized. The implications of this novel form of protein synthesis 
regulation provide a clear rational for this dissertation. The interaction would serve to regulate eIF2B 
activity and overall protein translation in the event of cellular stress or disruptions in VLCFA synthesis. 
This theory would be best tested by first characterizing the interaction itself, determining any additional 
factors that aide or mediate the interaction. A genetic and biochemical approach would then be used to 
determine what effects the interaction is having on cellular processes.  
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CHAPTER II 
 
THE YEAST eIF2B TRANSLATION INITIATION COMPLEX INTERACTS 
WITH THE FATTY ACID SYNTHESIS ENZYME YBR159W 
The following chapter was adapted from Browne et al. Mol. Cell Biol. 2013 Mar 33(5):1041-56 (Browne et 
al. 2012).  
 
Abstract 
 
Using affinity purifications coupled with mass spectrometry and yeast two-hybrid assays, we show 
the Saccharomyces cerevisiae translation initiation factor complex eIF2B and the very-long-chain-fatty 
acid (VLCFA) synthesis keto-reductase enzyme YBR159W physically interact. The data show the 
interaction is specifically between YBR159W and eIF2B and not between other members of the translation 
initiation or VLCFA pathways. Yeast two-hybrid analysis suggests subunits GCD6 and GCD7 as important 
for the interaction. YBR159Wp is an integral membrane protein localized to the endoplasmic reticulum. A 
ybr159wΔ null strain has a slow growth phenotype and reduced translation rate but a normal GCN4 
response to amino acid starvation. Affinity purifications show the eIF2B complex to be intact in a 
ybr159wΔ null strain though overall expression of the complex is reduced. No VLCFA synthesis defects 
are seen in a gcn3Δ null mutant. 
 
Introduction 
 
In eukaryotic translation initiation, the initiation factor eIF2 bound with GTP is required to interact 
with the initiator Meti-tRNA to form the ternary complex. Following start codon recognition, eIF2-GTP is 
hydrolyzed to GDP and eIF2-GDP dissociates from the translation initiation complex (Preiss and M 2003; 
Sonenberg 2000). eIF2-GDP must exchange GDP with GTP before it can initiate another round of 
translation (Fig. 2-1A). The initiation factor eIF2B is an essential guanine nucleotide exchange factor 
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(GEF) responsible for exchanging GDP for GTP on eIF2 (Pavitt 2005). It is the only known target of 
eIF2B. This exchange reaction is one of the rate limiting steps in translation initiation and is the target of 
numerous signaling pathways in yeast as well as higher eukaryotes (Harding et al. 1999; Olsen et al. 1998; 
Rowlands et al. 1988; Schneider and Mohr 2003; Sood et al. 2000; Wek et al. 1990; Zhan et al. 2004). 
While the majority of eukaryotic GEFs are monomeric, eIF2B is unique among GEFs in that it is composed 
of multiple subunits. In S. cerevisiae, eIF2B is composed of the five subunits GCD1, GCD2, GCN3, GCD6, 
and GCD7. The GCD6 subunit is necessary and sufficient for catalytic activity, although at a significantly 
reduced rate compared to the eIF2B complex (Fabian et al. 1997; Gomez and Pavitt 2000; Pavitt et al. 
1998). Co-expression of GCD6 with GCD1 yields similar GEF activity as the eIF2B holoenzyme (Pavitt et 
al. 1998). Of the other 3 subunits, previous studies show GCD2 and GCD7 to be involved in the stability of 
the complex and regulatory activity (Bushman et al. 1993; Pavitt et al. 1998; Pavitt et al. 1997). GCN3 is 
required for the role of eIF2B in the GCN4 stress response pathway (Hinnebusch 1985; Kubica et al. 2006). 
With the exception of GCN3, all of the yeast eIF2B genes are essential (Pavitt 2005). Figure 2-1 
summarizes the GEF exchange function of eIF2B as well as fatty acid elongation (Fig. 2-1). 
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Figure 2-1 eIF2B and the VLCFA Functional Pathways. (A) Diagram showing the GEF pathway of eIF2B that is 
required for recharging eIF2 with GTP to begin a new round of translation initiation. (B) Diagram showing the 
cyclical VLCFA elongase pathway and the genes required for the catalytic steps. Also depicted is the pathway 
utilizing VLCFAs by the ceramide synthase complex LAC1/LAG1 and LIP1 to make ceramide. Ceramide is later 
modified to generate various sphingolipids. 
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In eukaryotes two distinct complexes are responsible for the synthesis of fatty acids (Rossler et al. 
2003; Stoops and Wakil 1978). The cytoplasmic fatty acid synthase complex (FAS) elongates fatty acids 
from 2 to 20 carbons in length in a four reaction cycle. A second fatty acid synthesis complex, the elongase 
complex, is responsible for the elongation of fatty acids from 20-26 carbons (Fig. 2-1B) (Kihara 2012; 
Rezanka 1989). The longer chain fatty acids are known as very-long-chain fatty acids (VLCFA). In S. 
cerevisiae, VLCFAs make up 1-5% of total fatty acids (Dittrich et al. 1998; Welch and Burlingame 1973) 
and the predominant VLCFA is 26 carbons long (Dickson et al. 2006). VLCFAs are crucial for membrane 
stability and the formation of lipid rafts in yeast (Gaigg et al. 2006). Although the FAS and elongase 
complexes share very similar catalytic steps, different sets of enzymes catalyze the elongation reactions in 
the two pathways (Fig. 2-1B). The enzymes of the elongase complex localize to the endoplasmic reticulum 
membrane (ER) (Abraham et al. 1961; Klein 1957). The complex receives fatty acids from the cytoplasmic 
FAS complex and elongates them to VLCFAs (Tehlivets et al. 2007). Previous studies show YBR159W, 
also known as IFA38, is a keto-acyl reductase required for the second step in the yeast elongase pathway 
(Fig. 2-1B) (Beaudoin et al. 2002; Han et al. 2002). A ybr159w null yeast strain has a slow growth 
phenotype and altered VLCFA lipid composition (Han et al. 2002). Though both FEN1 and SUR4 catalyze 
the first enzymatic step in the elongase pathway, they are not redundant and are responsible for different 
chain-length precursor fatty acids. FEN1 prefers 20 carbon long precursors while SUR4 has a broader range 
of chain-length specificity but is required to convert 24 carbon long VLCFAs to their final 26 carbon long 
form (Oh et al. 1997). The elongase enzymes TSC13 and PHS1 are both essential (Schuldiner et al. 2005; 
Tuller et al. 1999). In yeast, newly synthesized VLCFAs are predominately incorporated first into ceramide 
and eventually into sphingolipids (Dickson et al. 2006). LIP1 is a component of the ceramide synthase 
complex required for the formation of ceramide from a VLCFA and a sphingoid base (Vallee and Riezman 
2005). Each sphingolipid contains one 24 to 26 carbon long VLCFA in addition to the long-chain base and 
head group (Dickson 2008). In yeast, VLCFA-containing sphingolipids are used predominately in a 
structural role. Sphingolipids are important for relieving mechanical stress on highly curved membrane 
formations (Schneiter et al. 2004; Schneiter et al. 1996). Sphingolipids are also important components of 
lipid rafts. Lipid rafts are subcompartmentalizations of certain lipids in lipid bilayers that are important in a 
large number of cellular processes including lipid trafficking, endocytosis, and signaling (Simons and 
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Ikonen 1997). In yeast, one example of an important function of lipid rafts is in the localization of the 
plasma membrane ATPase PMA1. Disruption of VLCA or sphingolipid synthesis can cause defects in 
PMA1 localization and function (Gaigg et al. 2006). 
Using protein affinity purifications coupled with mass spectrometry and yeast two-hybrid analysis, 
we provide direct evidence for an interaction between the S. cerevisiae eIF2B complex and YBR159W. 
The interaction does not include eIF2 or other members of the VLCFA synthesis pathway. The eIF2B 
subunits GCD6 and GCD7 are identified as being possible mediators of the interaction. The ybr159w null 
cells have a lower rate of translation but a normal GCN4 response to amino acid starvation. Overall, this 
work shows a novel interaction between the essential yeast translation initiation factor and the fatty acid 
synthesis enzyme YBR159W.  
 
Materials and Methods 
 
Strains and Media 
All yeast media, growth, and genetic manipulation was done using standard techniques (David C. Amberg 
2005). To create the ybr159wΔ strain AL401, the kanamycin resistance cassette from plasmid pFa6a-
kanmx6 was first amplified with primers CGTACGCTGCAGGTCGAC and 
ATCGATGAATTCGAGCTCG. Using the PCR double fusion approach (David C. Amberg 2005), the 
primers CGGATTTGGAAGTCCTTTATAG, 
GTCGACCTGCAGCGTACGCATTTCTTAAGCTGCACCG, 
CGAGCTCGAATTCATCGATTAGAATTATCGTTCTCG, and GGACTTGGTCCTTCCACC were used 
to expand the YBR159W genomic regions flanking the kanmx6 cassette. The YBR159W disruption 
cassette was transformed into strain BY4741 and transformants were selected on YPD + 300 mM G418 
plates and screened using Western blotting and -YBR159W polyclonal antibodies. Candidate BY4741 
ybr159wΔ strains were crossed with the HIS+ strain H1511 and sporulated to create the ybr159wΔ null 
strain AL401. An isogenic wild type HIS+ control strain AL400 was selected from the same sporulation. 
The lip1Δ strain RH5994 was kindly provided by Howard Riezman (Vallee and Riezman 2005). The 
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gcn3Δ, fen1Δ, and sur4Δ deletion strains were obtained from the MATa yeast deletion collection (Winzeler 
et al. 1999). The fen1Δ and sur4Δ deletion strains from the MATa yeast deletion collection were mated 
with the HIS+ strain H1511 and sporulated to create the fen1Δ and sur4Δ strains, AL413 and AL414 
respectively. The tandem affinity purification (TAP)-tagged strains were obtained from the yeast TAP-
tagged library (Ghaemmaghami et al. 2003). The GFP tagged strains were obtained from a GFP-tagged 
yeast library (Huh et al. 2003). To make the ybr159wΔ, GCD7-GFP strain, we mated the ybr159wΔ strain 
AL401 with the GCD7-GFP strain AL429 from the GFP-tagged yeast library and sporulated the diploids to 
obtain the ybr159wΔ, GCD7-GFP strain AL403. The yeast two-hybrid activation-domain strains derived 
from parent strain PJ69-4A, the binding-domain parent strain PJ69-4alpha, and yeast two-hybrid plasmids 
were obtained from the Yeast Resource Center (University of Washington) (James et al. 1996). Using the 
protocol previously described by the Yeast Resource Center (30), the AL408 (YBR159W-BD), AL409 
(GCD1-BD), AL410 (GCD2-BD), AL411 (GCD6-BD), and AL412 (GCD7-BD) strains expressing yeast 
two-hybrid binding-domain tagged alleles were generated from parent strain PJ69-4alpha. Briefly, initial 
forward and reverse primers were used to PCR the target gene from yeast genomic DNA. The PCR product 
and the common forward and reverse two-hybrid primers were used for a second round of PCR to extend 
the flanking sequences. The 2
nd
 PCR product and the PvuII and NcoI linearized pOBD2 plasmid were co-
transformed into yeast strain PJ69-4alpha and plated on SC-trp to select for recombinants fusing the target 
gene to the GAL4 binding domain. Table 2-1 lists the strains used in this study (Table 2-1). 
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Table 2-1 Strains used in this study. Abbreviations: Del. lib. = Deletion library, YRC = Yeast Resource 
Center. 
Strain Genotype Source or Reference 
AL400 MATa, ura3, leu2, HIS+ This study 
AL401 MATa, ura3, leu2, HIS+, YBR159W::KanR This study 
AL402 MATa, ura3, leu2, HIS+, YBR159W::KanR, [YCp-YBR159W] This study 
AL403 MATa, ura3, leu2, HIS+, YBR159W::KanR, GCD7-GFP This study 
AL404 MATa, ura3, leu2, HIS+, YBR159W::KanR, GCD7-GFP, [YCp-YBR159W] This study 
AL405 MATa, leu2, ura3, met15, GCD1-GFP, [YCp-YBR159W-dsRed] This study 
AL406 MATa, leu2, ura3, met15, GCD6-GFP, [YCp-YBR159W-dsRed] This study 
AL407 MATa, leu2, ura3, met15, GCD7-GFP, [YCp-YBR159W-dsRed] This study 
AL408 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, [YBR159W-GAL4DBD] This study 
AL409 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD1-GAL4DBD] This study 
AL410 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD2-GAL4DBD] This study 
AL411 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD6-GAL4DBD] This study 
AL412 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD7-GAL4DBD] This study 
AL413 MATa, leu2, ura3, met15, HIS+, FEN1::KanR This study 
AL414 MATa, leu2, ura3, met15, HIS+, SUR4::KanR This study 
AL415 MATa, ura3, leu2, HIS+ [p180] This study 
AL416 MATa, ura3, leu2, HIS+, YBR159W::KanR, [p180] This study 
AL417 MATa, ura3, leu2, HIS+, YBR159W::KanR, [YCp-YBR159W], [p180] This study 
AL418 MATa, leu2, ura3, met15, FEN1::KanR, [p180] This study 
AL419 MATa, leu2, ura3, met15, SUR4::KanR, [p180] This study 
AL420 MATalpha, ura3-52, gcd1-101, [p180] This study 
AL421 MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+, gcn2Δ, [p180] This study 
AL422 MATa, leu2, ura3, met15, FEN1-GFP, [YCp-YBR159W-dsRed] This study 
AL423 MATa, leu2, ura3, met15, DPM1-GFP, [YCp-YBR159W-dsRed] This study 
AL424 MATa, leu2, ura3, met15, his3, GCN3::KanR 
Del. lib. (Winzeler et al. 
1999) 
AL425 MATa, leu2, ura3, met15, YBR159W-GFP GFP lib. (Huh et al. 2003) 
AL426 MATa, leu2, ura3, met15, FEN1-GFP GFP lib. (Huh et al. 2003) 
AL427 MATa, leu2, ura3, met15, GCD1-GFP GFP lib. (Huh et al. 2003) 
AL428 MATa, leu2, ura3, met15, GCD6-GFP GFP lib. (Huh et al. 2003) 
AL429 MATa, leu2, ura3, met15, GCD7-GFP GFP lib. (Huh et al. 2003) 
AL430 MATa, leu2, ura3, met15, GCD2-TAP 
TAP lib. (Ghaemmaghami 
et al. 2003) 
AL431 MATa, leu2, ura3, met15, GCD7-TAP 
TAP lib. (Ghaemmaghami 
et al. 2003) 
AL432 MATa, leu2, ura3, met15, YBR159W-TAP 
TAP lib. (Ghaemmaghami 
et al. 2003) 
AL433 MATa, leu2, ura3, met15, FEN1-TAP 
TAP lib. (Ghaemmaghami 
et al. 2003) 
AL434 MATa, leu2, ura3, met15, SUR4-TAP 
TAP lib. (Ghaemmaghami 
et al. 2003) 
AL435 MATa, leu2, ura3, met15, TSC13-TAP TAP lib. (Ghaemmaghami 
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et al. 2003) 
AL436 MATa, leu2, ura3, met15, his3, FEN1::KanR 
Del. lib. (Winzeler et al. 
1999) 
AL436 MATa, leu2, ura3, met15, DPM1-GFP GFP lib. (Huh et al. 2003) 
AL437 MATa, leu2, ura3, met15, his3, SUR4::KanR 
Del. lib. (Winzeler et al. 
1999) 
F98 MATalpha, ura3-52, gcd1-101 A. Hinnebusch 
H1511 MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+ A. Hinnebusch 
H2557 MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+, gcn2Δ A. Hinnebusch 
pAD-
(GCD7) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD7-AD] YRC (James et al. 1996) 
PJ69-4a 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ YRC (James et al. 1996) 
PJ69-4alpha 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ YRC (James et al. 1996) 
pOAD-
(GCD1) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD1-AD] YRC (James et al. 1996) 
pOAD-
(GCD2) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD2-AD] YRC (James et al. 1996) 
pOAD-
(GCD6) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD6-AD] YRC (James et al. 1996) 
pOAD-
(GCN3) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCN3-AD] YRC (James et al. 1996) 
pOAD-
(SUI2) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [SUI2-AD] YRC (James et al. 1996) 
pOAD 
(TDH1) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [TDH1-AD] YRC (James et al. 1996) 
pOAD-
(YBR159W) 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [YBR159W-AD] YRC (James et al. 1996) 
RH5994 MATalpha, leu2, ura3, trp1, bar1, LIP1::HIS3 H. Riezman 
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Plasmids 
The plasmid pOBD2 used in generating yeast 2-hybrd binding-domain strains has been previously 
described (Hudson et al. 1997). To create a plasmid expressing endogenous level of YBR159W, we used 
PCR to amplify the YBR159W gene along with 600 bp of the genomic region upstream of the start codon 
of the gene and the stop codon of YBR159W using the primers 
CACCATGGTTTTTGTGACTTTACCTATAAATAGTACACAAC and 
CTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGGC. The PCR product was cloned into the 
pENTR entry vector using Directional TOPO Cloning (Invitrogen) to create pENTR-YBR159W 5’ UTR-
YBR159W. The YBR159W cassette was transferred to the pAG415GAL-ccdB yeast destination vector 
using LR Clonase recombination (Invitrogen) (Alberti et al. 2007) . To eliminate possible promoter 
interference, the endogenous GAL promoter of the vector was deleted using the restriction enzymes SacI 
and SpeI and replaced with the primer insert GGGAGCTCCATACTGATTAGTACACTAGTGG and 
CCACTAGTGTACTAATCAGTATGGAGCTCCC to create the YBR159W expression plasmid YCp-
YBR159W. To create a plasmid expressing RFP-tagged YBR159W, the YBR159W ORF without the stop 
codon was amplified by PCR and cloned into the pENTR vector creating pENTR-YBR159W. The 
YBR159W ORF insert was transferred by recombinational cloning into the pAG415GPD-ccdB-dsRed 
vector (Addgene) to create the final expression plasmid YCp-YBR159W-dsRed. Tables 2-2 and 2-3 list 
plasmids and primers used in this study. 
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Table 2-2 Plasmids used in this study. YRC = Yeast Resource Center 
Name backbone Notes Source 
pOBD2 pOBD2 ampR, TRP1, CEN4 ORI, GAL4-DBD 
YRC (James et 
al. 1996) 
YCp-YBR159W pAG415GAL-ccdB 
ampR, LEU2, CEN ORI, YBR159W 5' UTR-
YBR159W This study 
YCp-YBR159W-dsRed pAG415GPD-ccdB-dsRed ampR, LEU2, CEN ORI, PGPD-YBR159W-dsRed This study 
p180 YCp50 ampR, URA3, CEN ORI, GCN4 5' UTR-LacZ A. Hinnebusch 
pFa6a-kanmx6 pFa6a-kanmx6 ampR, KanR2 Addgene 
pENTR pENTR KanR Invitrogen 
pENTR-YBR159W 5' 
UTR-YBR159W 
pENTR KanR, YBR159W 5' UTR-YBR159W this study 
pENTR-YBR159W pENTR KanR, YBR159W this study 
pAG415GAL-ccdB pAG415GAL-ccdB ampR, LEU2, CEN ORI ccdB Addgene 
pAG415GPD-ccdB-
dsRed pAG415GPD-ccdB-dsRed ampR, LEU2, CEN ORI ccdB-dsRed Addgene 
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Table 2-3 Primers used in this study. Key: Dir = primer direction, F = forward, R = reverse. 
Primers Dir Primer Sequence (5’-3’) 
YBR159W deletion primer set 
 F CGTACGCTGCAGGTCGAC 
 R ATCGATGAATTCGAGCTCG 
5' homology extension primer set 
 F CGGATTTGGAAGTCCTTTATAG 
 R GTCGACCTGCAGCGTACGCATTTCTTAAGCTGCACCG 
3' homology extension primer set 
 F CGAGCTCGAATTCATCGATTAGAATTATCGTTCTCG 
 R GGACTTGGTCCTTCCACC 
two-hybrid common primer set 
 F 
CTATCTATTCGATGATGAAGATACCCCACCAAACCCAAAAAAAGAGATCGAATTCCAGCTGA
CCACCATG 
 R 
GTACCGTTAAGGGCCCCTAGGCAGCTGGACGTCTCTAGATACTTAGCATCTATGACTTTTTGG
GGCGTTC 
two-hybrid YBR159W primer set 
 F AATTCCAGCTGACCACCATGACTTTTATGCAACAGCTTCAAGAGGCTGG 
 R GATCCCCGGGAATTGCCATGCTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGG 
two-hybrid GCD1 primer set 
 F AATTCCAGCTGACCACCATGTCAATTCAGGCTTTTGTCTTTTGCGGTAAAGG 
 R GATCCCCGGGAATTGCCATGTTAACGCTCAAATAATCCGTCATCTTCGTACTCGTAC 
two-hybrid GCD2 primer set 
 F AATTCCAGCTGACCACCATGAGCGAATCGGAAGCCAAATCTAGGTCG 
 R GATCCCCGGGAATTGCCATGTTATGCGGAACCTTTGTACTCTCTTAAAATAACAGGGAC 
two-hybrid GCD6 primer set 
 F AATTCCAGCTGACCACCATGGCTGGAAAAAAGGGACAAAAGAAAAGTGGACTAG 
 R GATCCCCGGGAATTGCCATGTTATTCCTCTTCTGAGGAAGATTCTTCGTCAGCATTC 
two-hybrid GCD7 primer set 
 F AATTCCAGCTGACCACCATGTCCTCTCAAGCATTCACTTCAGTACATCCG 
 R GATCCCCGGGAATTGCCATGTCACGCCTTATTTTTATCCAAATGCACATCAATTTGC 
600 bp upstream YBR159W primer set 
 F CACCATGGTTTTTGTGACTTTACCTATAAATAGTACACAAC 
 R CTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGGC 
pAG415GAL-ccdB promoter remover insert 1 
  GGGAGCTCCATACTGATTAGTACACTAGTGG 
pAG415GAL-ccdB promoter remover insert 2 
  CCACTAGTGTACTAATCAGTATGGAGCTCCC 
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Antibodies 
The -YBR159W polyclonal antibodies were generated by inoculation of a rabbit with the synthetic 
peptide CETVKAENKKSGTRG (Covance). The peptide was covalently bound to cyanogen bromide beads 
(Sigma-Aldrich) to affinity purify -YBR159W from rabbit whole blood. The polyclonal antibody to yeast 
GCD6 was kindly provided by Dr. Alan Hinnebusch. The antibody to recognize yeast TDH1, TDH2, and 
TDH3 was obtained from Millipore.  
 
Mass Spectrometry-Proteomics 
For yeast TAP experiments, TAP-tagged protein complexes were purified as previously described (Powell 
et al. 2004; Sanders et al. 2002). For each TAP strain, a 2 L culture was grown to an optical density at 660 
nm (OD660) 1-2 in YPD. The purified TAP complexes were reduced with 1/10 volume of 50 mM DTT at 65 
°C for 5 min, and cysteines were alkylated with 1/10 volume of 100 mM iodoacetamide at 30 °C for 30 
min. The proteins were digested overnight at 37 °C with modified sequencing grade trypsin at 25:1 
subtrate:enzyme ratio (Promega, Madison, WI). Proteins were identified using Multidimensional Protein 
Identification Technology (MudPIT) and a LTQ linear ion trap mass spectrometer (ThermoFisher) (Link et 
al. 1999; Link et al. 2005). A fritless, microcapillary (100 μm-inner diameter) column was packed 
sequentially with 12 cm of 5 μm C18reverse-phase packing material (Synergi 4 μ Hydro RP80a, 
Phenomenex) and 3 cm of 5 μm strong cation exchange packing material (Partisphere SCX, Whatman). 
The entire trypsin-digested samples were loaded onto the biphasic column equilibrated in 0.1% formic acid, 
2% acetonitrile, which was then placed in-line with an LTQ linear ion trap mass spectrometer. An 
automated six-cycle multidimensional chromatographic separation was performed using buffer A (0.1% 
formic acid, 5% acetonitrile), buffer B (0.1% formic acid, 80% acetonitrile) and buffer C (0.1% formic 
acid, 5% acetonitrile, 500 mM ammonium acetate) at a flow rate of 300 nL/min. Cycles 1−6 consisted of 3 
min of buffer A, 2 min of 0−100% buffer C, 5 min of buffer A, followed by a 60-min linear gradient to 
60% buffer B. In cycles 1−6, the percent of buffer C was increased incrementally from 0, 15, 30, 50, 70, 
and 100% in each cycle. During the linear gradient, the eluting peptides were analyzed by one full MS scan 
(300−2000 m/z), followed by five MS/MS scans on the five most abundant ions detected in the full MS 
scan while operating under dynamic exclusion.  
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GFP Affinity Purification 
Two liters of the GCD7-GFP ybr159wΔ strain AL403, GCD7-GFP strain AL429, and untagged ybr159wΔ 
strain AL401 were grown to OD660 1-2 in YPD. Yeast cells were harvested by centrifuging at 1500 xg for 5 
min, and resuspended in 10 mL ice-cold NP-40 lysis buffer (6 mM Na2HPO4, 4 mM NaH2PO4, 1% NP-40, 
150 mM NaCl, 2 mM EDTA, 50 mM NaF, 4 µg/mL leupeptin, 0.1 mM Na3VO4). Cells were lysed for 10 
min with glass beads in NP-40 lysis buffer. The lysates were centrifuged at 500 xg for 5 min. The cleared 
supernatant was brought up to 25 mL with ice-cold lysis buffer. Five hundred µL bed volume of protein 
A/G agarose beads (Thermo Scientific) and 50 µg of anti-GFP antibody (ThermoFisher) were added 
simultaneously and allowed to incubate for 1 h at RT. The beads were centrifuged at 300 xg for 5 min, 
transferred to a Poly Prep Chromatography Column (Bio Rad) and washed at 4
o
C with 50 column volumes 
of wash buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% NP-40). Protein digestion was carried out directly 
on the agarose beads. The beads were suspended in 1 mL of digestion buffer (10 mM Tris pH 8.0, 150 mM 
NaCl, 0.5 mM EDTA, 1 mM DTT) and transferred to a 1.5 mL microcentrifuge tube. The resuspended 
beads were trypsin digested as described for yeast TAP complexes. After digestion the beads were 
centrifuged at 13,000 xg for 1 min and the supernatant was transferred to a fresh microcentrifuge tube. 
MudPIT was performed identical as described for the TAP purifications. Mass spectrometry data was 
analyzed as previously described using Cn scoring filters of 1.5 (+1), 3.5 (+2) and 3.5 (+3) (McAfee et al. 
2006).  
 
Fatty Acid Profiling 
The protocol for extracting lipids from yeast cells was adapted from Ejsing et al. 2008 (Ejsing et al. 2009). 
Each yeast strain was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. Fifty mg of wet weight yeast cells 
was incubated in 200 μL PBS with 100µg/mL lyticase (Sigma) for 1 h at 37°C. Next, 990 μL of 
chloroform/methanol (17:1 V/V) was added and incubated for 2 h at 37°C. The lower organic layer was 
collected and vacuum evaporated. Next, 990 μL of chloroform/methanol (2:1 V/V) was added to the upper 
aqueous layer and incubated for 2 h at 37°C. The lower layer was collected and pooled with the evaporated 
fraction taken from the first extraction and vacuum evaporated. The sample was solubilized with 100μL 
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chloroform/methanol (1:2 V/V) and mixed 1:1 with 0.4 mM methylamine in methanol. Samples were 
directly injected into an ESI-LTQ OrbitrapXL at 2 μL/min and precursor ions were scanned using the 
Orbitrap analyzer at a resolution of 30,000 in negative ion mode. Using published inositolphosphoceramide 
(IPC) precursor m/z values, precursor ion peaks were identified using a mass tolerance of 10 ppm (Ejsing et 
al. 2006; Sud et al. 2007). The following nomenclature was used for sphingolipid species: <lipid class> 
<carbons in fatty acid (FA) moiety> : <double bonds in FA moiety> ; <hydroxyl groups in FA moiety>. 
Using inositolphosphoceramide (IPC) structure data at the LIPID MAPS Lipidomics Gateway (Sud et al. 
2007), the following theoretical precursor [M-H]
-
 ion m/z values were used to identify the IPC ions in the 
high resolution scan: IPC 46:0;4 (980.717), IPC 44:0;4 (952.686), IPC 42:0;4 (924.655), IPC 40:0;4 
(896.623), IPC 38:0;4 (868.592). To validate the identity of these IPC ions, the IPC precursor ions were 
fragmented by CID in the linear ion trap. The observed m/z values of the MS/MS fragment ions for each 
IPC precursor was compared to predicted [ceramide phosphate – H2O]
-
 and [ceramide phosphate]
-
 m/z 
values at a mass tolerance of 0.1 Da. The following theoretical m/z [ceramide phosphate – H2O]
-
 and 
[ceramide phosphate]
-
 fragment ions were used to validate the IPC lipids: IPC 38:0;4 (688.53, 706.54), IPC 
40:0;4 (716.56, 734.57), IPC 42:0;4 (744.59, 762.60), and IPC 46:0;4 (800.65, 818.66). In addition, to 
validate the identification of IPC 44:0;4, the fragmentation spectrum of precursor m/z 952.68 at a mass 
tolerance of 0.1 Da was compared to the previously published fragment ions [ceramide phosphate – H2O]
-
, 
m/z 772.62 and [ceramide phosphate]
-
, m/z 790.63 values (Ejsing et al. 2006). To compare the observed 
abundance for each IPC species between strains, the precursor ion signal intensity for each identified IPC 
species was normalized to the signal intensity of the m/z 835.53 base peak corresponding to the 
phosphatidyl inositol (PI) species PI 16:1-18:0 and PI 16:0-18:1. The following nomenclature was used for 
PI species: <lipid class> <carbons in 1
st
 FA moiety> : <double bonds in 1
st
 FA moiety> - <carbons in 2
nd
 
FA moiety> : <double bonds in 2
nd
 FA moiety>. 
 
Growth Rate Analysis 
Yeast strains were grown overnight at 30 
o
C in YPD. Relative cell number was measured at OD660 using a 
Beckman DU 530 Spectrophotometer. Cells were diluted in 50 mL of fresh YPD to ~0.05 OD660 units/mL. 
Individual strains were grown at 30 
o
C and an OD660 measurement was taken every 2 h. The formula for 
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used for converting OD660 readings to cell numbers was y = 1.1564x
3
 - 0.6815x
2
 + 1.3996x with y = cell 
number/mL and x = OD660 value (David C. Amberg 2005). Cell doubling time was determined by plotting 
the growth curve for each strain and measuring the maximum rate of cell growth during logarithmic 
growth. 
 
Yeast Two-Hybrid 
Mating type A strains containing AD tagged alleles and mating type  strains containing BD tagged alleles 
have been previously described (Fields and Song 1989). The A and  strains were allowed to mate in liquid 
YPD at 30
o
C overnight. Relative cell number was determined by measuring OD660 and 4 μL of a 1x10
7
 
cells/mL solution was plated onto SC -leu, -trp, -his, 1.5 mM 3-AT agar plates. Plates were scanned after 
48 h.  
 
GCN4-LacZ Induction 
The yeast reporter plasmid p180 containing the GCN4 5′ untranslated region (UTR) coupled to a -
lacZ reporter has been previously described (Hinnebusch 1985). Yeast strains transformed with p180 were 
grown overnight at 30 
o
C in SC-ura. Cultures were diluted 1:10 and allowed to continue growing for 2 h in 
SC -ura, -his. Cells were spun down and split into two tubes containing 10 mL of SC -ura, -his media. A 1 
M 3-AT solution was added to the starvation tube to a final concentration of 10 mM. The cells continued to 
grow for 4 h at 30 
o
C. -galactosidase assays were performed as previously described (Rose and Botstein 
1983). Cells were centrifuged at 1500 xg for 5 min and lysed with glass beads in 1 mL of ice-cold breaking 
buffer (100mM Tris pH 8.0, 1mM DTT, 20% glycerol). Twenty microliters of whole cell extract was added 
to 900 μL of Z buffer (16.1 g/L Na2HPO4-7H2O, 5.5 g/L NaH2PO4-H2O, 0.75 g/L KCl, 0.246 g/L MgSO4-
7H2O, 2.7 mL/L βME, pH 7.0) and incubated at 28 
o
C for 5 min. The reaction was initiated by adding 200 
μL of 4 mg/mL ONPG in Z buffer and incubated at 28 oC. After the reaction turned a pale yellow color, 0.5 
mL of 1 M Na2CO3 was added. LacZ expression was determined by measuring the absorbance at 420 nm 
using a Beckman DU 530 Spectrophotometer. Protein concentration of the extracts was determined using 
the BioRad Dc protein assay. LacZ specific activity was determined using the equation: (OD420 x 
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1.7)/(0.0045 x protein conc. (mg/mL) x extract volume(mL) x time (min)) (David C. Amberg 2005). 
Values were normalized to wild type. 
 
35
S-Met Incorporation 
Overnight cultures of yeast grown in YPD were diluted 1:10 in 10 mL of SC-Met and grown for 3 h at 30 
o
C. The OD660 of the culture was measured to determine cell numbers. For labeling, 
35
S-methionine (MP 
Biomedicals) was added to 5 mL of the cell culture to a final concentration of 10 μCi/mL. Samples were 
incubated with shaking for 30 min at 30 
o
C. Labeling was stopped by the addition of 1/10 volume 100% 
TCA and heating to 100 
o
C for 30 min. TCA precipitates were collected on GFC filters (Whatman) then 
washed sequentially with 5 mL each of 10% TCA and 95% ethanol. Filters were then placed in 5 mL 
EcoLume scintillation fluid (MP Biomedicals) and 
35
S-Met incorporation was measured using a Beckman 
LS 6500 scintillation counter. Values were reported as (Counts per minute) / (OD660 unit). 
 
Microscopy 
Epifluorescence microscopy was performed using live yeast cells grown in SC media to an OD660 1.0-1.5 at 
30 
o
C. Cells were mounted on slides and visualized using a Zeiss Axiophot brightfield microscope with a 
63x / 1.40 Plan-Apochromat oil DIC lense. Images were analyzed with MetaMorph imaging software 
(Molecular Devices). Live yeast cells imaged using confocal microscopy were grown in SC media to an 
OD660 1.0-1.5 at 30 
o
C., Cells were visualized with a Zeiss LSM 510 META inverted confocal microscope 
using a 63x / 1.40 Plan Apochromat oil immersion lens.  
 
Polysome Profiling 
Polysome analysis was performed as previously described (Gerbasi et al. 2004). Yeast strains were grown 
in YPD to an OD660 of ~1. Cells were lysed with glass beads in ice-cold breaking buffer (10 mM Tris pH 
7.0, 100 mM NaCl, 30 mM MgCl2, 50 μg/mL cycloheximide, 200 μg/mL heparin). The crude lysate was 
cleared by centrifugation at 500 xg for 3 min and 20 OD660 units of cells was loaded on top of a 7 to 47% 
continuous sucrose gradient (wt/vol) cast in 50 mM Tris pH 7.0, 50 mM NH4Cl, 12 mM MgCl2, 50 μg/mL 
cycloheximide in a 14 x 89 mm ultracentrifuge tube (Beckman). Gradients were centrifuged in a Beckman 
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SW-41 rotor at 14,000 rpm for 18 h at 4 
o
C. Absorbance profile at 254 nm was collected from the gradients 
as previously described (16). One mL fractions were used for Western blotting. Monosome and polysome 
peak areas were determined using ImageJ software (Schneider et al. 2012). A moving baseline for each 
profile was established by connecting the minima between each peak and the area under each peak above 
this line was calculated. The polysome peak areas were summed and compared to the monosome peak area.  
 
Results 
 
In a tandem affinity purification proteomics screen of S. cerevisiae translation initiation factors 
followed by liquid-chromatography mass spectrometry analysis, we discovered that all five subunits of 
eIF2B co-purified with the VLCFA enzyme YBR159W (Link et al, in preparation; and Fig. 2-2A). 
Subsequent LC-MS/MS analysis of TAP-YBR159W affinity purification showed YBR159W co-purified 
with all five subunits of the eIF2B complex and several members of the VLCFA synthesis pathway. In this 
study, additional TAP experiments examined whether other members of the VLCFA synthesis pathway 
also interact with eIF2B subunits. With the exception of YBR159W, our data showed that other members 
of the VLCFA synthesis pathway did not interact with eIF2B (Fig. 2-2A). To rule out the possibility that 
the YBR159W-eIF2B interaction was due to an artifact of the TAP-tagged strains, we performed a GFP 
affinity purification using the GCD7-GFP strain AL429. LC-MS/MS analysis identified YBR159W co-
purifying with all five subunits of eIF2B (Fig. 2-4E). Next, we utilized yeast two-hybrid to identify 
interactions between eIF2B subunits and YBR159W. The activation-domain tagged strains 
pOAD(YBR159W), pOAD(GCD1), pOAD(GCD2), pOAD(GCN3), pOAD(GCD6), pOAD(GCD7), 
pOAD(SUI2), and pOAD(TDH1) were mated with binding-domain tagged strains AL408 (YBR159W), 
AL409 (GCD1), AL410 (GCD2), AL411 (GCD6) and AL412 (GCD7). The positive interactions between 
different subunits of the eIF2B complex validated the ability of the experiment to detect previously 
described interactions (Fig. 2-2B). The two-hybrid analysis showed that YBR159W positively interacted 
with both the GCD6 and GCD7 subunits of eIF2B (Fig. 2-2B). 
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Figure 2-2 YBR159W’s interaction with eIF2B is unique among VLCFA genes. (A)  Mass 
spectrometry analysis of the affinity-purified TAP-GCD2, TAP-YBR159W, and other TAP-tagged 
VLCFA protein complexes. Listed are unique peptide identifications with the percent coverage of 
identified peptides in the protein in parentheses. A “-“ indicates no peptides were identified for the 
gene. (B)  Yeast two-hybrid (Y2H) analysis of interactions between YBR159W and eIF2B subunits 
GCD6 and GCD7. Shown is both the assay plate used for scoring the Y2H interactions and a table of 
the interactions tested at each spot. Shading on the table corresponds to a positive interaction on the 
plate.
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The GFP-tagged YBR159W strain AL425 showed the YBR159W protein localizes to the ER 
membrane using epifluorescence microscopy (Fig. 2-3A). DPM1 encodes the enzyme dolichol phosphate 
mannose synthase which adds a mannose moiety to dolichyl phosphate on the cytosolic side of the 
endoplasmic reticulum (Orlean 1990; Orlean et al. 1988). Dpm1p is an ER membrane protein unrelated to 
VLCFA synthesis or utilization (Orlean et al. 1988). Confocal microscopy using the FEN1-GFP, 
YBR159W-RFP strain AL422 and the DPM1-GFP, YBR159W-RFP strain AL423 confirmed that RFP-
tagged YBR159W expressed from a low-copy plasmid co-localizes with the VLCFA protein Fen1p and ER 
protein Dpm1p (Fig. 2-3B).  
We constructed a ybr159wΔ yeast strain AL401 to examine the null phenotype. The mutant strain 
had a slow growth phenotype (Fig. 2-3C) and was temperature sensitive at 37
o
 C (data not shown). To 
show the slow growth phenotype was due to the deletion of ybr159wΔ and not a second site mutation in the 
strain, the ybr159wΔ null yeast strain was complemented in strain AL402 expressing YBR159W from the 
low-copy plasmid YCp-YBR159W (Fig. 2-3C). Our results agreed with previous studies using an unrelated 
ybr159wΔ null strain (Beaudoin et al. 2002).  
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Figure 2-3 Cellular analysis of YBR159W. (A)  Live cell 
epifluorescence imaging of endogenously tagged YBR159W-
GFP indicates YBR159W localizes mainly to the ER 
membrane. (B)  Live cell confocal microscopy showing the 
co-localization of YBR159W with the VLCFA pathway 
enzyme Fen1p and ER membrane protein Dpm1p. 
YBR159W is expressed on a low-copy plasmid and tagged 
with dsRed. FEN1 and DPM1 are endogenously expressed 
and tagged with GFP. (C)  Deletion of YBR159W results in a 
very slow growth rate.  
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To determine if YBR159W has a role in translation, we examined if the ybr159wΔ strain AL401 
causes a defect in protein synthesis. We used 
35
S-methionine incorporation to quantify the global 
translation rate. The 
35
S-methionine incorporation experiments showed that the ybr159wΔ strain has a 
reduced translation rate (Fig. 2-4A). The ceramide synthase mutant lip1Δ strain RH5994 also showed a 
reduction in the rate of translation. The lip1Δ strain had a similar slow growth rate as the ybr159wΔ strain. 
However, the VLCFA mutant strains AL413 (fen1Δ) and AL414 (sur4Δ) showed no reduction in 
translation or growth rates (Fig. 2-4A).  
Next, we performed polyribosome profiling to examine the distribution of 40S, 60S, 80S, and 
polyribosomes in the ybr159wΔ strain AL401. Compared to the WT strain, we observed the polysome 
profiles for the ybr159wΔ strain showed an increase in the 80S monosome peak and a decrease in polysome 
peaks (Fig. 2-4B). As expected, the complemented ybr159wΔ strain AL402 showed a similar polysome 
profile to WT. To normalize and quantify the observed differences in the peak areas, the ratio of the 80S 
monosome to polysome peak areas was calculated. The monosome:polysome ratio significantly increased 
for the ybr159wΔ strain compared to the WT and complemented strains (Fig 2-4D). Polysome profiles of 
the lip1Δ strain RH5994 showed similar defects to the ybr159wΔ strain (Fig. 2-4B and 2-4D). Polysome 
profiling of the fen1Δ strain AL413 and sur4Δ strain AL414 showed no noticeable differences from wild 
type strain AL400 (Fig. 2-4B and 2-4D). These polysome distributions were consistent with the reduced 
global translation rates seen previously in the 
35
S-methionine labeling experiments. 
We next examined the effect of ybr159wΔ deletion on eIF2B activity. We used a GCN4-lacZ 
expression assay to examine GCN4 expression during the starvation response (Hinnebusch 1994). Strains 
AL400 (HIS+ control strain), AL401 (ybr159wΔ), AL402 (ybr159wΔ +YCp-YBR159W), AL413 (fen1Δ), 
AL414 (sur4Δ), RH5994 (lip1Δ), H2557 (gcn2) and F98 (gcd1) were transformed with the GCN4-lacZ 
reporter plasmid p180. Our results showed that the ybr159wΔ, fen1Δ, sur4Δ, and lip1Δ null strains did not 
affect the induction of GCN4 during amino acid starvation (Fig. 2-4C). This suggested that the role of 
eIF2B in the regulation of GCN4 response is not affected by the ybr159wΔ null or other VLCFA pathway 
mutation.  
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Figure 2-4 Translation assays on the ybr159wΔ strain. (A)  Translation efficiency as measured by 35S-
methionine incorporation. Values are counts per minute per OD660 unit of cells. Results shown are 
from at least three replicates. (B)  Polysome profiling of ybr159wΔ and other VLCFA null strains. At 
least three replicates were performed for each strain. Though the example ybr159wΔ plot does not 
show a 40S ribosome peak, all other replicates of the strain showed a 40S peak similar to WT. (C)  
Assay for GCN4 pathway competence by GCN4-LacZ induction. Results are LacZ expression per mg 
of protein per min normalized to the WT starvation condition. Starvation conditions were induced by 
10 mM 3-AT in synthetic complete minus histidine media for 4 h. The gcd1-100 strain has a 
constitutively derepressed GCN4 pathway and constant Gcn4p protein translation while the gcn2Δ 
strain is incapable of derepression of GCN4 and cannot produce significant amounts of Gcn4p protein. 
(D) Ratio of monosome:polysome peak areas for the polysome profiles. P values were generated using 
a Student’s t-test from at least 3 individual replicates. (E) GFP pull-down of eIF2B complexes in a 
ybr159wΔ background. Following pull-down LC-MS/MS was performed to identify the proteins. An 
untagged ybr159wΔ strain and GCD7-GFP tagged strain were used as controls. Displayed are unique 
peptide hits and percentage coverage as described in Figure 2-2A. (F) Western blot analysis of WT, 
ybr159wΔ, and GCD7-GFP strains. Yeast strains in Fig. 2-4D and WT strain AL400 were used. 
Equivalent amounts of whole cell extracts were loaded on the SDS-PAGE gel. The Western signals 
for GCD6 and TDH1-3 were determined by densitometry. The ratio of the α-GCD6/α-TDH1-3 signal 
is shown for each strain. The -TDH1-3 antibody does not distinguish between the three GAPDH 
gene duplications in yeast.  
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We next tested if the ybr159wΔ mutation affected the composition of the eIF2B complex. Using 
the ybr159wΔ, GCD7-GFP tagged strain AL403, the untagged ybr159wΔ strain AL401, and the GCD7-
GFP strain AL429, we performed GFP affinity purifications and LC-MS/MS mass spectrometry analysis of 
the affinity purified complexes. All five subunits of eIF2B were identified in the ybr159wΔ, GCD7-GFP 
strain and the GCD7-GFP strain (Fig. 2-4E). No subunits of eIF2B were identified in the untagged 
ybr159wΔ control strain AL401. These results suggested that the composition of eIF2B is not dependent 
upon presence of YBR159W.  
While the composition of eIF2B appeared to be independent of YBR159W, the consistently lower 
number of identified peptides for each eIF2B subunit from the mass spectrometry data for the GCD7-GFP, 
ybr159wΔ null strain compared to the GCD7-GFP strain suggested that the cellular abundance of eIF2B 
was lower in the ybr159wΔ null background (Fig. 2-4E). To determine if the cellular abundance of eIF2B is 
lower in a ybr159wΔ null strain, Western analysis was performed on the yeast strains used in the GCD7-
GFP affinity purification of eIF2B complexes. Lack of signal for YBR159W in the ybr159wΔ strains 
confirmed the expected null genotype (Fig. 2-4F). In concordance with the mass spectrometry results, the 
GCD7-GFP, ybr159wΔ strain had a lower abundance of eIF2B compared to GCD7-GFP strain (Fig. 2-4E). 
To validate this observation in untagged strains, Western analysis was also performed using the WT strain 
AL400 and the untagged ybr159wΔ null strain AL401. The ybr159wΔ null strain again showed lower 
abundance of eIF2B compared to the WT strain (Fig. 2-4F)  
We next tested whether eIF2B played a role in VLCFA synthesis. Previous studies had shown a 
ybr159wΔ null strain had an altered VLCFA lipid composition (Han et al. 2002). Since four of the five 
subunits of eIF2B are essential, we used a gcn3Δ strain AL424 to test for VLCFA defects. WT strain 
AL400, ybr159wΔ strain AL401, ybr159wΔ rescue strain AL402, sur4Δ strain AL414, and lip1Δ strain 
RH5994 were used as positive and negative controls. To profile the VLCFAs, lipids were extracted from 
yeast cells and directly infused into an ESI-LTQ-OrbitrapXL mass spectrometer while scanning at high 
resolution in negative ion mode. Several inositolphosphoceramides (IPC), a class of VLCFA-containing 
sphingolipid, were identified using previously published m/z values at 10 ppm mass accuracy (Ejsing et al. 
2009; Sud et al. 2007). We validated the identification of the IPC species using either previously observed 
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fragmentation spectrum or expected m/z values for the [ceramide phosphate – H2O]
-
 and [ceramide 
phosphate]
-
 fragment ions of the IPCs (Fig. 2-5) (Ejsing et al. 2006).  
 
54 
 
  
Figure 2-5 Validation and Identification of IPCs. (A) Mass spectrometry precursor and MS/MS 
fragmentation spectrum for IPC 44:0;4 from WT yeast. The observed precursor ion m/z 952.681 
represents the expected ion IPC 44:0;4 (952.686). The observed m/z 835.529 corresponds to the 
phosphotidyl inositols PI 16:0-18:1 and PI 16:1-18:0 used to normalize the relative abundance of each 
IPC species. In the lower MS/MS spectra of the 952.681 precursor ion, the first and second most abundant 
peaks correspond to the expected IPC 44:0;4 fragment ions [Ceramide Phosphate – H2O]
-
, m/z 772.62 and 
[Ceramide Phosphate]
-
, m/z 790.63. (B) Theoretical fragmentation database for IPCs 38:0;4, 40:0;4, 
42:0;4, and 46:0;4. Shown are the theoretical m/z values for fragment ions [ceramide phosphate – H2O]
-
 
and [ceramide phosphate]
-
 for IPCs 38:0;4, 40:0;4, 42:0;4, and 46:0;4. (C) MS/MS fragmentation spectra 
for IPCs 38:0;4, 40:0;4, 42:0;4, and 46:0;4. The observed precursor m/z values “Pre” of 868.586, 896.617, 
924.648, and 980.712 correspond to the expected m/z values of IPC 38:0;4 (868.592), IPC 40:0;4 
(896.623), IPC 42:0;4 (924.655), and IPC 46:0;4 (980.717) respectively. In the MS/MS spectra, the peaks 
corresponding to the expected theoretical IPC fragment ions [Ceramide Phosphate – H2O]
-
 and [Ceramide 
Phosphate]
-
 are mark with a “*”. In each case, the peak corresponding to the expected [Ceramide 
Phosphate – H2O]
-
 fragment ion was the most intense ion in the MS/MS spectrum. 
 
55 
 
The IPC 44:0;4 and IPC 46:0;4 sphingolipids contain full-length VLCFAs and are the most abundant yeast 
sphingolipid species (Dickson et al. 2006). Compared to WT, the gcn3Δ, ybr159wΔ, and other VLCFA and 
ceramide synthase mutant strains all showed a reduction in the IPC 44:0;4 and IPC 46:0;4 sphingolipids 
containing full-length VLCFAs (Fig. 2-6A). The IPC sphingolipid species IPC 38:0;4, IPC 40:0;4, and IPC 
42:0;4 contain shorter-chain fatty acids and are typically only detected in VLCFA biosynthesis mutant 
strains (Dickson et al. 2006). As previously observed, the sur4Δ strain had elevated shorter-chain fatty acid-
containing IPC species 38:0;4, 40:0;4, and 42:0;4 (36). We observed IPC 38:0;4 and IPC 42:0;4 were also 
elevated in the ybr159wΔ strain. The gcn3Δ strain showed no significant changes in the levels of the 
shorter-chain fatty acid sphingolipids IPC 38:0;4, 40:0;4, and 42:0;4 (Fig. 2-6B). The lip1Δ strain contained 
barely perceptible levels of any IPC, supporting its requirement for ceramide synthesis (Vallee and 
Riezman 2005).  
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Figure 2-6 Fatty Acid profiling of WT and mutant yeast strains. (A)  Longer-chain fatty acid-containing 
sphingolipid species. IPC species with 44 and 46 carbon-containing acyl chains are shown. The VLCFA 
and ceramide synthase mutants sur4Δ and lip1Δ are included as controls. (B) Shorter-chain fatty acid-
containing sphingolipid species. Three IPC species with 38, 40, and 42 carbon-containing acyl chains are 
shown. For both A and B, data represents percentage of signal of each lipid species normalized to the 
signal of the PI 16:0-18:1 and PI 16:1-18:0 ion. 
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Discussion 
 
Previous large-scale yeast interactions studies failed to show eIF2B interacting with the VLCFA 
pathway (Gavin et al. 2002; Krogan et al. 2006; Miller et al. 2005). We show using TAP-tagged and GFP-
tagged affinity purifications as well as yeast-two-hybrid that the VLCFA keto-reductase YBR159W 
interacts with the translation initiation factor complex eIF2B. Because our unpublished proteomic screen of 
translation factor interactions identified YBR159W interacting with eIF2B, we named the S. cerevisiae 
locus Initiation Factor Associated protein of 38 kD or IFA38 (Link et al., unpublished). Affinity 
purification and LC-MS/MS experiments show that YBR159W co-purifies with all five subunits of eIF2B 
and not with controls. No other member of the VLCFA pathway co-purifies in the eIF2B affinity 
purifications. Interestingly, the TAP-tagged members of the VLCFA pathway do not seem to strongly 
interact with each other. Our Y2H data suggest the eIF2B subunits GCD6 and GCD7 physically interact 
with YBR159W. 
Several models for the eIF2B-YBR159W interaction can be hypothesized. Figure 2-7 presents 
several models for the interaction at the ER membrane (Fig. 2-7). One argument is for a direct interaction 
between eIF2B and YBR159W (Fig. 2-7A). The simplest model, this could be tested by pull-down of 
eIF2B subunits by YBR159W in an unrelated organism. Additionally, if eIF2B associates indirectly with 
lipid membranes via YBR159W, a deletion of ybr159w should abolish this membrane association. 
Another possibility is that eIF2B subunits can be lipid modified and so directly localize to the ER 
membrane for interaction with YBR159W (Fig. 2-7B). This would mean eIF2B would still be membrane 
bound in the absence of YBR159W. Yeast cells possess several mechanisms for lipid modification 
including myristoylation and palmitoylation (Boutin 1997; Dietrich and Ungermann 2004). As 
myristoylation requires an N-terminal glycine, this form of lipid modification is unlikely for any of the 
eIF2B subunits. Targets of palmitoylation are much less specific; no clear consensus sequence for the 
modification exists. Palmitoylation is also reversible, with proteins being directed on or off the membrane 
depending on cellular events (Bijlmakers and Marsh 2003). Use of the palmitoylation prediction software 
tool CSS-Palm shows some evidence for a number of possibly modified sites on eIF2B subunits GCD1, 
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GCD2 and GCD6 (Table 2-4) (Zhou et al. 2006). Two subunits of eIF2 are also predicted to contain 
possible palmitoylation sites. The unreliability of software prediction tools means experiments looking 
specifically for eIF2B palmitoylation in vivo are required. 
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Figure 2-7 Models for the interaction between eIF2B and 
YBR159W. (A,B)  Direct interaction models between ER bound 
YBR159W (A) and the ER membrane (B). (C,D) Indirect interaction 
models between YBR159W (C) and the ER membrane (D). In both 
C and D an as yet unknown factor(s) mediates the interaction seen 
between eIF2B and YBR159W. 
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Table 2-4 Putative palmitoylation sites on eIF2B and eIF2 subunits as predicted by CSS-Palm. Position is 
for the predicted modified cysteine residue. For details on CSS-Palm and CSS scoring see (Zhou et al. 
2006). 
Gene Peptide Position CSS Score 
GCD1    
 SIQAFVFCGKGSNLA 9 3.31 
 LNSFIYFCSFELCQL 280 2.64 
GCD2    
 KAAKKDLCEKIGQFA 368 2.69 
 RNIPVLVCCESLKFS 506 3.41 
 NIPVLVCCESLKFSQ 507 5.15 
GCD6    
 QSCKIGKCTAIGSGT 342 3.77 
SUI3    
 YILEYVTCKTCKSIN 236 3.54 
 EYVTCKTCKSINTEL 239 3.15 
 NRLFFMVCKSCGSTR 259 3.87 
 FFMVCKSCGSTRSVS 262 4.62 
GCD11    
 LIAGNESCPQPQTSE 224 4.08 
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An additional explanation for the eIF2B-YBR159W interaction is that it is indirect, with an as yet 
unidentified factor or set of factors mediating the interaction. This factor could be either soluble and bind 
both the eIF2B complex and YBR159W (Fig. 2-7C) or membrane bound (Fig. 2-7D). Figure 2-7D depicts 
this unknown factor as integral to the ER membrane. The model does not rule out the possibility that the 
unknown factor is peripherally association with the ER membrane. Statistical analysis of the LC-MS/MS 
data did not identify any particular factors, either cytoplasmic or membrane bound, that also showed a 
significant interaction with both eIF2B subunits and YBR159W. This does not mean such a factor does not 
exist; only that TAP purifications and mass spectrometry analysis did not identify it. It is possible the 
amino acid sequence of the factor does not allow for easily identifiable trypsin digested peptides or the 
factor(s) is not soluble during the TAP enrichment. Though use of alternative proteases may solve this 
problem, it is still possible it would be missed. A final theory for the interaction could be a combination of 
the previous models. eIF2B could have multiple redundant interaction sites with YBR159W, some direct 
and some indirect. More intense biochemical analysis of the interaction between eIF2B and YBR159W is 
needed to determine the exact sites on the proteins important for the interaction and to identify any 
additional factors that mediate it. 
Theorizing about the function of the interaction between the VLCFA synthesis pathway and the 
eIF2B translation initiation pathway raises a number of possibilities. Is one pathway regulating the other or 
vice versa? It can be hypothesized that the cell might need to regulate VLCFA synthesis if translation is 
disrupted. Alternatively, it might be advantageous to reduce translational activity if VLCFAs are being 
down regulated. Finally, the YBR159W-eIF2B complex could be involved in a novel function. A link 
between a translation initiation factor and lipid membranes is not totally unique. Experiments in human 
cells have shown an interaction between the translation initiation factor eIF4E and the Golgi apparatus 
(Willett et al. 2011). 
To test the hypothesis that YBR159W and VLCFA synthesis play a role in translation, we used 
35
S-methionine incorporation and polysome profiling to assay translation activity in mutant strains. Both 
experiments show a reduction in the translation rate for the ybr159wΔ strain. However, a similar phenotype 
is seen for the slow growing lip1Δ strain. The VLFCA mutant fen1Δ and sur4Δ strains have wild type 
growth rates and do not share a translation defect with the slower growing members of the pathway. It is 
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not known if the cause of the translation defect seen in the ybr159wΔ strain is directly related to its 
interaction with eIF2B or is an indirect consequence of slow growth or a VLCFA defect.  
When Gcn4p expression is examined using the GCN4-LacZ assay, the ybr159wΔ strain has WT 
levels of GCN4 induction. The GCN4-LacZ assay was normalized to protein concentration so the slow 
growth rate of ybr159wΔ should not affect the results. The data indicates that the ybr159wΔ strain does not 
have a defect in the GCN4 pathway. We cannot rule out the possibility that the slow growth of ybr159wΔ 
may be masking a subtle defect in the GEF activity of eIF2B unrelated to the GCN4 pathway. Our affinity 
purification experiments of eIF2B in a ybr159wΔ deletion background showed that the eIF2B complex is 
intact. A Western blot of ybr159wΔ strains showed that the overall abundance of eIF2B was lower in the 
deletion background compared to WT. It is not clear if the lower level of eIF2B is caused by the slow 
growth phenotype of the ybr159wΔ null background or some other factor. 
An unusual and poorly understood property of the eIF2B catalytic ε subunit (GCD6 in yeast, 
eIF2B5 in humans) is its inhibition by high concentrations of nicotinamide adenine dinucleotide phosphate 
(NADP
+
) and the subsequent rescue from inhibition by equal concentrations of the reduced form of NADP
+
 
(NADPH) (Dholakia et al. 1986; Oldfield and Proud 1992; Wang et al. 2012). A predicted dinucleotide 
binding site exists on eIF2Bε but in vivo binding of NADP+/NADPH has not been shown. The fact that 
equimolar concentrations of NADPH counteract the inhibiting effect of NADP
+
 has led researchers to 
assume the effect is not significant in vivo. NADPH is often several fold more abundant in the cell than 
NADP
+
. NADP
+
 also typically exists in the cell at much lower concentrations than those needed to see 
eIF2B inhibition (Veech et al. 1969). YBR159W specifically binds NADPH as a cofactor in its enzyme 
function (Beaudoin et al. 2002). This presents a possible model for the function of the interaction. By being 
in close proximity to NADP
+
/NADPH bound YBR159W via the interaction eIF2B might experience an 
increased local concentration of the dinucleotide. Following its reduction reaction, if NADP
+
 does not 
immediately dissociate from YBR159W, eIF2B could be inhibited by the YBR159W-bound NADP
+
. 
YBR159W in a NADP
+
-bound state for an extended period of time could represent either a disruption of 
VLCFA synthesis or an unfavorable redox state in the cell. Either possibility could be reasons to limit 
protein synthesis via regulation of eIF2B. Figure 2-8 illustrates several models for eIF2B inhibition by 
binding of NADP
+
 to GCD6 (Fig. 2-8). One model depicts an oxidizing environment and a corresponding 
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increase in YBR159W bound with NADP
+
 (Fig. 2-8B). This model could be tested by examination of the 
translation response of ybr159wΔ null cells to oxidative stress. The model would predict a lessened 
response to the stress. A second model depicts how a disruption in VLCFA synthesis could lead to an 
increase in enzymatically inactive YBR159W bound with NADP
+
 and thus inhibition of eIF2B activity 
(Fig. 2-8C). This model could be tested by examination of translation initiation rates in cells with a deletion 
of either fen1Δ or sur4Δ and a conditional allele for the other second gene. This would deplete the 
precursors for YBR159W catalytic activity and leave it in an inactive state.  
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Figure 2-8 Functional models of the interaction between eIF2B and YBR159W. (A) Normal cellular 
conditions allow for synthesis of both VLCFAs and proteins via interactions between NADPH bound 
YBR159W and eIF2B. (B) During oxidation stress, NADP
+
 bound to YBR159W could inhibit eIF2B 
GEF exchange via eIF2B subunit GCD6. It is not known if an oxidizing environment also inhibits 
YBR159W. (C) Disruptions in VLCFA synthesis could inhibit eIF2B activity. Downregulation of 
YBR159W activity could increase the occupancy of NADP
+
 over NADPH and thus inactivate GCD6. 
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To test the hypothesis that eIF2B plays a role in VLCFA synthesis, several limitations arose that 
made answering the question problematic. Of the 5 yeast eIF2B subunits, only GCN3 is nonessential. The 
gcn3Δ strain did not show a defect in VLCFA production or utilization. While the gcn3Δ strain showed a 
reduction in the sphingolipid species IPC 44:0;4 and IPC 46:0;4, it did not show a concomitant rise in 
shorter-chain fatty acid-containing IPC species indicative of a defect in VLCFA production. The presence 
of shorter-chain sphingolipids would indicate the cell is trying to compensate for a lack of VLCFAs. 
Therefore, we postulate the lower levels of IPC 44:0;4 and IPC 46:0;4 seen in the gcn3Δ strain are 
unrelated to a defect in VLCFA production. The VLCFA defect in ybr159wΔ is modest; with only a small 
rise in the shorter-chain fatty acid-containing sphingolipids. The loss of IPC 46:0;4 is the most striking 
characteristic of the strain. Previous work suggests that Ayr1p is able to perform 3-ketoacyl activity in the 
absence of YBR159W (Han et al. 2002). The same study showed ayr1 and ybr159w are synthetically lethal 
(Han et al. 2002).  
A gcn3 null strain is unable to fully derepress Gcn4p expression during amino acid starvation 
(Hannig and Hinnebusch 1988). GCN4 is a transcription factor involved in the expression of several 
hundred genes during a wide variety of cellular stresses (Natarajan et al. 2001). Though growth conditions 
for the gcn3Δ strain should not have activated a stress response, we suspected analysis of the lipid content 
of the gcn3Δ strain could prove problematic if the VLCFA pathway was a downstream target of the GCN4 
transcription factor. We examined the effects of loss of GCN4 using expression data for gcn4Δ strains from 
the Gene Expression Omnibus (GEO) Database (Barrett et al. 2011). Two separate datasets showed no 
significant changes in the expression of various VLCFA genes (data not shown, GEO Accession 
GSE24057 (Fendt et al. 2010) and GSE25582). We concluded that under the conditions used for the 
analysis of sphingolipids, loss of GCN4 did not significantly alter VLCFA gene expression. We concluded 
our gcn3Δ strain was not experiencing alterations in VLCFA gene expression due to repression of GCN4. 
The lack of a direct translation defect in the ybr159wΔ strain and the lack of a VLCFA defect in the gcn3Δ 
strain suggest there is no significant cross-talk between the GEF and VLCFA pathways. 
It remains to be determined if the translation defect seen in the ybr159wΔ strain is the cause of the 
slow growth of the strain or vice versa. Further experiments are required to determine the functional role of 
YBR159W interacting with eIF2B. Up until now, the interaction between eIF2B and YBR159W has been 
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assumed to occur on the ER membrane. Our data indicates that YBR159W is ER bound while eIF2B is 
thought to be a soluble cytoplasmic complex. Because eIF2B is the more mobile component of the 
interaction, it is assumed that it moves relative to YBR159W. From the interaction it can be theorized that 
there would be a fraction of eIF2B interacting with YBR159W at the membrane. Experiments need to be 
performed to see if membrane-associated eIF2B is visible using other methods such as fluorescent 
microscopy or subcellular fractionation. It would be expected that membrane-associated eIF2B would co-
fractionate with membranes. If this were not seen it might be that YBR159W has a soluble form and that 
the interaction is occurring in the cytoplasm. Another approach is to see if eIF2B co-localizes with the ER 
membrane using fluorescent confocal microscopy. If co-localization is seen between eIF2B and YBR159W 
that would indicate a substantial amount of the proteins are interacting. Lack of co-localization under 
fluorescent microscopy would not necessarily indicate that the interaction is not happening, just that the 
total amount of eIF2B and YBR159W interacting are well below the levels of non-interacting proteins and 
thus the interaction is too small to properly visualize with microscopy. As eIF2B has been shown to 
localize to eIF2B bodies in yeast, it needs to be seen if these bodies also display any membrane 
localization. These findings could show a never before seen characteristic of the eIF2B complex and 
strengthen the impact of the novel interaction between eIF2B and YBR159W. 
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CHAPTER III 
 
THE YEAST eIF2B TRANSLATION INITIATION COMPLEX SHOWS 
INTERACTIONS WITH ER MEMBRANES AND ABNORMAL CELLULAR 
LOCALIZATION FOLLOWING DELETION OF VLCFA PATHWAY GENES 
The following chapter was adapted from Browne et al. Mol. Cell Biol. 2013 Mar 33(5):1041-56. 
 
Abstract 
 
Previous work has shown that the eukaryotic translation factor eIF2B interacts with the very-long-
chain fatty acid 3-ketoacyl reductase enzyme YBR159W. YBR159W is an integral membrane protein of 
the endoplasmic reticulum. The eIF2B complex shows two different forms of cellular localization; one 
form is diffuse, cytoplasmic localization, the other is in distinct foci termed eIF2B bodies. Up to now, 
eIF2B bodies have been thought to be mobile cytoplasmic complexes that appear as one to two large 
cytoplasmic bodies. Our work confirms that YBR159W localizes to the ER membrane. Using subcellular 
fractionation experiments, I have found that a pool of eIF2B cofractionates with lipid membranes in a 
ribosome-independent and YBR159W-independent manner. Though the majority of cellular eIF2B and 
YBR159W do not appear to colocalize under fluorescent microscopy, confocal imaging strongly suggests 
that eIF2B bodies have an affinity for ER membranes. We show that a ybr159w yeast strain and other 
strains with null mutations in the VLCFA pathway disrupt the normal localization of eIF2B in the cell and 
cause eIF2B to appear as numerous small foci throughout the cytoplasm.  
 
Introduction 
 
In eukaryotes, the translation initiation guanine-nucleotide exchange factor (GEF) eIF2B is 
responsible for exchanging GDP with GTP on eIF2. eIF2-GDP is unable to bind initiator tRNA or interact 
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with the 40S ribosomal subunit during translation initiation (Merrick W. C.). eIF2B is the only GEF of eIF2 
and eIF2 is the only target of eIF2B (Pavitt 2005). eIF2B exists in the cell as a complex of 5 protein 
subunits. These 5 subunits are conserved from yeast to humans. In yeast, the subunits are GCN3 (α), GCD7 
(β), GCD1 (γ), GCD2 (δ) and GCD6 (ε). Only GCN3 is nonessential in yeast; all 5 subunits are essential in 
humans. Studies in yeast have shown the ε subunit GCD6 to be responsible for eIF2B GEF activity. The γ 
subunit GCD1 aids GCD6 and greatly increases the nucleotide exchange rate of GCD6 (Pavitt et al. 1998). 
The α subunit GCN3 serves a regulatory role in a number of stress response pathways. The δ and β subunits 
GCD2 and GCD7 share homology with regions of GCN3 that allow for intersubunit interactions; all three 
subunits form a regulatory subcomplex (Pavitt et al. 1998). 
Recent studies show that a significant fraction of yeast eIF2B resides in distinct foci in the 
cytoplasm known as eIF2B bodies (Campbell and Ashe 2006; Campbell et al. 2005). During logarithmic 
growth, yeast cells often contain 1 to 2 eIF2B bodies. The presence of eIF2B bodies under normal growth 
conditions is a striking difference between eIF2B bodies and the stress-induced processing-bodies (P-
bodies) and stress granules. GFP fluorescence microscopy shows the eIF2B bodies contain both eIF2B and 
eIF2 (Buchan and Parker 2009; Parker and Sheth 2007). As more evidence eIF2B bodies are unique 
structures, eIF2B and eIF2 are not present in P-bodies or stress granules. The initiation factor eIF2 appears 
to shuttle in and out of the eIF2B bodies (Campbell et al. 2005). The shuttling occurs quickly during 
logarithmic growth and slower following disruptions of translation initiation. The presence of eIF2B in the 
bodies is more stable. These findings have created a model where eIF2 moves into the eIF2B body for 
nucleotide exchange and then leaves it to complete its translation initiation function. The eIF2B bodies are 
thus thought to be important sites for the GEF activity of eIF2B.  
In eukaryotes, fatty acids longer than 20 carbons in length are synthesized by a special fatty acid 
synthesis complex known as the elongase complex (see Fig. 2-1B in previous chapter) (Jakobsson et al. 
2006; Leonard et al. 2004). Fatty acids longer than 20 carbons are known as very-long-chain fatty acids 
(VLCFA). In yeast, the elongase pathway is composed of the 3-ketoacyl synthetases FEN1 and SUR4, the 
3-ketoacyl reductase YBR159W, the 3-hydroxyacyl dehydratase PHS1, and the enoyl reductase TSC13 (Oh 
et al. 1997; Rossler et al. 2003; Schuldiner et al. 2005). The pathway predominately synthesizes 26-carbon 
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long VLCFAs. These VLCFAs are incorporated into sphingolipids in yeast where they largely serve a 
structure role by both relieving mechanical stress in highly-curved membranes and stabilizing lipid rafts 
(Dickson et al. 2006; Gaigg et al. 2006; Schneiter et al. 2004; Schneiter et al. 1996). VLCFAs are 
synthesized in the ER membrane where the elongase complex resides. Both PHS1 and TSC13 are essential 
genes. Deletion of FEN1 along with SUR4 is synthetically lethal (Revardel et al. 1995; Silve et al. 1996). 
While a ybr159wΔ null mutant is viable, it is thought the reductase gene AYR1 can compensate for the loss 
of ketoacyl reducatase activity in the mutant (Han et al. 2002). A ybr159wΔ, ayr1Δ double null mutant is 
synthetically lethal. 
YBR159W, also known as IFA38, is responsible for the second step in VLCFA synthesis, the 
reduction of a 3-ketoacyl intermediate to a 3-hydroxyacyl intermediate. YBR159W binds NADPH as a 
cofactor and oxidizes it as part of its enzymatic activity. A ybr159wΔ null yeast strain is extremely slow 
growing, temperature-sensitive, and has reduced levels of VLCFA-containing sphingolipids (Beaudoin et 
al. 2002; Han et al. 2002). In ybr159wΔ null cells, sphingolipids contain shorter-chain fatty acids instead of 
the wild-type VLCFA. Like other members of the elongase pathway, YBR159W is an integral ER 
membrane protein. 
The ER in budding yeast is composed of the classical membrane network connected to the nuclear 
envelope as well as a network of tubules known as the cortical ER. The cortical ER extends throughout the 
cell and encases the inner face of the entire plasma membrane (Preuss et al. 1991). In microscopy, the 
cortical ER can often be mistaken as the plasma membrane itself (Preuss et al. 1991). While the bulk of 
yeast cortical ER lies under the plasma membrane, in most metazoan cells, including mammalian cells, the 
ER is continuous with the nuclear envelope and forms a network of tubules throughout the cytoplasm that 
closely align with microtubules (Lowe and Barr 2007). 
Recently, studies in our laboratory have found a novel protein-protein interaction between the 
eIF2B complex and the 3-ketoacyl reductase YBR159W. The interaction is unique in that eIF2B has been 
thought to only localize to the cytoplasm and has not been previously shown to strongly interact with any 
ER membrane proteins. We showed that the interaction is specific for all 5 subunits of eIF2B and 
YBR159W and does not include either eIF2 or other members of the VLCFA synthesis pathway. Yeast 2-
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hybrid (Y2H) data showed the interaction with the eIF2B complex is possibly mediated by subunits GCD6 
and GCD7. Functional assays showed that a ybr159wΔ null strain has a reduced rate of translation though 
the exact cause of the phenotype could not be determined. In this study, we examine the effects the 
interaction of eIF2B and YBR159W have on the localization of each other. Supporting our previous work 
that shows eIF2B interacting with ER membrane protein YBR159W, we find that in wild-type cells eIF2B 
co-localizes with lipid membranes. We show that this membrane co-localization is not altered in a 
ybr159wΔ strain, indicating eIF2B is interacting with the membrane in an as yet undetermined manner. Our 
experiments show that a ybr159wΔ mutation causes eIF2B to appear as numerous foci. The appearance of 
numerous eIF2B foci does not appear to correlate with the cell’s translation rate as other VLCFA mutant 
strains showing multiple eIF2B foci have WT translation rates. We find that all strains displaying multiple 
eIF2B foci also display abnormal internal membrane structures. This work shows an until now undescribed 
membrane localization for translation initiation factor eIF2B and presents a possible link between lipid 
membranes and the eIF2B body. 
 
Materials and Methods 
 
Strains and Media 
All yeast media, growth, and genetic manipulation was done using standard techniques (David C. Amberg 
2005). To create the ybr159wΔ strain AL401, the kanamycin resistance cassette from plasmid pFa6a-
kanmx6 was first amplified with primers CGTACGCTGCAGGTCGAC and 
ATCGATGAATTCGAGCTCG. Using the PCR double fusion approach (David C. Amberg 2005), the 
primers CGGATTTGGAAGTCCTTTATAG, 
GTCGACCTGCAGCGTACGCATTTCTTAAGCTGCACCG, 
CGAGCTCGAATTCATCGATTAGAATTATCGTTCTCG, and GGACTTGGTCCTTCCACC were used 
to expand the YBR159W genomics flanking the kanmx6 cassette. The YBR159W disruption cassette was 
transformed into strain BY4741 and transformants were selected on YPD + 300 mM G418 plates and 
screened using Western blotting and -YBR159W polyclonal antibodies. Candidate BY4741 ybr159wΔ 
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strains were crossed with the HIS+ strain H1511 and sporulated to create the ybr159wΔ null strain AL401. 
An isogenic wild type HIS+ control strain AL400 was selected from the same sporulation. The lip1Δ strain 
RH5994 was kindly provided by Howard Riezman (Vallee and Riezman 2005). The fen1Δ, and sur4Δ 
deletion strains were obtained from the MATa yeast deletion collection (Winzeler et al. 1999). The fen1Δ 
and sur4Δ deletion strains from the MATa yeast deletion collection were mated with the HIS+ strain H1511 
and sporulated to create the fen1Δ and sur4Δ strains, AL413 and AL414 respectively. The TAP tagged 
strains were obtained from the yeast TAP-tagged library (Ghaemmaghami et al. 2003). The GFP tagged 
strains were obtained from a GFP-tagged yeast library (Huh et al. 2003). To make the ybr159wΔ, GCD7-
GFP strain, we mated the ybr159wΔ strain AL401 with the GCD7-GFP strain AL429 from the GFP-tagged 
yeast library and sporulated the diploids to obtain the ybr159wΔ, GCD7-GFP strain AL403. See Table 2-1 
is the last chapter for a full list of strains used in this study. 
 
Plasmids 
The plasmid pOBD2 used in generating yeast 2-hybrd binding-domain strains has been previously 
described (Hudson et al. 1997). To create a plasmid expressing endogenous level of YBR159W, we used 
PCR to amplify the YBR159W gene along with 600 bp of the genomic region upstream of the start codon 
of the gene and the stop codon of YBR159W using the primers 
CACCATGGTTTTTGTGACTTTACCTATAAATAGTACACAAC and 
CTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGGC. The PCR product was cloned into the 
pENTR entry vector using Directional TOPO Cloning (Invitrogen) to create pENTR-YBR159W 5’ UTR-
YBR159W. The YBR159W cassette was transferred to the pAG415GAL-ccdB yeast destination vector 
using LR Clonase recombination (Invitrogen) (Alberti et al. 2007) . To eliminate possible promoter 
interference, the endogenous GAL promoter of the vector was deleted using the restriction enzymes SacI 
and SpeI and replaced with the primer insert GGGAGCTCCATACTGATTAGTACACTAGTGG and 
CCACTAGTGTACTAATCAGTATGGAGCTCCC to create the YBR159W expression plasmid YCp-
YBR159W. To create a plasmid expressing RFP-tagged YBR159W, the YBR159W ORF without the stop 
codon was amplified by PCR and cloned into the pENTR vector creating pENTR-YBR159W. The 
YBR159W ORF insert was transferred by recombinational cloning into the pAG415GPD-ccdB-dsRed 
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vector (Addgene) to create the final expression plasmid YCp-YBR159W-dsRed. All plasmids and primers 
used in this study are listed in Table 2-2 and Table 2-3 respectively in the previous chapter. 
 
Antibodies 
The -YBR159W polyclonal antibodies were generated by inoculation of a rabbit with the synthetic 
peptide CETVKAENKKSGTRG (Covance). The peptide was covalently bound to cyanogen bromide beads 
(Sigma-Aldrich) to affinity purify -YBR159W from rabbit whole blood. Polyclonal antibodies to yeast 
Sui2 were kindly provided by Dr. Tom Dever. Polyclonal antibodies to yeast Gcd6 and Gcd1 were kindly 
provided by Dr. Allan Hinnebusch. The mouse -DPM1 was obtained from Molecular Probes. Antibodies 
to the yeast Tdh1, 2, 3 proteins were obtained from Millipore. The antibody to yeast Rpl32 was kindly 
provided by Dr. Jonathan Warner. 
 
Membrane Flotation 
Membrane flotation of yeast extracts was performed as previously described (Bergmann and Fusco 1988). 
Fifty mL of each yeast strain was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. The cells were lysed with 
glass beads in ice-cold breaking buffer (30 mM Tris pH 7.0, 1 mM EDTA). The lysate was cleared by 
centrifugation at 500 xg for 3 min. Lysate corresponding to 10 OD660 units of cells in 222 μL was mixed 
with 1778 μL of ice-cold 90% sucrose (wt/vol), 10 mM Tris pH 7.0 solution. The 2 mL of lysate/sucrose 
solution was transferred to the bottom of a 14 x 89 mm ultracentrifuge tube (Beckman, cat. # 344059) and 
layered with 6 mL of 65% sucrose, 10mM Tris pH7.0 and then 3 mL of 10% sucrose, 10mM Tris pH 7.0. 
The tubes were centrifuged in a Beckman SW-41 rotor at 24,000 rpm for 18 h. Individual 1.5 mL fractions 
were collected from the top of the gradient and the proteins TCA precipitated. Ten percent of each fraction 
was used for SDS-PAGE and Western blotting. 
 
Membrane Flotation Fractions Affinity Purifications 
For each TAP strain, a 1 L culture was grown to OD600 ~1 in YPD and the cells were split into 6 fractions. 
Each cell fraction was separated using the membrane flotation gradients as described above. The 10%-65% 
sucrose interface layer and 80% sucrose layer from each gradient were collected and pooled. TAP 
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purification was performed as previously described up to TEV protease cleavage (Powell et al. 2004; 
Sanders et al. 2002).  
 
Mass Spectrometry-Proteomics 
For yeast TAP experiments of membrane float membrane and cytoplasmic fractions, a modified MudPIT 
protocol was utilized (Powell et al. 2004; Sanders et al. 2002). For each TAP strain, a 2 L culture was 
grown to OD660 1-2 in YPD. The yeast were lysed and split into 6 tubes for membrane floatation. The 
membrane floatation and affinity purification were performed as described in the previous section. The 
purified TAP complexes were reduced with 1/10 volume of 50 mM DTT at 65 °C for 5 min, and cysteines 
were alkylated with 1/10 volume of 100 mM iodoacetamide at 30 °C for 30 min. The proteins were 
digested overnight at 37 °C with modified sequencing grade trypsin at 25:1 subtrate:enzyme ratio 
(Promega, Madison, WI). Proteins were identified using Multidimensional Protein Identification 
Technology (MudPIT) and a LTQ linear ion trap mass spectrometer (ThermoFisher) (Link et al. 1999; Link 
et al. 2005). A fritless, microcapillary (100 μm-inner diameter) column was packed sequentially with 12 cm 
of 5 μm C18reverse-phase packing material (Synergi 4 μ Hydro RP80a, Phenomenex) and 3 cm of 5 μm 
strong cation exchange packing material (Partisphere SCX, Whatman). The entire trypsin-digested samples 
were loaded onto the biphasic column equilibrated in 0.1% formic acid, 2% acetonitrile, which was then 
placed in-line with an LTQ-OrbitrapXL mass spectrometer. An automated twelve-cycle multidimensional 
chromatographic separation was performed using buffer A (0.1% formic acid, 5% acetonitrile), buffer B 
(0.1% formic acid, 80% acetonitrile) and buffer C (0.1% formic acid, 5% acetonitrile, 1 M ammonium 
acetate) at a flow rate of 500 nL/min. Cycles 1−12 consisted of 3 min of buffer A, 2 min of 0−100% buffer 
C, 5 min of buffer A, followed by a 60-min linear gradient to 60% buffer B. In cycles 1−12, buffer C salt 
pulses of 0mM, 25mM, 50mM, 75mM, 100mM, 150mM, 200mM, 250mM, 300mM, 500mM, 750mM and 
1M ammonium acetate were used. Eluting peptides were analyzed by one full MS scan (300-2000 m/z) 
using an LTQ-OrbitrapXL mass spectrometer with preview mode and monoisotopic precursor selection 
enabled. The top 10 precursors ions based on intensity were fragmented using CID in the ion trap using 
35% normalized collision energy. Dynamic exclusion was enabled for 180s with repeat count of 1 at 30 s 
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duration, list size of 500, mass tolerance of 10 ppm. Mass spectrometry data was analyzed as previously 
described (McAfee et al. 2006).  
 
Microscopy 
Epifluorescent microscopy was performed using live yeast cells grown in SC media to an OD660 1.0-1.5 at 
30 
o
C. Cells were mounted on slides and visualized using a Zeiss Axiophot brightfield microscope with a 
63x / 1.40 Plan-Apochromat oil DIC lense. Images were analyzed with MetaMorph imaging software 
(Molecular Devices). Live yeast cells imaged using confocal microscopy were grown in SC media to an 
OD660 1.0-1.5 at 30 
o
C., Cells were visualized with a Zeiss LSM 510 META inverted confocal microscope 
using a 63x / 1.40 Plan Apochromat oil immersion lens. Microscopic images used for quantitative analysis 
were analyzed using ImageJ imaging software (Schneider et al. 2012). To quantify the percentage of eIF2B 
bodies that co-localized with the ER, a eIF2B body was judged to be co-localized with the ER only if the 
eIF2B body signal overlapped with an area of YBR159W at least half as bright as the brightest YBR159W 
signal seen in the cell. Cells were pooled into groups of approximately 25 cells to calculate a standard 
deviation for the percentage of eIF2B bodies co-localized with the ER. The bright regions of the ER were 
subtracted from the total area of the cell minus the nuclear area to determine the fraction of the cell taken 
up by the ER. The compound 3,3’-dihexyloxacarbocyanine iodide (DiOC6(3)) was used to stain and image 
the membranes of wild type strain AL400, and ybr159wΔ strain AL401 as previously described (Terasaki et 
al. 1984). Yeast cells were incubated in media containg 2.5 µg/mL DiOC6(3) for 10 min before imaging.  
 
Subcellular Fractionation 
WT yeast strain AL400 was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. To isolate subcellular 
fractions, 45 OD660 units of cells were split into three samples: control, puromycin treatment, and EDTA 
treatment. The control sample was lysed using glass beads in 750 µL of ice-cold control buffer (10 mM 
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 10 mM KCl, 30 mM MgCl2). The puromycin and EDTA 
treatment samples were lysed using glass beads in 750 µL of ice-cold ribosome dissociation buffer (10 mM 
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA). The control sample was diluted in 750 µL of control buffer. 
The puromycin treated sample was diluted with750 µL of ribosome dissociation buffer containing 2 mM 
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puromycin to a final concentration of 1 mM. The EDTA-treated sample was diluted in Ribosome 
dissociation buffer (20mM EDTA) to a final concentration of 10 mM EDTA. Lysates were gently mixed at 
RT for 30 min to facilitate dissociation of ribosomes from the ER. Lysates were centrifuged at 900 xg for 5 
min, and the supernatant was centrifuged at 11,000 xg for 20 min. The soluble fraction was recovered from 
the supernatant. The pellets was resuspended in either control buffer (1 mM puromycin, 10 mM Tris pH 
8.0, 100 mM NaCl, 1 mM EDTA) or EDTA solution (10mM EDTA, 10 mM Tris pH 8.0, 100 mM NaCl, 1 
mM EDTA) and centrifuged at 11,000 xg for 20 min. The pellets were resuspended in 1.5 mL of 
resuspension buffer (1 mM puromycin, 10 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% SDS) and 15 
µL of each fraction was used for Western blotting. 
 
Results 
 
Given the previously identified interaction between eIF2B and YBR159W, we wanted to look at 
cellular localization of eIF2B and YBR159W in the cell. Previous work in our laboratory confirmed that 
YBR159W localizes to the ER membrane (Fig. 2-3A and B). To look for possible co-localization between 
eIF2B and YBR159W, we used strains with subunits of eIF2B endogenously tagged with GFP and the 
YBR159W-RFP expression plasmid YCp-YBR159W-dsRed. To show the RFP-tagged YBR159W allele 
was functional, the plasmid YCp-YBR159W-dsRed complemented the ybr159wΔ null strain AL401. 
Confocal microscopy of the dual-fluorescently-labeled strains was used to look for co-localization between 
eIF2B and YBR159W (Fig. 3-1). As observed in previous studies and Fig. 2-3, our YBR159W-RFP 
construct localized to membranes corresponding to the endoplasmic reticulum (Fig. 3-1 and Fig. 2-3). 
Using strains with different eIF2B subunits tagged with GFP, we observed eIF2B localized as 1-2 large foci 
(Fig. 3-1). This agrees with previous studies showing eIF2B localization in eIF2B bodies (Campbell et al. 
2005). In addition, GFP-tagged eIF2B is seen dispersed throughout the cytoplasm . Surprisingly, the 
confocal microscopy images did not convincingly show the majority of YBR159W signal co-localizing 
with eIF2B subunits. Because we observed that the eIF2B body localized in close proximity to ER 
membrane-bound YBR159W, we performed a statistical analysis to test if eIF2B and YBR159W co-
localize. We examined 221 individual eIF2B bodies from 140 dual labeled cells by pooling results from the 
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YCp-YBR159W-dsRed transformed GCD1-GFP, GCD6-GFP, and GCD7-GFP strains (AL405, AL406, 
and AL407). We found 60.1% ±6.6% of eIF2B bodies examined showed partial co-localization with a 
bright area of YBR159W signal. Based on the area of the cell taken up by bright areas of YBR159W signal, 
it would be expected that only 30.7% ±6.9% of eIF2B bodies would co-localize with YBR159W signal if 
the two signals were independent of each other. A Student’s t-test (P=2.9x10-8) shows this difference to be 
significant. 
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Figure 3-1 eIF2B and YBR159W localization in live 
cells. Confocal microscopy of live yeast cells showing 
localization of eIF2B subunits in relation to the 
localization of YBR159W. eIF2B subunits are 
endogenously tagged with GFP while YBR159W-RFP 
is expressed on a centromeric plasmid. 
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To observe the effects of the ybr159wΔ deletion on eIF2B localization, we performed live cell 
imaging using epifluorescence microscopy on the yeast strains ybr159wΔ, GCD7-GFP (AL403), GCD7-
GFP (AL429), and ybr159wΔ, GCD7-GFP, [YCp-YBR159W] (AL404). Cells from the GCD7-GFP 
control strain were found to contain 1 to 2 large eIF2B bodies (Fig. 3-2A). In the ybr159wΔ strain AL403, 
eIF2B appeared as multiple foci (Fig. 3-2A). The ybr159wΔ phenotype of AL403 was rescued by 
expression of plasmid YCp-YBR159W in strain AL404 (Fig. 3-2A). Using these strains, we counted the 
number of cells containing 1 to 2 large eIF2B bodies compared to the number of cells having the multiple 
eIF2B foci or diffuse cytoplasmic localization. We found that the majority of ybr159wΔ cells had the 
multiple eIF2B foci phenotype (Table 3-1A). For the GCD7-GFP WT control strain, no cells had the 
multiple eIF2B foci phenotype and a majority of cells had either 1 or 2 eIF2B bodies. The rescued 
ybr159wΔ, GCD7-GFP, [YCp-YBR159W] strain AL404 did not have multiple eIF2B foci (Table 3-1A). 
To show the eIF2B body phenotype was independent of the GFP-tagged alleles, we performed 
immunofluorescence microscopy on untagged yeast strains using polyclonal antibody against the eIF2B 
subunit Gcd6 (Fig. 3-2B). We observed the 1 to 2 large eIF2B body foci phenotype for the majority of the 
WT control AL400 cells while the majority of the ybr159wΔ cells (AL401) displayed multiple eIF2B foci 
(Table 3-1B). The ybr159wΔ, [YCp-YBR159W] rescue strain AL402 showed a majority of cells had eIF2B 
present as either a single eIF2B foci or no detectable foci (Table 3-1B). The VLCFA and ceramide synthase 
mutants AL413 (fen1Δ), AL414 (sur4Δ), and RH5994 (lip1Δ) were all found to have the multiple eIF2B 
foci phenotype (Table 3-1B). 
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Figure 3-2 eIF2B localization in the ybr159wΔ 
background. (A)  Live cell fluorescence microscopy 
of endogenously tagged eIF2B subunit GCD7-GFP. 
Brightfield (BF) images are included for clarity. (B) 
Immunofluorescence microscopy of formaldehyde 
fixed yeast cells. A polyclonal antibody against 
yeast eIF2B subunit Gcd6 was used along with an 
Alexa Fluor 488 tagged secondary. Nuclei are 
stained with DAPI for clarity. 
 
80 
 
Table 3-1 Statistics for eIF2B localization phenotypes. (A) Live Yeast. Statistics for eIF2B localization 
phenotypes in live yeast cells are given. The strains are described in Fig 3-3A. (B) Fixed Yeast. Shown are 
statistics for eIF2B localization phenotypes via immunofluorescence of fixed yeast cells. The strains are 
described in Fig 3-3B. 
Strains Cell # Single 2B body (%) Multi-Foci (%) No Foci (%) 
A. Live Yeast     
WT 173 50.9 0.0 49.1 
ybr159wΔ 122 3.3 71.3 24.6 
Rescue 72 44.4 0.0 55.6 
     
B. Fixed Yeast     
WT 105 63.8 7.6 28.6 
ybr159wΔ 59 1.7 83.1 15.3 
Rescue 111 35.1 15.3 49.5 
lip1Δ 29 6.9 93.1 0.0 
fen1Δ 96 4.2 63.5 32.3 
sur4Δ 122 1.6 58.2 40.2 
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Previous work has shown that disruption of VLCFA utilization in yeast causes abnormal 
formation of lipid membranes (Schneiter et al. 2004). The compound 3,3’-dihexyloxacarbocyanine iodide 
(DiOC6(3)) is a lipophilic dye used to label a variety of lipid membranes (Terasaki et al. 1984). We used 
DiOC6(3) to stain membranes of wild type strain AL400, ybr159wΔ strain AL401, and the VLCFA mutant 
strains AL413 (fen1Δ), and AL414 (sur4Δ), and the ceramide synthase mutant strain RH5994 (lip1Δ). The 
ybr159wΔ, fen1Δ, sur4Δ, and lip1Δ null strains all displayed disrupted lipid membranes using 
epifluorescence imaging (Fig. 3-3). This supported previous work showing that VLCFAs are important for 
proper membrane formation (Schneiter et al. 2004). 
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Figure 3-3 Null mutations of genes in the VLCFA pathway 
disrupt lipid membranes. The lipophilic dye DiOC6(3) was 
used to label membranes in live yeast cells. Dye was applied 
to cells in suspension 10 min before plating on a microscope 
slide and imaging. Included are the VLCFA and ceramide 
synthase mutants fen1Δ, sur4Δ, and lip1Δ as controls. 100% 
of these mutants showed abnormal membranes (N=246) 
versus 1.1% for WT (N=89) and 9.7% for the rescue (N=93). 
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Because eIF2B is thought to be a soluble cytoplasmic protein and YBR159W has been shown to 
be an integral membrane protein in the endoplasmic reticulum (Han et al. 2002; Klein 1957), we performed 
membrane float experiments to determine if a population of eIF2B complexes physically interacted with 
lipid membranes. The lack of signal from the Western blot for the control yeast GAPDH analogs TDH1, 2, 
and 3 in the membrane fraction showed the fractionation was efficient at separating cytoplasmic proteins 
from membrane-associated proteins (Fig. 3-4A). A significant lipid membrane signal was seen for the ER 
proteins YBR159W and Dpm1. A portion of the YBR159W and control ER membrane protein Dpm1 
signals was still present in the soluble fraction indicating the membrane-associated proteins do not appear 
to completely separate from the soluble fraction. The membrane float experiments showed that in WT 
AL400 cells, a significant fraction of the eIF2B subunit GCD6 localized to the lipid membrane fractions 
(Fig. 3-4A). The Western blot profiles of the membrane and soluble fractions for GCD6 showed the same 
pattern as the known ER membrane proteins YBR159W and Dpm1 (Fig. 3-4A). Interestingly, the SUI2 
component of eIF2 also showed a similar membrane association pattern. The data indicates a fraction of 
eIF2 complexes are associated with membranes in yeast cells. 
To validate our observation that eIF2B is membrane-associated, we used whole cell extracts 
prepared from TAP-tagged eIF2B and control strains and the membrane float separation experiment to 
collect fractions from the membrane-associated and soluble protein region of the density gradients. Next, 
we performed a modified TAP purification on each fraction and analyzed the affinity purified complexes 
using LC-MS/MS. Our data showed that the interaction between eIF2B and YBR159W was still present in 
both the membrane-associated and soluble protein fractions (Fig. 3-4B). Because of the incomplete 
separation of membrane proteins in the assay, it is not known if both soluble and membrane-associated 
eIF2B interact with YBR159W or if only membrane-associated eIF2B interacts with YBR159W. To see if 
YBR159W was required for the membrane association of eIF2B, we performed the membrane floatation 
assay and Western blots using the ybr159wΔ strain AL401. We found that eIF2B associated with the 
membrane fraction in the ybr159wΔ strain at similar levels as seen in the control strain (Fig. 3-4C). Overall, 
the membrane float experiments showed a fraction of yeast eIF2B is associated with membranes but the 
interaction is independent of YBR159W. 
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To determine if the membrane association seen for eIF2B is possibly mediated by rough ER-
bound ribosomes, we performed a sub-cellular fractionation experiment to isolate smooth membranes. Cell 
lysates from WT strain AL400 were treated with either elevated levels of EDTA or the ribosome releasing 
antibiotic puromycin (Adelman et al. 1973). Following fractionation and Western blotting, ribosomal 
protein signal in the insoluble membrane fraction was significantly reduced in both the EDTA and 
puromycin treated cell extracts compared to untreated control extracts. However, the eIF2B signal in the 
rough or smooth membrane fraction did not noticeably change (Fig. 3-4D). The data indicates that the 
eIF2B-membrane association is independent of ribosomes. 
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Figure 3-4 eIF2B and YBR159W localization using membrane floatation assays. (A)  Western blot of 
membrane floatation assay fractions using protein extracts from WT yeast showing the localization of the 
eIF2B subunit GCD6 and YBR159W. Controls include the eIF2 subunit SUI2, ER integral membrane 
protein DPM1, and the cytosolic protein GAPDH. TDH1-3 are the three GAPDH genes in yeast. The 
lanes represent 20% of fractions from the membrane floatation gradients. Labels show the location of the 
membrane-associated and soluble protein fractions. (B)  Mass spectrometry analysis of affinity purified 
TAP complexes from the membrane and soluble fractions of membrane floatation experiments. Unique 
peptides, percent coverage and “-” are described in Fig 2-2A. (C)  Western blot of membrane floatation 
assay fractions comparing WT and ybr159wΔ strains. Conditions are the same as in “A”. (D) Western 
blot of crude fractionation following EDTA or puromycin treatment. Abbreviations are WCE = whole 
cell extract, Con = non-treated control, EDTA = EDTA treatment, Puro = puromycin treatment, S = 
supernatant, P = pellet. ASC1 is a component of the small ribosomal subunit and RPL32 is a large 
ribosomal subunit protein. Lanes represent 15 µL of WCE following fractionation, pellets were 
resuspended in starting volume. 
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Discussion 
 
Membrane floatation and subcellular fractionation assays show eIF2B interacts with lipid 
membranes. Our data and previous studies showed YBR159W is an integral membrane protein that co-
localizes with the ER membrane (Abraham et al. 1961; Han et al. 2002; Klein 1957). We interpret these 
findings to mean that the membranes eIF2B is interacting with are ER membranes. It is unknown if ER-
associated eIF2B is actively engaged in guanine nucleotide exchange. A number of conclusions can be 
made about this ER membrane-interacting eIF2B. First, the eIF2B-membrane interaction is not mediated by 
rough ER-bound ribosomes. Treatment of cell extracts with EDTA or puromycin greatly reduces the 
amount of ribosomes that fractionate with lipid membranes but does not reduce the portion of eIF2B that 
fractionates with membranes. This fits the prevailing theory that the role of eIF2B in translation is 
independent of the ribosome (Merrick W. C.). Second, YBR159W is not required for the interaction. The 
ybr159wΔ null strain does not affect the interaction of eIF2B with the membrane showing that the 
interaction of eIF2B with ER membranes is YBR159W independent. This indicates that other factor(s) are 
possibly required. 
This new data modifies the models to explain the interaction between eIF2B and YBR159W 
presented in the previous chapter (Fig. 2-7). Model A, which states that eIF2B and YBR159W interact 
directly and independently of other factors can be ruled out based on the fact that eIF2B still associates 
with membranes in the ybr159wΔ null strain. Model C, where an as yet unidentified soluble factor binds 
directly to YBR159W and mediates the interaction with eIF2B can also be ruled out based on the same 
data. This leaves models B and D. Model B posits that eIF2B is palmitoylated for its membrane association 
and interaction with YBR159W. Model D states eIF2B is interacting with another unknown membrane-
associated protein, this membrane protein then is interacting with YBR159W. This unknown factor could 
be an intergral membrane protein like YBR159W or a soluble factor that is peripherally anchored to the 
membrane by a lipid modification. Figure 3-5 presents modified models for the eIF2B-YBR159W 
interaction (Fig. 3-5). The possibility that a number of these possibilities all happen simultaneously is also 
available. In Figure 3-5, model D1is very similar to model C in Figure 2-7 from the previous chapter. An 
unknown soluble protein is mediating the observed interaction between eIF2B and YBR159W. By lipid 
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modifying the factor in model D1, the membrane association of eIF2B no longer becomes YBR159W-
dependent. As before, no new data is available for identification of an unknown membrane-associated 
interactor with eIF2B. 
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Figure 3-5 Modified Models for the interaction of eIF2B and 
YBR159W. Parts B and D are taken from Figure 2-7. (B) Model 
for direct lipid modification of eIF2B subunits GCD1, GCD2, and 
GCD6. (D1) Model for peripheral membrane-association of an 
unknown factor interacting with both eIF2B and YBR159W. (D2) 
Model for an unknown integral membrane protein interacting with 
eIF2B and YBR159W. 
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Possibilities for palmitoylation of either eIF2B itself or an unkown factor need to be considered. In 
Table 2-1 the palmitoylation site predictor CSS-Palm predicted possible palmitoylation sites on eIF2B 
subunits GCD1, GCD2, and GCD6 (Table 2-1). Unfortunately, no structures are available for GCD1 or 
GCD2 in yeast. A structure for the catalytic domain of yeast eIF2Bε gene GCD6 is available but the 
structure does not include the cysteine 342 residue predicted to be palmitoylated on GCD6 (Boesen et al. 
2004). This makes it impossible to determine whether the predicted sites are exposed and able to be 
palmitoylated and interact with the membrane. A global analysis of yeast palmitoylated proteins did not 
identify any subunits of eIF2B as containing a palmitoyl modification (Roth et al. 2006). Interestingly, this 
study did find some evidence that eIF2 subunit GCD11 is potentially palmitoyl modified. From Table 2-1, 
the CSS-Palm generated CSS score for the predicted palmitoylation site on GCD11 is actually lower than 
the score for a predicted site on eIF2B subunit GCD2 (Table 2-1). It is quite possible a subpopulation of 
palmitoylated eIF2B could have been missed in the study. Direct examination of eIF2B palmitoylation is 
required. Sensitive, non-radioactive methods can be used to determine the palmitoylation of proteins 
(Kostiuk et al. 2009). 
Confocal microscopy shows that the majority of eIF2B bodies are in close proximity to 
YBR159Wp and ER membranes, supporting the model that eIF2B bodies and the ER interact. This could 
indicate that the eIF2B shown to interact with ER membranes resides in eIF2B bodies. A possible 
conflicting interpretation of the data is that YBR159W-RFP is being overexpressed and its localization is 
an artifact. The co-localization experiment used a RFP-tagged YBR159W allele expressed from a GPD 
promoter on a centromeric plasmid. Global protein expression analysis shows that the target protein of the 
GPD promoter, tdh3p, is expressed at roughly 4 times that of YBR159W (Ghaemmaghami et al. 2003). The 
fact that the RFP-tagged YBR159W localization agrees with endogenously expressed YBR159W-GFP 
localization leads us to believe that artifacts caused by the RFP tagged construct are not disrupting the 
localization of YBR159W. In addition, the RFP-tagged allele complements a ybr159wΔ null strain. How 
and why eIF2B might be interacting with the ER membrane is unknown. A population of membrane-
interacting eIF2B bodies might possibly explain recent findings that eIF2B bodies can exist in a mobile or 
static state with mobile eIF2B bodies free in the cytoplasm and static eIF2B bodies being associated with 
membranes (Taylor et al. 2010). Further work is needed to prove this hypothesis.  
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Figure 3-6 displays several models for the eIF2B-ER membrane association in the cell (Fig. 3-6). 
Model A depicts the interaction occurring between diffuse, cytoplasmic eIF2B not in eIF2B bodies with the 
entire surface of the ER membrane. If the interaction is weak, it may not be detected by co-localization in 
microscopy. The large surface area of the ER in the cell gives the most opportunity for the interaction to 
occur in this model. In yeast cells, eIF2B bodies often appear as a line or thread about a half to a third the 
diameter of the cell. Figure 3-6D displays several examples of the linearity of eIF2B bodies in the cell (Fig. 
3-6D). As the linear bodies have numerous 3-dimensional orientations in the cell, the Z-slice of a single 
confocal microscope image often shows the bodies as points instead of lines. Model B posits that the entire 
length of the linear eIF2B body interacts with a cortical ER tubule membrane. Because of the relative 
intensity of eIF2B body signal this interaction should show a large amount of co-localization under 
microscopy if this model were true. The lack of co-localization makes this model unlikely to be the case. 
Model C posits that the eIF2B body is only anchored to the ER membrane and the majority of the body is 
free in the cytoplasm. Co-localization between the eIF2B body and the ER membrane would be small under 
this model. Figure 3-6C shows only one anchor point for the eIF2B body with the ER, though nothing 
precludes multiple anchor points with the membrane. Confocal microscopy showing a high proportion of 
eIF2B bodies having some amount of co-localization with ER membrane-bound YBR159W supports this 
model. One way to test between models A and C is to find a way to completely disrupt eIF2B body 
formation. Evidence suggests that treatment of cells with cycloheximide as being able to disrupt eIF2B 
body formation (Campbell et al. 2005). This finding would need to be confirmed. If eIF2B membrane 
association is not greatly affected after cycloheximide treatment, the model that non-eIF2B body-bound 
eIF2B is interacting with membranes is favored (Fig. 3-6A). If the membrane association of eIF2B is 
reduced after cycloheximide treatment and subsequent loss of eIF2B bodies then the model that eIF2B 
bodies are anchored to the membrane would be favored (Fig. 3-6C). To test model C directly, strains 
containing mutations in eIF2B subunits could be constructed that abolish the membrane association of 
eIF2B. If the percentage of eIF2B bodies showing preferential localization with the cortical ER membrane 
goes down in the eIF2B mutants, then the bodies may be membrane anchored. If the percentage stays the 
same it would be assumed the proximity of eIF2B bodies with the ER membrane is a coincidence and not 
representative of an actual interaction with ER membranes. This set of experiments assumes the mechanism 
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of eIF2B membrane association can be readily determined and abolished through mutations without 
affecting any other property of the eIF2B complex. 
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Figure 3-6 Models for the ER membrane association of eIF2B. (A) Diffuse 
cytoplasmic eIF2B interacts with ER membranes. The interaction would occur 
across the entire ER membrane. (B) eIF2B bodies interact with ER membranes 
across their entire lengths. (C) eIF2B bodies are anchored to ER membranes. 
The eIF2B-ER membrane interaction would occur only at the anchor point. (D) 
Examples of eIF2B bodies showing their linearity. GCD1-GFP is endogenously 
expressed while YBR159W-RFP is overexpressed from a plasmid. 
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The observation that the ybr159wΔ null strain leads to multiple eIF2B foci is intriguing. This 
phenotype is also seen in other VLCFA mutants. The fact that these mutants all display disrupted lipid 
membranes lends itself to the theory that properly formed membranes are required for the integrity of 
eIF2B bodies. Figure 3-7 depicts this model for eIF2B body disruption via membrane disruption (Fig. 3-7). 
An interesting question is whether the membrane disruption prevents the eIF2B bodies from forming 
properly or whether the eIF2B bodies are unable to be maintained once formed? For the first model, an as 
yet unknown factor in membranes required for eIF2B body formation could be scattered by membrane 
disruption and cause eIF2B bodies to form throughout the cell. We speculate that this membrane-associated 
factor could serve as a nucleating site for the formation of eIF2B bodies. The second model would predict 
that membrane disruption is affecting a factor needed for eIF2B body stability. Loss of this factor leads to 
eIF2B bodies dissociating into multiple smaller foci. A previous study showed VLCFAs were important for 
lipid raft formation (Gaigg et al. 2006). It is possible that lipid raft disruption in the VLCFA mutants causes 
the multiple eIF2B foci phenotype. Translation assays using the ybr159wΔ strain suggested the disruption 
of eIF2B bodies into multiple foci does not affect translation. The translation activity of yeast cells does not 
appear to be affected by the change from a single eIF2B body to multiple eIF2B foci. The model in Figure 
3-7 predicts that the continued membrane association of eIF2B in elongase mutants is the cause of the 
multiple eIF2B foci. This could be tested if the mediator of the membrane association of eIF2B can be 
found. If eIF2B bodies form normally after disruption of the membrane association of eIF2B even in an 
elongase mutant background, it would suggest the model is correct. 
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Figure 3-7 Model of multiple eIF2B body phenotypes seen in yeast elongase mutants. (A) Wild-type 
yeast showing a eIF2B body anchored at multiple points to the ER membrane as presented in Fig. 3-
6C. (B) Mutations in elongase genes lead to disruption of lipid membranes in the cell. The disrupted 
ER membranes causes anchor points for eIF2B bodies to be scattered throughout the cell, leading to 
the multiple eIF2B body phenotype. 
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Our work sheds light on the recently discovered eIF2B body. The data show a relationship 
between eIF2B localization and an ER membrane bound protein. We discovered the membrane co-
localization of eIF2B while examining its interaction with YBR159W. This membrane association has not 
been described previously and opens up new possibilities for eIF2B function. A possible function of the 
membrane association of eIF2B is to increase translation efficiency of membrane proteins and secreted 
proteins. Faster guanine nucleotide exchange at the ER could increase the efficiency of rough ER-bound 
ribosomes. If a means of disabling the membrane association of eIF2B can be found this hypothesis could 
be readily tested using quantitative proteomics. By examining membrane and secreted proteins with and 
without membrane-associated eIF2B it could be seen if there is increased expression of the levels of these 
proteins. Our data suggest that YBR159W is not necessary for the co-localization of eIF2B with the 
membrane. This data supports the model that YBR159W is not directly mediating the membrane 
association of eIF2B. The primary mediator of the membrane association of eIF2B is unknown. Future 
work will need to determine if eIF2B itself is interacting with the membrane via palmitoylation or if an 
unknown factor is responsible. 
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The purpose of this dissertation was the biochemical and genetic investigation of novel functions 
for yeast genes in the process of protein translation. In this chapter, I will analyze the significance of my 
findings and discuss its relevance to the study of protein translation and molecular biology as a whole. I 
will discuss how my research has advanced our scientific understanding of protein synthesis and will 
propose additional experiments to further the work I have done and answer new questions that have arisen 
due to my research. 
 
The Translation Initiation Factor eIF2B and Its Interaction with the Elongase Enzyme YBR159W 
 The translation initiation factor eIF2B is an essential regulator of protein synthesis (Pavitt 2005). 
Numerous studies during the last several decades have shown eIF2B to be a key component of the cell’s 
response to stress (Bushman et al. 1993; Hinnebusch 1985; Pavitt et al. 1998; Rowlands et al. 1988; Taylor 
et al. 2010). The very-long-chain fatty acid (VLCFA) ketoacyl reductase YBR159W is an ER membrane 
bound enzyme important for VLCFA synthesis and eventually sphingolipid synthesis in yeast cells 
(Beaudoin et al. 2002). My laboratory discovered a novel protein-protein interaction in yeast between 
eIF2B and YBR159W. As part of my dissertation research, I set out to biochemically characterize this 
interaction and determine the reason for its existence in the cell. This work led to a publication detailing not 
only the interaction between eIF2B and YBR159W, but also the previously uncharacterized membrane 
association of eIF2B (Browne et al. 2012). This report indicates that eIF2B associates with ER membranes 
and that VLCFA synthesis and the elongase pathway that controls it is important for proper localization of 
eIF2B complexes in the cell. My work presents a never before seen interaction for eIF2B and further 
solidifies the importance of very-long-chain fatty acids in the cell. 
 My work strongly suggests that eIF2B interacts with YBR159W alone. Initiation factor eIF2 is not 
found to co-purify with YBR159W, and other members of the elongase complex do no co-purify with 
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eIF2B. The latter observation could be explained by the fact that the elongase enzymes do not seem to 
strongly co-purify with each other. This would lend itself to the presiding model that each member of the 
pathway binds its substrate in the lipid bilayer, conducts its enzyme activity, and then releases the product 
back into the bilayer (Beaudoin et al. 2002; Han et al. 2002; Jakobsson et al. 2006; Kihara 2012). In this 
way members of the pathway do not have to physically interact with each other for their enzymatic 
function. The lack of interaction between eIF2 and YBR159W is more intriguing. The confocal microscopy 
that I conducted looking at the colocalization of eIF2B bodies and the ER suggests that the bodies show 
some preference for close proximity to the cortical ER. Previous work showed that eIF2B bodies also 
contain eIF2 (Campbell and Ashe 2006; Campbell et al. 2005). Though I did not look at co-localization of 
eIF2 and YBR159W, this could imply that either the eIF2B bodies near the ER do not contain eIF2 or that 
the bodies near the ER are not interacting with YBR159W. There is no evidence that a population of eIF2B 
bodies does not also contain eIF2 so this option is unlikely. Of course, the only evidence that eIF2B bodies 
and the ER are interacting is from statistical analysis of confocal microscopy so it is always possible the 
proximity between the two is just coincidence. This would mean a fraction of eIF2B not in 2B bodies is 
interacting with YBR159W and is not detected using immunofluorescence microscopy. A third possibility 
is that eIF2 and eIF2B in the eIF2B bodies does not strongly interact and eIF2 is dissociating during the 
affinity purification of YBR159W. A simple way to prove this hypothesis would be to gently cross-link 
proteins in a YBR159W TAP-tagged strain. If YBR159W now copurifies with both eIF2B and eIF2 this 
would again open the possibility for eIF2B bodies interacting with YBR159W and the ER membrane. In 
the event that eIF2 is still not identified in a YBR159W-TAP affinity purification, it would have to be 
assumed that eIF2B bodies do not interact with YBR159W and that the eIF2B-YBR159W interaction is 
truly eIF2-free.  
Regardless of whether eIF2B bodies interact with ER membranes, fractionation experiments that I 
performed unquestionably show that eIF2B complexes themselves associate with lipid membranes. I was 
able to show that this membrane association is ribosome-independent. This fits with the current model of 
translation initiation where eIF2B performs it GEF exchange separate from the ribosome (Merrick W. C. ; 
Pavitt 2005). Intriguingly, I also found eIF2B associates with membranes independently from YBR159W. 
To attempt to explain this one can think of two explanations. A complex explanation is that eIF2B 
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associates with membranes in at least two separate ways, one association is with the ER membrane and is 
mediated by YBR159W while the second is through an as yet unknown mechanism and is with an as yet 
undetermined lipid membrane. In this model, only the YBR159W interaction can be identified by affinity 
purification and mass spectrometry. Assays that I performed using wild-type and ybr159wΔ null strains did 
not show a noticeable change in the amount of eIF2B that associates with lipid membranes between the two 
strains. This would tend to discredit the first explanation that eIF2B is interacting with two sets of 
membranes. The second and simpler explanation is that eIF2B is associating with only one set of lipid 
membranes and that the protein-protein interaction we see with YBR159W is a consequence of the 
association. This theory would be supported by future research examining whether eIF2B subunits are 
palmitoylated in yeast or eIF2B interacts with another unidentified membrane protein. 
 The yeast 2-hybrid analysis I performed suggested that eIF2B subunits GCD6 and GCD7 are 
mediating the interaction with YBR159W. GCD6 is the primary catalytic subunit of eIF2B and is part of a 
separate subcomplex from the regulatory subunit GCD7 (Pavitt et al. 1998). This finding represents a new 
functionality for eIF2B. If YBR159W is acting as a regulator of eIF2B function, this would be a completely 
new regulatory activity in yeast. Only a handful of factors have been found to regulate translation by direct 
interaction with eIF2B outside of the canonical eIF2 and phospho-eIF2 pathways (Pavitt 2005). Direct 
regulation of eIF2B by various protein kinases and butanol has been identified (Taylor et al. 2010; Woods 
et al. 2001). Phosphorylation of eIF2B has only been shown in mammals and is mediated by the dual-
specificity tyrosine-phosphorylated and regulated kinase (DYRK) and glycogen synthase kinase 3(GSK3) 
(Woods et al. 2001). YBR159W interacting with Gcd6 and Gcd7 to regulate eIF2B would be the first 
protein shown outside of eIF2α to directly regulate eIF2B function in yeast. Alternatively, if eIF2B was 
serving to regulate YBR159W and the elongase pathway, this would represent a totally new role for eIF2B 
in the cell.  
 Taken together, this data suggests several models for the eIF2B-YBR159W interaction. At least 
one theory can be disregarded; the membrane-association of eIF2B is not dependent on it interaction with 
YBR159W, either direct or indirect. The existence of membrane-associated eIF2B in a ybr159wΔ null 
strains shows this in Chapter 3, Fig. 3-4C. Because of this result, either eIF2B is interacting with another 
membrane protein or eIF2B can independently associate with membranes. I have no evidence to support 
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another membrane protein interaction but that does not mean it does not exist. Software prediction fits with 
the direct association of eIF2B with lipid membranes via palmitoylation. This theory is intriguing and 
straightforward to test. Mass spectrometry methods are available to identify palmitoylated proteins. In 
addition, biochemistry methods exit to directly identify palmitoylated proteins (Drisdel and Green 2004). 
The existence of palmitoylated eIF2B would definitely put a new twist on the function of eIF2B in the cell. 
It supports the idea that eIF2B is needed at the ER membrane for more efficient translation of integral 
membrane and secreted proteins. If eIF2B subunits were found to be palmitoylated, it would be fairly 
straightforward to mutate the modified cysteine residues from the proteins and observe the effects it has on 
the cell. An interesting idea is if it leads to a slow growth rate similar to the ybr159wΔ deletion mutant. 
This would give additional evidence to the theory that the growth defect of the ybr159wΔ strain is not 
caused by reduced VLCFA synthesis. 
 The eIF2B body is one of several translation-associated foci in yeast only observable under 
fluorescence-microscopy (Buchan and Parker 2009; Campbell et al. 2005; Parker and Sheth 2007). At the 
time they were discovered, 2B bodies were implicated as important sites of eIF2B-GEF exchange 
(Campbell et al. 2005). Fluorescence recovery after photobleaching (FRAP) suggested that eIF2 shuttles 
slower in and out of the bodies during stress events compared to logarithmic growth (Campbell et al. 2005). 
The reduced shuttling of eIF2 correlated with reduced eIF2B activity. The authors hypothesized that eIF2 
enters the eIF2B body for the purpose of nucleotide exchange (Campbell et al. 2005). When I examined 
eIF2B localization in a ybr159wΔ null strain as well as other elongase enzyme null strains, I found that 
eIF2B bodies are forming into dozens of individual foci in the cells. Although I have immunofluorescence 
data showing that other elongase pathway mutants in the also display the multiple eIF2B body phenotype, I 
will refer only to the ybr159wΔ strain when discussing the foci. My live-cell microscopy of the ybr159wΔ 
strain shows this multiple, small foci phenotype (Chapter 3, Fig. 3-2). Morphologically, the multiple eIF2B 
foci are distinct from eIF2B bodies. In wide-field microscopy, the eIF2B bodies are linear in shape and take 
up one half to one third of the diameter of the cell (Chapter 3, Fig. 3-6D). The multiple foci in the 
ybr159wΔ strains are each single points. Furthermore, a population of eIF2B bodies can be seen vibrating 
and moving in the cell. The vibrations cause the bodies to move in place. While vibrations are occurring, 
the 2B bodies will also transit across the length of the cell in the span of 15 to 30 seconds. The movement 
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of the bodies causes them to constantly move in and out of the focal plane of the microscope. The foci seen 
in the ybr159wΔ null strain do not appear to move within the cell nor do they vibrate in place. 
Colocalization between the eIF2B in the multiple foci and eIF2 in the ybr159wΔ null strain has not been 
performed. If it were found that eIF2 is not present in the foci, it would be difficult to call the foci eIF2B 
bodies. They may represent some new microscopic body or granule only seen in specific mutant strains. 
Until more evidence is available supporting the naming of a new body/granule separate from the already 
known examples (eIF2B bodies, P-bodies, and stress granules), eIF2B foci will serve as an accurate and 
adequate description. Other studies have so far not described the multiple foci phenotype for eIF2B that I 
see in the ybr159wΔ strain. Mark Ashe’s laboratory, who discovered eIF2B bodies, has observed a similar 
phenotype in strains with mutations in the eIF2B subunit GCN3 (M. Ashe, personal communication). The 
fact a similar phenotype is seen in eIF2B mutants suggests the interaction between eIF2B and YBR159W 
and the ER membrane is significant. 
Previous to my work, little evidence existed suggesting that eIF2B interacted with an ER 
membrane protein. Work had shown several other translation factors interact with membranes, including 
eIF4E and eIF4GI interacting with the Golgi (Willett et al. 2011). There is proteomics data suggesting that 
the eIF2 subunit Gcd11p is palmitoylated (Roth et al. 2006; Willett et al. 2011). In eukaryotic organisms, 
the rough ER has translating ribosomes
 
 interacting on the cytosolic face (Merrick W. C.). These examples 
suggest that the interaction between eIF2B and YBR159W is feasible. The rough ER synthesizes both the 
integral-membrane and secreted proteins in the cell. The existence of a mechanism to increase the 
efficiency of translation at the rough ER is possible. The interaction of eIF2B and the ER protein 
YBR159W might be such a mechanism.  
 
The Consequences of the Interaction of eIF2B and YBR159W on Protein Translation and the 
Elongase Pathway 
 My first assumption concerning the interaction between eIF2B and YBR159W was that it 
represented a new form of translation regulation. As my training mainly focuses on protein translation, I 
will attest that there may have been some bias in this hypothesis. My tests were based on the assumption 
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that a ybr159wΔ strain would have deficiencies in protein synthesis. Right away, issues arose in analyzing 
the translation efficiency of the ybr159wΔ mutant strain. Although translation is reduced in the mutant, the 
growth rate of the strains was also slow. A slow growing lip1Δ null strain was employed to see if it also had 
translation defects. Evidence showed a very similar translation phenotype between the two strains, lending 
itself to the possibility that the slowed translation rate of the ybr159wΔ strain could be explained by its slow 
growth rate. The wild-type growth rate fen1Δ and sur4Δ strains have similar VLCFA synthesis defects to 
the ybr159wΔ strain so a VLCFA defect was considered unlikely to account for the translation defects. 
Later immunofluorescence microscopy of the lip1Δ strain revealed that it possessed the same multiple 
eIF2B foci seen in the ybr159wΔ strain. However, the VLCFA mutant fen1Δ and sur4Δ strains has the 
multiple eIF2B foci phenotype but wild-type growth-rates. Translation assays using the fen1Δ and sur4Δ 
strains did not show any defects in protein translation. Whether the slow growth of the ybr159wΔ strain was 
caused by VLCFA synthesis defects or something else would need to be considered 
Two theories could explain the translation defects and slow growth in the ybr159wΔ strain. The 
first theory is that disruptions in VLCFA synthesis in the ybr159wΔ mutant are causing slow growth. While 
examining and quantifying sphingolipid defects in elongase mutants, I observed the consequence of 
ybr159wΔ deletion on sphingolipid content. My data show that the effects of ybr159wΔ deletion on 
sphingolipids are rather modest when compared to other elongase and ceramide synthase mutants. 
Compared to wild-type, the ybr159wΔ strain has reduced IPC 46:0;4 sphingolipid species, about 10% of the 
wild-type IPC 44:0;4, and about 6 times the levels of IPC 42:0;4 (Chapter 2, Fig. 2-6). The ybr159wΔ strain 
also has increased levels of the IPC 38:0;4 species which is not found in wild-type cells. The  sur4Δ strain 
had almost no detectable IPC 46:0;4 or IPC 44:0;4, 12 times the IPC 42:0;4 as wild-type, and large 
amounts of the non-wild-type sphingolipid species IPC 40:0;4 and IPC 38:0;4. When comparing ybr159wΔ 
and sur4Δ sphingolipids, the sphingolipids from ybr159wΔ are similar to wild-type levels. The sur4Δ strain 
did not have a translation defect. Given this evidence, it is not unreasonable to think that the slow growth of 
the ybr159wΔ strain is not caused by defects in VLCFA synthesis. A new theory is needed to explain the 
slow growth and translation defect seen in the ybr159wΔ mutant. One theory could be that the interaction of 
YBR159W with eIF2B is disrupted and causing the translation defect. The translation defect is then 
causing slow growth in the strain. It is currently impossible to rescue elongase mutants with supplemental 
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VLCFAs. Thus, one option to determine the cause of slow growth in the ybr159wΔ deletion mutant is to 
rescue VLCFA synthesis with an exogenous VLCFA ketoacyl reductase. One candidate for rescue is the 
human homologue of YBR159W, HSD17B12 (Moon and Horton 2003). If sphingolipid analysis shows that 
the rescue strain has sphingolipids similar to wild-type and is still slow growing, the theory that the slow 
growth seen in the ybr159wΔ strain is unrelated to VLCFA synthesis would be supported. Affinity 
purifications of ybr159wΔ deletion strains with tagged eIF2B subunits that express HSD17B12 from a 
plasmid followed by mass spectrometry analysis of the purified complexes would confirm whether eIF2B 
also interacts with the human homolog of YBR159W. 
An important point that needs to be tested is whether YBR159W plays a role in translation by 
regulating eIF2B during stress. If YBR159W was important during a specific cellular stress, it would 
follow that the ybr159wΔ strain would be susceptible to that same stress. The ybr159wΔ null strain has 
been shown to be temperature sensitive at 37 ˚C (Beaudoin et al. 2002). This sensitivity could be caused by 
the cell’s inability to regulate translation following an increase in temperature. If this were the case, it 
would be predicted that there would be upregulation of genes involved in the unfolded protein response 
(UPR). In yeast, the serine-threonine kinase and endoribonuclease IRE1 mediates the UPR via the cleavage 
of the mRNA of transcription factor HAC1 (Cox et al. 1993; Mori et al. 1996). UPR activation can be 
easily tested by looking at expression of HAC1. A recent study shows that activation of the UPR in yeast 
and rats leads to increased levels of ceramide in the cell (Epstein et al. 2012). The study shows that one of 
the genes activated by the UPR is a ceramide synthase which is able to rescue the deletion of the ceramide 
synthase LCB1. This illustrates the importance of ceramides and sphingolipids and may be a model for the 
function of the interaction between eIF2B and YBR159W in the cell. It is possible eIF2B is regulating the 
activity of YBR159W enzyme activity and VLCFA synthesis. 
Another question is the unexplained phenomenon of eIF2B being regulated by NADP
+
/NADPH in 
mammals (Dholakia et al. 1986; Oldfield and Proud 1992; Wang et al. 2012). My model presented in 
Figure 2-8 of Chapter II details possible mechanisms for YBR159W regulating eIF2B activity through 
interactions with the NADP
+
/NADPH bound to YBR159W. Obviously, the regulation via dinucleotide 
would first need to be observed in yeast. This could be done with in vitro GEF exchange assays using 
eIF2B containing cell extracts with and without NADP
+
 and NADPH. If yeast eIF2B was under the same 
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regulation, then addition of NADP
+
 should inhibition GEF exchange. Addition of equimolar concentrations 
of NADPH should rescue eIF2B activity if the effect is identical to that in mammals. If this could be shown 
in yeast, testing whether YBR159W is a mediator of the effect would be the next step. For the model to be 
correct, NADP
+
-bound YBR159Wp would need to be able to inhibit eIF2B activity at NADP
+
 
concentrations lower than those used in the previous studies (Dholakia et al. 1986; Oldfield and Proud 
1992). An in vitro assay would use purified eIF2B, YBR159W, and low concentrations of NADP
+
 and test 
if eIF2B GEF activity is lowered. The model would predict that NADP
+
 concentrations closer to 
physiological levels would be sufficient to inhibit eIF2B GEF activity in the presence of YBR159W. 
NADPH would be expected to reverse the inhibition. This would present a very interesting explanation for 
an effect on eIF2B that until now has been unexplainable. 
Though the possibility that YBR159W played a role in translation regulation is still an open 
question, I wanted to examine whether eIF2B had an effect on VLCFA synthesis. The importance of eIF2B 
in protein translation proved to be problematic for these experiments since only the GCN3 subunit of eIF2B 
is nonessential. Regardless, I used the gcn3Δ null strain for examination of sphingolipid levels. My results 
showed that this mutant strain did possess less VLCFA containing sphingolipids when compared to wild-
type (Chapter 2, Fig. 2-6). However, the strain did not have shorter-chain fatty acid-containing 
sphingolipids that would be indicative of an attempt by the cell to compensate for a lack of sphingolipids. I 
interpreted this result to mean the levels of VLCFA containing sphingolipids in the gcn3Δ null strain were 
not indicative of a defect in VLCFA synthesis.  
Originally, I wanted to use temperature-sensitive degron alleles of the essential eIF2B subunits to 
see if they possessed VLCFA synthesis defects. Analysis of degron-tagged GCD2, GCD6, and GCD7 yeast 
strains did not show any sphingolipid defects. To complicate the matter, a degron-tagged YBR159W strain 
also did not show sphingolipid defects. Western blots of the YBR159W degron-tagged strain confirmed 
that YBR159Wp protein was being depleted in as little as 30 min after shifting to the non-permissive 
temperature. For the sphingolipid analysis, cells were grown for up to 8 h at the non-permissive 
temperature. This apparently was not long enough for defects in VLCFA synthesis to affect sphingolipids 
in the YBR159W degron-tagged strain. A longer time course at the non-permissive temperature would be 
needed to determine the amount of time required for VLCFA defects to start to manifest. This time would 
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be used to verify that the GCD2, GCD6, and GCD7 subunits do not play a role in VLCFA synthesis. 
Growth assays showed the GCD2, GCD6, and GCD7 degron-tagged strains were unable to grow at the 
non-permissive temperature. This is an understandable consequence of depleting essential genes but it 
confounds the analysis of the cells for VLCFA synthesis defects. If the cells are not growing, it is unknown 
if there would be any turnover of sphingolipids. A genuine VLCFA synthesis defect could thus be masked 
in the non-growing cells. One of the essential elongase genes such as PHS1 or TSC13 would need to be 
degron-tagged and examined to account for this possibility. With the gcn3Δ null strain not showing a 
VLCFA synthesis defect, I chose not to continue this line of investigation. 
Functional analysis of the eIF2B-YBR159W interaction revealed evidence that translation is 
negatively affected in a ybr159wΔ mutant. My data points to slow growth being a major factor in the 
translation defect. What is not known is the exact mechanism for the slow growth in the null strain. In the 
following section I will discuss the future of research into the interaction between eIF2B and YBR159W. 
 
The Future of eIF2B-YBR159W Research 
A number of experiments are still required to develop a proper understanding of the mechanism 
and function of the eIF2B-YBR159W interaction. For determining the mechanism of the interaction, 
crosslinking followed by affinity purification might reveal other components interacting with eIF2B and 
YBR159W that are transiently associated and fail to be purified by the standard TAP protocol. This could 
also provide evidence that eIF2B is interacting with eIF2 and YBR159W at the same time and would lend 
support to the theory that eIF2B bodies are interacting with YBR159W and the ER membrane. 
Examination of whether eIF2B subunits are palmitoylated in yeast needs to be performed. The 
results would open up a whole new line of questions about the function of eIF2B on the membrane. Is 
eIF2B on the membrane aiding in translation of membrane and secreted proteins? Is its membrane-
association regulated during stress or other cellular events? If so, which palmitoylating and 
depalmitoylating enzymes are responsible? I’m excited by the results of these future experiments. 
Palmitoylation requires specific cysteine residues so mutation of these cysteines could be used to disrupt 
eIF2B membrane association. Quantitative proteomics of yeast membranes from these eIF2B 
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palmitoylation mutants could be used to determine if rough ER associated protein translation is upregulated 
because of eIF2B membrane association. Microarrays or RNA-seq of mRNA present in rough ER bound 
ribosomes would show if there is a change in the proteins being translated at the membrane in the eIF2B 
palmitoylation mutants. 
I have shown that eIF2B in a ybr159wΔ null background forms multiple eIF2B foci. Are these foci 
compositionally identical to eIF2B bodies? Dual labeling colocalization of eIF2 and eIF2B would prove 
this model. FRAP experiments would show if eIF2 is shuttling in and out of individual foci in the same 
manner as eIF2B bodies. Additionally, what other mutations cause the phenotype? My research showed 
that mutants in the elongase pathway cause the phenotype. Do other sphingolipid synthesis mutants cause it 
as well? Does growth rate play a role in the effect? These questions will need to be answered before the 
cause and consequences of the multiple eIF2B foci phenotype can be truly understood. 
Further assays looking at whether the ybr159wΔ null strain has disrupted translation during stress 
are needed. Heat stress starting at 37 ˚C is the most straightforward and promising from a phenotypic 
standpoint. The null mutants already stop growing at this temperature. Translation assays of cells shifted to 
higher temperatures could answer whether the lack of growth is caused by eIF2B and if protein synthesis is 
being inhibited in the mutant. Another set of experiments that may reveal the function for the eIF2B-
YBR159W interaction would be toexamine the effects of NADP
+
/NADPH on eIF2B in the presence of 
YBR159W. My model predicts that NADP
+
 bound YBR159Wp inhibits eIF2B activity at much lower 
concentrations than the concentrations used in previous studies (Dholakia et al. 1986; Oldfield and Proud 
1992). This would implicate that YBR159W has a regulatory function on eIF2B during oxidative stress. 
Finally, examination of whether possible homologs of YBR159W like human HSD17B12 can 
rescue the VLCFA synthesis defects of a ybr159wΔ null strain would allow us to examine the effects of 
ybr159wΔ deletion without VLCFA defects interfering. The first experiment that would need to be 
performed is the successful rescue of wild-type VLCFA synthesis by HSD17B12 in a ybr159wΔ null strain. 
Following a demonstration that HSD17B12 is capable of rescuing the ybr159wΔ VLCFA phenotype, 
affinity purification of mammalian eIF2B complexes followed by mass spectrometry analysis would 
determine if eIF2B-HSD17B12 physically interact. With only 32% sequence identity, I find it unlikely that 
the two would interact. A lack of interaction would then allow us to examine the eIF2B-YBR159W 
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interaction independent of the role of YBR159W in VLCFA synthesis. Translation assays on this 
HSD17B12 rescued ybr159wΔ strain could definitively show YBR159W is affecting protein translation. 
Microscopy of the strain would show if the multiple eIF2B foci phenotype seen in a ybr159wΔ strain is due 
to a defect in VLCFA synthesis or some other cause. 
My research has revealed an intriguing interaction between the translation initiation factor eIF2B 
and the ER membrane bound fatty acid synthesis enzyme YBR159W. I have shown a novel requirement for 
members of the elongase pathway in eIF2B localization. My work has identified a previously unknown 
membrane association for eIF2B that may represent a new form of regulation of protein synthesis of 
integral membrane proteins and secreted proteins. My work  has only scratched the surface of the 
mechanism and role of the eIF2B-YBR159W interaction. Many more experiments are needed to gain a full 
understanding of what is truly taking place during this protein-protein interaction. 
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Abstract 
Using affinity purifications coupled with mass spectrometry and yeast-2-hybrid assays, we show the 
Saccharomyces cerevisiae translation initiation factor complex eIF2B and the very-long-chain-fatty acid 
(VLCFA) synthesis keto-reductase enzyme YBR159W physically interact. The data show the interaction is 
specifically between YBR159W and eIF2B and not between other members of the translation initiation or 
VLCFA pathways. A ybr159wΔ null strain has a slow growth phenotype and reduced translation rate but a 
normal GCN4 response to amino acid starvation. While YBR159W localizes to the ER membrane, 
subcellular fractionation experiments show that a fraction of eIF2B co-fractionates with lipid membranes in 
a YBR159W-independent manner. We show that a ybr159w yeast strain and other strains with null 
mutations in the VLCFA pathway cause eIF2B to appear as numerous foci throughout the cytoplasm. 
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Introduction 
In eukaryotic translation initiation, the initiation factor eIF2 bound with GTP is required to interact 
with the initiator Met-tRNA to form a ternary complex. Following start codon recognition, eIF2-GTP is 
hydrolyzed to GDP and eIF2 dissociates from the translation initiation complex (Preiss and M 2003; 
Sonenberg 2000). eIF2-GDP must exchange GDP with GTP before it can initiate another round of 
translation (Fig. 1A). The initiation factor eIF2B is an essential guanine nucleotide exchange factor (GEF) 
responsible for exchanging GDP for GTP on eIF2 (Pavitt 2005). It is the only known target of eIF2B. This 
exchange reaction is one of the rate limiting steps in translation initiation and is the target of numerous 
signaling pathways in yeast as well as higher eukaryotes (Harding et al. 1999; Olsen et al. 1998; Rowlands 
et al. 1988; Schneider and Mohr 2003; Sood et al. 2000; Wek et al. 1990; Zhan et al. 2004). While the 
majority of eukaryotic GEFs are monomeric, eIF2B is unique among GEFs in that it is composed of 
multiple subunits. In S. cerevisiae, eIF2B is composed of the five subunits GCD1, GCD2, GCN3, GCD6, 
and GCD7. The GCD6 subset is necessary and sufficient for catalytic activity, although at a significantly 
reduced rate compared to the eIF2B complex (Fabian et al. 1997; Gomez and Pavitt 2000; Pavitt et al. 
1998). Co-expression of GCD6 with GCD1 yields similar GEF activity as the eIF2B holoenzyme (Pavitt et 
al. 1998). Of the other 3 subunits, previous studies show GCD2 and GCD7 to be involved in the stability of 
the complex and regulatory activity (Bushman et al. 1993; Pavitt et al. 1998; Pavitt et al. 1997). GCN3 is 
required for eIF2B’s role in the GCN4 stress response pathway (Hinnebusch 1985; Kubica et al. 2006). 
With the exception of GCN3, all of the yeast eIF2B genes are essential (Pavitt 2005).  
Recent studies show that a significant fraction of yeast eIF2B resides in distinct foci in the 
cytoplasm known as “2B bodies” (Campbell and Ashe 2006; Campbell et al. 2005). GFP fluorescence 
microscopy shows the bodies contain both eIF2B and eIF2. The initiation factor eIF2 appears to shuttle in 
and out of the 2B bodies (Campbell et al. 2005). The shuttling occurs quickly during logarithmic growth 
and slower following disruptions of translation initiation. The 2B bodies are thought to be sites of eIF2B’s 
GEF activity.  
In eukaryotes two distinct complexes are responsible for the synthesis of fatty acids (Rossler et al. 
2003; Stoops and Wakil 1978). The cytoplasmic fatty acid synthase complex (FAS) elongates fatty acids 
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from 2 to 18 carbons in length in a four reaction cycle. A second fatty acid synthesis complex, the elongase 
complex, is responsible for the elongation of fatty acids from 18-26 carbons (Fig. 1B) (2). The longer chain 
fatty acids are known as very-long-chain fatty acids (VLCFA). In S. cerevisiae, VLCFAs make up 1-5% of 
total fatty acids (Dittrich et al. 1998; Welch and Burlingame 1973) and the predominant VLCFA is 26 
carbons long (Dickson et al. 2006). The VLCFAs are crucial for the formation of lipid rafts in yeast (Gaigg 
et al. 2006). Although the FAS and elongase complexes share very similar catalytic steps, different sets of 
enzymes catalyze the elongation reactions in the two pathways (Fig. 1B). The elongase complex’s enzymes 
localize to the endoplasmic reticulum membrane (ER) (Abraham et al. 1961; Klein 1957). The complex 
receives fatty acids from the cytoplasmic FAS complex and elongates them to VLCFAs (Tehlivets et al. 
2007). Previous studies show YBR159W, also known as IFA38, is a keto-acyl reductase required for the 
second step in the yeast elongase’s pathway (Fig. 1B) (Beaudoin et al. 2002; Han et al. 2002). A ybr159w 
null yeast strain has a slow growth phenotype and altered VLCFA lipid composition (Han et al. 2002). 
Though both FEN1 and SUR4 catalyze the first enzymatic step in the elongase pathway, they are not 
redundant and are responsible for different chain-length precursor fatty acids. FEN1 prefers 20 carbon long 
precursors while SUR4 has a broader range of chain-length specificity but is required to convert 24 carbon 
long VLCFAs to their final 26 carbon long form (Oh et al. 1997). The elongase enzymes TSC13 and PHS1 
are both essential (Schuldiner et al. 2005; Tuller et al. 1999). In yeast, newly synthesized VLCFAs are 
predominately incorporated first into ceramide and eventually into sphingolipids (Dickson et al. 2006). 
LIP1 is a component of the ceramide synthase complex required for the formation of ceramide from a 
VLCFA and a sphingoid base (Vallee and Riezman 2005). Each sphingolipid contains one 24-26 carbon 
long VLCFA in addition to the long-chain base and head group (Dickson 2008).  
The ER in budding yeast is composed of the classical membrane network connected to the nuclear 
envelope as well as a network of tubules known as the cortical ER that extend throughout the cell and 
encase the inner face of the entire plasma membrane (Preuss et al. 1991). In microscopy, the cortical ER 
can often be mistaken as the plasma membrane itself (Preuss et al. 1991). While the bulk of yeast’s cortical 
ER lies under the plasma membrane, in most metazoan cells, including mammalian cells, the ER is 
continuous with the nuclear envelope and forms a network of tubules throughout the cytoplasm that closely 
align with microtubules (Lowe and Barr 2007). 
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Using protein affinity purifications coupled with mass spectrometry and yeast 2-hybrid analysis, 
we provide direct evidence for an interaction between the S. cerevisiae eIF2B complex and YBR159W. We 
find that in wild-type cells eIF2B co-localizes with lipid membranes and that this membrane co-localization 
is not altered in a ybr159wΔ strain. Our experiments show that a ybr159wΔ mutation causes eIF2B to 
appear as numerous foci. While ybr159w null cells have a lower rate of translation, the appearance of 
numerous eIF2B foci does not appear to correlate with the cell’s translation rate. Other VLCFA mutant 
strains showing multiple eIF2B foci have WT translation rates. Overall, this work shows a novel interaction 
between the  essential yeast translation initiation factor and the  fatty acid synthesis enzyme YBR159W.  
 
MATERIALS AND METHODS 
Strains and Media 
All yeast media, growth, and genetic manipulation was done using standard techniques (David C. Amberg 
2005). To create the ybr159wΔ strain AL401, the kanamycin resistance cassette from plasmid pFa6a-
kanmx6 was first amplified with primers CGTACGCTGCAGGTCGAC and 
ATCGATGAATTCGAGCTCG. Using the PCR double fusion approach (David C. Amberg 2005), the 
primers CGGATTTGGAAGTCCTTTATAG, 
GTCGACCTGCAGCGTACGCATTTCTTAAGCTGCACCG, 
CGAGCTCGAATTCATCGATTAGAATTATCGTTCTCG, and GGACTTGGTCCTTCCACC were used 
to expand the YBR159W genomics flanking the kanmx6 cassette. The YBR159W disruption cassette was 
transformed into strain BY4741 and transformants were selected on YPD + 300 mM G418 plates and 
screened using Western blotting and -YBR159W polyclonal antibodies. Candidate BY4741 ybr159wΔ 
strains were crossed with the HIS+ strain H1511 and sporulated to create the ybr159wΔ null strain AL401. 
An isogenic wild type HIS+ control strain AL400 was selected from the same sporulation. The lip1Δ strain 
RH5994 was kindly provided by the Howard Riezman Laboratory (Vallee and Riezman 2005). The gcn3Δ, 
fen1Δ, and sur4Δ deletion strains were obtained from the MATa yeast deletion collection (Winzeler et al. 
1999). The fen1Δ and sur4Δ deletion strains from the MATa yeast deletion collection were mated with the 
HIS+ strain H1511 and sporulated to create the fen1Δ and sur4Δ strains, AL413 and AL414 respectively. 
The TAP tagged strains were obtained from the yeast TAP-tagged library (Ghaemmaghami et al. 2003). 
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The GFP tagged strains were obtained from a GFP-tagged yeast library (Huh et al. 2003). To make the 
ybr159wΔ, GCD7-GFP strain, we mated the ybr159wΔ strain AL401 with the GCD7-GFP strain AL429 
from the GFP-tagged yeast library and sporulated the diploids to obtain the ybr159wΔ, GCD7-GFP strain 
AL403. The yeast 2-hybrid activation-domain strains derived from parent strain pJ69 Ra, the binding-
domain parent strain pJ69-4alpha, and yeast 2-hybrid plasmids were obtained from the Yeast Resource 
Center (University of Washington) (James et al. 1996). Using the protocol previously described by the 
Yeast Resource Center (30), the AL408 (YBR159W-BD), AL409 (GCD1-BD), AL410 (GCD2-BD), 
AL411 (GCD6-BD), and AL412 (GCD7-BD) strains expressing yeast 2-hybrid binding-domain tagged 
alleles were generated from parent strain pJ69-4alpha. Briefly, initial forward and reverse primers were 
used to PCR the target gene from yeast genomic DNA. The PCR product and the common forward and 
reverse 2-hybrid primers were used for a second round of PCR to extend the flanking sequences. The 2
nd
 
PCR product and the PvuII and NcoI linearized pOBD2 plasmid were co-transformed into yeast strain 
PJ69-4alpha and plated on SC-trp to select for recombinants fusing the target gene to the GAL4 binding 
domain. Tables 1, 2, and 3 list all strains, plasmids, and primers used in this study. 
 
Plasmids 
The plasmid pOBD2 used in generating yeast 2-hybrd binding-domain strains has been previously 
described  (Hudson et al. 1997). To create a plasmid expressing endogenous level of YBR159W, we used 
PCR to amplify the YBR159W gene along with 600 bp of the genomic region upstream of the gene’s start 
codon and the YBR159’s stop codon using the primers 
CACCATGGTTTTTGTGACTTTACCTATAAATAGTACACAAC and 
CTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGGC. The PCR product was cloned into the 
pENTR entry vector using Directional TOPO Cloning (Invitrogen) to create pENTR-YBR159W 5’ UTR-
YBR159W. The YBR159W cassette was transferred to the pAG415GAL-ccdB yeast destination vector 
using LR Clonase recombination (Invitrogen) (Alberti et al. 2007) . To eliminate possible promoter 
interference, the vector’s endogenous GAL promoter was deleted using the restriction enzymes SacI and 
SpeI and replaced with the primer insert GGGAGCTCCATACTGATTAGTACACTAGTGG and 
CCACTAGTGTACTAATCAGTATGGAGCTCCC to create the YBR159W expression plasmid YCp-
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YBR159W. To create a plasmid expressing RFP-tagged YBR159W, the YBR159W ORF without the stop 
codon was amplified by PCR and cloned into the pENTR vector creating pENTR-YBR159W. The 
YBR159W ORF insert was transferred by recombinational cloning into the pAG415GPD-ccdB-dsRed 
vector (Addgene) to create the final expression plasmid YCp-YBR159W-dsRed. All plasmids used in this 
study are listed in Table 2. 
 
Antibodies 
The -YBR159W polyclonal antibodies were generated by inoculation of a rabbit with the synthetic 
peptide CETVKAENKKSGTRG (Covance). The peptide was covalently bound to cyanogen bromide beads 
(Sigma-Aldrich) to affinity purify -YBR159W from rabbit whole blood. Polyclonal antibodies to yeast 
SUI2 were kindly provided by Dr. Tom Dever. Polyclonal antibodies to yeast GCD6 and GCD1 were 
kindly provided by Dr. Allan Hinnebusch. The mouse -DPM1 was obtained from Molecular Probes. 
Antibodies to yeast TDH1, 2, 3 were obtained from Millipore. The antibody to yeast RPL32 was kindly 
provided by Dr. Jonathan Warner. 
 
Mass Spectrometry-Proteomics 
For yeast TAP experiments, TAP-tagged protein complexes were purified as previously described (Powell 
et al. 2004; Sanders et al. 2002). For each TAP strain, a 2 L culture was grown to OD600 1-2 in YPD. The 
purified TAP complexes were reduced with 1/10 volume of 50 mM DTT at 65 °C for 5 min, and cysteines 
were alkylated with 1/10 volume of 100 mM iodoacetamide at 30 °C for 30 min. The proteins were 
digested overnight at 37 °C with modified sequencing grade trypsin at 25:1 subtrate:enzyme ratio 
(Promega, Madison, WI). Proteins were identified using Multidimensional Protein Identification 
Technology (MudPIT) and a LTQ linear ion trap mass spectrometer (ThermoFisher) (Link et al. 1999; Link 
et al. 2005). A fritless, microcapillary (100 μm-inner diameter) column was packed sequentially with 12 cm 
of 5 μm C18reverse-phase packing material (Synergi 4 μ Hydro RP80a, Phenomenex) and 3 cm of 5 μm 
strong cation exchange packing material (Partisphere SCX, Whatman). The entire trypsin-digested samples 
were loaded onto the biphasic column equilibrated in 0.1% formic acid, 2% acetonitrile, which was then 
placed in-line with an LTQ linear ion trap mass spectrometer. An automated six-cycle multidimensional 
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chromatographic separation was performed using buffer A (0.1% formic acid, 5% acetonitrile), buffer B 
(0.1% formic acid, 80% acetonitrile) and buffer C (0.1% formic acid, 5% acetonitrile, 500 mM ammonium 
acetate) at a flow rate of 300 nL/min. Cycles 1−6 consisted of 3 min of buffer A, 2 min of 0−100% buffer 
C, 5 min of buffer A, followed by a 60-min linear gradient to 60% buffer B. In cycles 1−6, the percent of 
buffer C was increased incrementally from 0, 15, 30, 50, 70, and 100% in each cycle. During the linear 
gradient, the eluting peptides were analyzed by one full MS scan (200−2000 m/z), followed by five MS/MS 
scans on the five most abundant ions detected in the full MS scan while operating under dynamic 
exclusion.  
For proteomic analysis of membrane float experiment’s membrane and cytoplasmic fractions, a 
modified MudPIT protocol was utilized. Purified yeast protein and subcellular complexes were processed 
and analyzed essentially as described above except a 12 step MuDPIT experiments was used with the salt 
pulses of 0mM, 25mM, 50mM, 75mM, 100mM, 150mM, 200mM, 250mM, 300mM, 500mM, 750mM and 
1M ammonium acetate. Eluting peptides were analyzed using an LTQ-OrbitrapXL mass spectrometer with 
preview mode and monoisotopic precursor selection enabled. The top 10 precursors ions based on intensity 
were fragmented using CID in the ion trap using 35% normalized collision energy. Dynamic exclusion was 
enabled for 180s with repeat count of 1 at 30 s duration, list size of 500, mass tolerance of 10 ppm. Mass 
spectrometry data was analyzed as previously described (McAfee et al. 2006). 
 
GFP Affinity Purification 
Two liters of the GCD7-GFP, ybr159wΔ strain AL403,GCD7-GFP strain AL429, and untagged ybr159wΔ 
strain AL401 were grown to OD600 1-2 in YPD. Yeast cells were harvested by centrifuging at 1500 xg for 5 
min, and resuspended in 10 mL ice-cold NP-40 lysis buffer (6 mM Na2HPO4, 4 mM NaH2PO4, 1% NP-40, 
150 mM NaCl, 2 mM EDTA, 50 mM NaF, 4 µg/mL leupeptin, 0.1 mM Na3VO4). Cells were lysed for 10 
min with glass beads in NP-40 lysis buffer. The lysates were centrifuged at 500 xg for 5 min. The cleared 
supernatant was brought up to 25 mL with ice-cold lysis buffer. Five hundred µL bed volume of protein 
A/G agarose beads (Thermo Scientific) and 50 µg of anti-GFP antibody (ThermoFisher) were added 
simultaneously and allowed to incubate for 1 h at RT. The beads were centrifuged at 300 xg for 5 min, 
transferred to a Poly Prep Chromatography Column (Bio Rad) and washed at 4
o
C with 50 column volumes 
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of wash buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% NP-40). Protein digestion was carried out directly 
on the agarose beads. The beads were suspended in 1 mL of digestion buffer (10 mM Tris pH 8.0, 150 mM 
NaCl, 0.5 mM EDTA, 1 mM DTT) and transferred to a 1.5 mL microcentrifuge tube. The resuspended 
beads were trypsin digested as described for yeast TAP complexes. After digestion the beads were 
centrifuged at 13,000 xg for 1 min and the supernatant was transferred to a fresh microcentrifuge tube. 
MudPIT was performed identical as described for the TAP purifications. Mass spectrometry data was 
analyzed as previously described using Cn scoring filters of 1.5 (+1), 3.5 (+2) and 3.5 (+3) (McAfee et al. 
2006).  
 
Fatty Acid Profiling 
The protocol for extracting lipids from yeast cells was adapted from Ejsing et al. 2008 (Ejsing et al. 2009). 
Each yeast strain was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. Fifty mg of wet weight yeast cells 
was incubated in 200 μL PBS with 100µg/mL lyticase (Sigma) for 1 h at 37°C. Next, 990 μL of 
chloroform/methanol (17:1 V/V) was added and incubated for 2 h at 37°C. The lower organic layer was 
collected and vacuum evaporated. Next, 990 μL of chloroform/methanol (2:1 V/V) was added to the upper 
aqueous layer and incubated for 2 h at 37°C. The lower layer was collected and pooled with the evaporated 
fraction taken from the first extraction and vacuum evaporated. The sample was solubilized with 100μL 
chloroform/methanol (1:2 V/V) and mixed 1:1 with 0.4 mM methylamine in methanol. Samples were 
directly injected into an ESI-LTQ OrbitrapXL at 2 μL/min and precursor ions were scanned using the 
Orbitrap analyzer at a resolution of 30,000 in negative ion mode. Using published inositolphosphoceramide 
(IPC) precursor m/z values, precursor ion peaks were identified using a mass tolerance of 10 ppm (Ejsing et 
al. 2006; Sud et al. 2007). Using inositolphosphoceramide (IPC) structure data at the LIPID MAPS 
Lipidomics Gateway (Sud et al. 2007), the following theoretical precursor [M-H]
-
 ion m/z values were used 
to identify the IPC ions in the high resolution scan: IPC 46:0;4 (980.717),  IPC 44:0;4 (952.686), IPC 
42:0;4 (924.655), IPC 40:0;4 (896.623), IPC 38:0;4 (868.592). To validate the identity of these IPC ions, 
the IPC precursor ions were fragmented by CID in the linear ion trap. The observed m/z values of the 
MS/MS fragment ions for each IPC precursor was compared to predicted [ceramide phosphate – H2O]
-
 and 
[ceramide phosphate]
-
 m/z values at a mass tolerance of 0.1 Da. The following theoretical m/z [ceramide 
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phosphate – H2O]
-
 and [ceramide phosphate]
-
 fragment ions were used to validate the IPC lipids: IPC 
38:0;4 (688.53, 706.54), IPC 40:0;4 (716.56, 734.57), IPC 42:0;4 (744.59, 762.60), and IPC 46:0;4 (800.65, 
818.66). In addition, to validate the identification of IPC 44:0;4, the fragmentation spectrum of precursor 
m/z 952.68 at a mass tolerance of 0.1 Da was compared to the previously published fragment ions 
[ceramide phosphate – H2O]
-
, m/z 772.62 and [ceramide phosphate]
-
, m/z 790.63 values (Ejsing et al. 2006). 
To compare the observed abundance for each IPC species between strains, the precursor ion signal intensity 
for each identified IPC species was normalized to the signal intensity of the m/z 835.53 base peak 
corresponding to the phosphatidyl inositol (PI) species PI 16:1-18:0 and PI 16:0-18:1. 
 
Growth Rate Analysis 
Yeast strains were grown overnight at 30 
o
C in YPD. Relative cell number was measured at OD660 using a 
Beckman DU 530 Spectrophotometer. Cells were diluted in 50 mL of fresh YPD to ~0.05 OD660 units/mL. 
Individual strains were grown at 30 
o
C and an OD660 measurement was taken every 2 h. The formula for 
used for converting OD660 readings to cell numbers was y = 1.1564x
3
 - 0.6815x
2
 + 1.3996x with y = cell 
number/mL and x = OD660 value (David C. Amberg 2005). Cell doubling time was determined by plotting 
the growth curve for each strain and measuring the maximum rate of cell growth during logarithmic 
growth. 
 
Yeast 2-Hybrid 
Mating type A strains containing AD tagged alleles and mating type  strains containing BD tagged alleles 
have been previously described (Fields and Song 1989). The A and  strains were allowed to mate in liquid 
YPD at 30
o
C overnight. Relative cell number was determined by measuring OD660 and 4 μL of a 1x10
7
 
cells/mL solution was plated onto SC -leu, -trp, -his, 1.5 mM 3-AT agar plates. Plates were scanned after 
48 h.  
 
Membrane Flotation 
Membrane flotation of yeast extracts was performed as previously described (Bergmann and Fusco 1988). 
Fifty mL of each yeast strain was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. The cells were lysed with 
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glass beads in ice-cold breaking buffer (30 mM Tris pH 7.0, 1 mM EDTA). The lysate was cleared by 
centrifugation at 500 xg for 3 min. Lysate corresponding to 10 OD660 units of cells in 222 μL was mixed 
with 1778 μL of ice-cold 90% sucrose (wt/vol), 10 mM Tris pH 7.0 solution. The 2 mL of lysate/sucrose 
solution was transferred to the bottom of a 14 x 89 mm ultracentrifuge tube (Beckman, cat. # 344059) and 
layered with 6 mL of 65% sucrose, 10mM Tris pH7.0 and then 3 mL of 10% sucrose, 10mM Tris pH 7.0. 
The tubes were centrifuged in a Beckman SW-41 rotor at 24,000 rpm for 18 h. Individual 1.5 mL fractions 
were collected from the top of the gradient and the proteins TCA precipitated. Ten percent of each fraction 
was used for SDS-PAGE and Western blotting. 
 
Membrane Flotation Fractions Affinity Purifications 
For each TAP strain, a 1 L culture was grown to OD600 ~1 in YPD and the cells were split into 6 fractions. 
Each cell fraction was separated using the membrane flotation gradients as described above. The 10%-65% 
sucrose interface layer and 80% sucrose layer from each gradient were collected and pooled. TAP 
purification was performed as previously described up to TEV protease cleavage (Powell et al. 2004; 
Sanders et al. 2002).  
 
GCN4-LacZ Induction 
The yeast reporter plasmid p180 containing the GCN4 5′ untranslated region (UTR) coupled to a -
lacZ reporter has been previously described (Hinnebusch 1985). Yeast strains transformed with p180 were 
grown overnight at 30 
o
C in SC-ura. Cultures were diluted 1:10 and allowed to continue growing for 2 h in 
SC -ura, -his. Cells were spun down and split into two tubes containing 10 mL of SC -ura, -his media. A 1 
M 3-AT solution was added to the starvation tube to a final concentration of 10 mM. The cells continued to 
grow for 4 h at 30 
o
C. -galactosidase assays were performed as previously described (Rose and Botstein 
1983). Cells were centrifuged at 1500 xg for 5 min and lysed with glass beads in 1 mL of ice-cold breaking 
buffer (100mM Tris pH 8.0, 1mM DTT, 20% glycerol). Twenty microliters of whole cell extract was added 
to 900 μL of Z buffer (16.1 g/L Na2HPO4-7H2O, 5.5 g/L NaH2PO4-H2O, 0.75 g/L KCl, 0.246 g/L MgSO4-
7H2O, 2.7 mL/L βME, pH 7.0) and incubated at 28 
o
C for 5 min. The reaction was initiated by adding 200 
μL of 4 mg/mL ONPG in Z buffer and incubated at 28 oC. After the reaction turned a pale yellow color, 0.5 
118 
 
mL of 1 M Na2CO3 was added. LacZ expression was determined by measuring the absorbance at 420 nm 
using a Beckman DU 530 Spectrophotometer. Protein concentration of the extracts was determined using 
the BioRad Dc protein assay. LacZ specific activity was determined using the equation: (OD420 x 
1.7)/(0.0045 x protein conc. (mg/mL) x extract volume(mL) x time (min)) (David C. Amberg 2005). 
Values were normalized to wild type. 
 
35
S-Met Incorporation 
Overnight cultures of yeast grown in YPD were diluted 1:10 in 10 mL of SC-Met and grown for 3 h at 30 
o
C. The OD660 of the culture was measured to determine cell numbers. For labeling, 
35
S-methionine (MP 
Biomedicals) was added to 5 mL of the cell culture to a final concentration of 10 μCi/mL. Samples were 
incubated with shaking for 30 min at 30 
o
C. Labeling was stopped by the addition of 1/10 volume 100% 
TCA and heating to 100 
o
C for 30 min. TCA precipitates were collected on GFC filters (Whatman) then 
washed sequentially with 5 mL each of 10% TCA and 95% ethanol. Filters were then placed in 5 mL 
EcoLume scintillation fluid (MP Biomedicals) and 
35
S-Met incorporation was measured using a Beckman 
LS 6500 scintillation counter. Values were reported as (Counts per minute) / (OD660 unit). 
 
Microscopy 
Epifluorescent microscopy was performed using live yeast cells grown in SC media to an OD660 1.0-1.5 at 
30 
o
C. Cells were mounted on slides and visualized using a Zeiss Axiophot brightfield microscope with a 
63x / 1.40 Plan-Apochromat oil DIC lense. Images were analyzed with MetaMorph imaging software 
(Molecular Devices). Live yeast cells imaged using confocal microscopy were grown in SC media to an 
OD660 1.0-1.5 at 30 
o
C., Cells were visualized with a Zeiss LSM 510 META inverted confocal microscope 
using a 63x / 1.40 Plan Apochromat oil immersion lens. Microscopic images used for quantitative analysis 
were analyzed using ImageJ imaging software (Schneider et al. 2012). To quantify the percentage of 2B 
bodies that co-localized with the ER, a 2B body was judged to be co-localized with the ER only if the 2B 
body signal overlapped with an area of YBR159W at least half as bright as the brightest YBR159W signal 
seen in the cell. Cells were pooled into groups of approximately 25 cells to calculate a standard deviation 
for the percentage of 2B bodies co-localized with the ER. The bright regions of the ER were subtracted 
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from the total area of the cell minus the nuclear area to determine the fraction of the cell taken up by the 
ER. The compound 3,3’-dihexyloxacarbocyanine iodide (DiOC6(3)) was used to stain and image the 
membranes of wild type strain AL400, and  ybr159wΔ strain AL401 as previously described (Terasaki et al. 
1984). Yeast cells were incubated in media containg 2.5 µg/mL DiOC6(3) for 10 min before imaging.  
 
Polysome Profiling 
Polysome analysis was performed as previously described (Gerbasi et al. 2004). Yeast strains were grown 
in YPD to an OD660 of ~1. Cells were lysed with glass beads in ice-cold breaking buffer (10 mM Tris pH 
7.0, 100 mM NaCl, 30 mM MgCl2, 50 μg/mL cycloheximide, 200 μg/mL heparin). The crude lysate was 
cleared by centrifugation at 500 xg for 3 min and 20 OD660 units of cells was loaded on top of a 7 to 47% 
continuous sucrose gradient (wt/vol) cast in 50 mM Tris pH 7.0, 50 mM NH4Cl, 12 mM MgCl2, 50 μg/mL 
cycloheximide in a 14 x 89 mm ultracentrifuge tube (Beckman). Gradients were centrifuged in a Beckman 
SW-41 rotor at 14,000 rpm for 18 h at 4 
o
C. Absorbance profile at 254 nm was collected from the gradients 
as previously described (16). One mL fractions were used for Western blotting. Monosome and polysome 
peak areas were determined using ImageJ software (Schneider et al. 2012). A moving baseline for each 
profile was established by connecting the minima between each peak and the area under each peak above 
this line was calculated. The polysome peak areas were summed and compared to the monosome peak area.  
 
 
Subcellular Fractionation 
WT yeast strain AL400 was grown to OD660 1.0-1.5 in YPD media at 30 
o
C. To isolate subcellular 
fractions, 45 OD660 units of cells were split into three samples: control, puromycin treatment, and EDTA 
treatment. The control sample was lysed using glass beads in 750 µL of ice-cold control buffer (10 mM 
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 10 mM KCl, 30 mM MgCl2). The puromycin and EDTA 
treatment samples were lysed using glass beads in 750 µL of ice-cold ribosome dissociation buffer (10 mM 
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA). The control sample was diluted in 750 µL of control buffer. 
The puromycin treated sample was diluted with750 µL of ribosome dissociation buffer containing 2 mM 
puromycin to a final concentration of 1 mM. The EDTA-treated sample was diluted in Ribosome 
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dissociation buffer (20mM EDTA) to a final concentration of 10 mM EDTA. Lysates were gently mixed at 
RT for 30 min to facilitate dissociation of ribosomes from the ER. Lysates were centrifuged at 900 xg for 5 
min, and the supernatant was centrifuged at 11,000 xg for 20 min. The soluble fraction was recovered from 
the supernatant. The pellets was resuspended in either control buffer (1 mM puromycin, 10 mM Tris pH 
8.0, 100 mM NaCl, 1 mM EDTA) or EDTA solution (10mM EDTA, 10 mM Tris pH 8.0, 100 mM NaCl, 1 
mM EDTA) and centrifuged at 11,000 xg for 20 min. The pellets were resuspended in 1.5 mL of 
resuspension buffer (1 mM puromycin, 10 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% SDS) and 15 
µL of each fraction was used for Western blotting. 
 
RESULTS 
In a tandem affinity purification proteomics screen of S. cerevisiae translation initiation factors 
followed by liquid mass spectrometry analysis, we discovered that all five subunits of eIF2B co-purified 
with the VLCFA enzyme YBR159W (Link et al, in preparation; and Fig. 2A). Subsequent LC-MS/MS 
analysis of TAP-YBR159W affinity purification showed YBR159W co-purified with all five subunits of 
the eIF2B complex and several members of the VLCFA synthesis pathway. In this study, additional TAP 
experiments examined whether other members of the VLCFA synthesis pathway also interact with eIF2B 
subunits. With the exception of YBR159W, our data showed that other members of the VLCFA synthesis 
pathway did not interact with eIF2B (Fig. 2A). To rule out the possibility that the YBR159W-eIF2B 
interaction was due to an artifact of the TAP-tagged strains, we performed a GFP affinity purification using 
the GCD7-GFP strain AL429. LC-MS/MS analysis identified YBR159W co-purifying with all five 
subunits of eIF2B (Fig. 5E). Next, we utilized yeast 2-hybrid to identify interactions between eIF2B 
subunits and YBR159W. The activation-domain tagged strains pOAD(YBR159W), pOAD(GCD1), 
pOAD(GCD2), pOAD(GCN3), pOAD(GCD6), pOAD(GCD7), pOAD(SUI2), and pOAD(TDH1) were 
mated with binding-domain tagged strains AL408 (YBR159W), AL409 (GCD1), AL410 (GCD2), AL411 
(GCD6) and AL412 (GCD7). The positive interactions between different subunits of the eIF2B complex 
validated the experiment’s ability to detect previously described interactions (Fig. 2B). The 2-hybrid 
analysis showed that YBR159W positively interacted with both the GCD6 and GCD7 subunits of eIF2B 
(Fig. 2B). 
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The GFP-tagged YBR159W strain AL425 showed the YBR159W protein localizes to the ER 
membrane using epifluorescence microscopy (Fig. 3A). DPM1 encodes the enzyme dolichol phosphate 
mannose synthase which adds a mannose moiety to dolichyl phosphate on the cytosolic side of the 
endoplasmic reticulum (Orlean 1990; Orlean et al. 1988). DPM1 is an ER membrane protein unrelated to 
VLCFA synthesis or utilization (Orlean et al. 1988). Confocal microscopy using the FEN1-GFP, 
YBR159W-RFP strain AL422 and the DPM1-GFP, YBR159W-RFP strain AL423 confirmed that RFP-
tagged YBR159W expressed from a low-copy plasmid co-localizes with the VLCFA protein FEN1 and ER 
protein DPM1 (Fig. 3B).  
We constructed a ybr159wΔ yeast strain AL401 to examine the null phenotype. The mutant strain 
had a slow growth phenotype (Fig. 3C) and was temperature sensitive at 37
o
 C (data not shown). To show 
the slow growth phenotype was due to the deletion of ybr159wΔ and not a second site mutation in the 
strain, the ybr159wΔ null yeast strain was complemented in strain AL402 expressing YBR159W from the 
low-copy plasmid YCp-YBR159W (Fig. 3C). Our results agreed with previous studies using an unrelated 
ybr159wΔ null strain (Beaudoin et al. 2002).  
Previous work has shown that disruption of VLCFA utilization in yeast causes abnormal 
formation of lipid membranes (Schneiter et al. 2004). The compound 3,3’-dihexyloxacarbocyanine iodide 
(DiOC6(3)) is a lipophilic dye used to label a variety of lipid membranes (Terasaki et al. 1984). We used 
DiOC6(3) to stain membranes of wild type strain AL400,  ybr159wΔ strain AL401, and the VLCFA mutant 
strains AL413 (fen1Δ), and AL414 (sur4Δ), and the ceramide synthase mutant strain RH5994 (lip1Δ). The 
ybr159wΔ, fen1Δ, sur4Δ, and lip1Δ null strains all displayed disrupted lipid membranes using 
epifluorescence imaging (Fig. 4). This supported previous work showing that VLCFAs are important for 
proper membrane formation (Schneiter et al. 2004). 
To determine if YBR159W has a role in translation, we examined if the ybr159wΔ strain AL401 
causes a defect in protein synthesis. We used 
35
S-methionine incorporation to quantify the global 
translation rate. The 
35
S-methionine incorporation experiments showed that the ybr159wΔ strain has a 
reduced translation rate (Fig. 5A). The ceramide synthase mutant lip1Δ strain RH5994 also showed a 
reduction in the rate of translation. The lip1Δ strain had a similar slow growth rate as the ybr159wΔ strain. 
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However, the VLCFA mutant strains AL413 (fen1Δ) and AL414 (sur4Δ) showed no reduction in 
translation or growth rates (Fig. 5A).  
Next, we performed polyribosome profiling to examine the distribution of 40S, 60S, 80S, and 
polyribosomes in the ybr159wΔ strain AL401. Compared to the WT strain, we observed the polysome 
profiles for the ybr159wΔ strain showed an increase in the 80S monosome peak and a decrease in polysome 
peaks (Fig. 5B). As expected, the complemented ybr159wΔ strain AL402 showed a similar polysome 
profile to WT. To normalize and quantify the observed differences in the peak areas, the ratio of the 80S 
monosome to polysome peak areas was calculated. The monosome:polysome ratio significantly increased 
for the ybr159wΔ strain compared to the WT and complemented strains (Fig 5D). Polysome profiles of the 
lip1Δ strain RH5994 showed similar defects to the ybr159wΔ strain (Fig. 5B and 5D). Polysome profiling 
of the fen1Δ strain AL413 and sur4Δ strain AL414 showed no noticeable differences from wild type strain 
AL400 (Fig. 5B and 5D). These polysome distributions were consistent with the reduced global translation 
rates seen previously in the 
35
S-methionine labeling experiments. 
We next examined ybr159wΔ’s effect on eIF2B’s activity. We used a GCN4-lacZ expression 
assay to examine GCN4 expression during the starvation response (Hinnebusch 1994). Strains AL400 
(HIS+ control strain), AL401 (ybr159wΔ), AL402 (ybr159wΔ +YCp-YBR159W), AL413 (fen1Δ), AL414 
(sur4Δ), RH5994 (lip1Δ), H2557 (gcn2) and F98 (gcd1) were transformed with the GCN4-lacZ reporter 
plasmid p180. Our results showed that the ybr159wΔ, fen1Δ, sur4Δ, and lip1Δ null strains did not affect the 
induction of GCN4 during amino acid starvation (Fig. 5C). This suggested that eIF2B’s role in the 
regulation of GCN4 response is not affected by the ybr159wΔ null or other VLCFA pathway mutation.  
We next tested if the ybr159wΔ mutation affected the composition of the eIF2B complex. Using 
the ybr159wΔ, GCD7-GFP tagged strain AL403, the untagged ybr159wΔ strain AL401, and the GCD7-
GFP strain AL429, we performed GFP affinity purifications and LC-MS/MS mass spectrometry analysis of 
the affinity purified complexes. All five subunits of eIF2B were identified in the ybr159wΔ, GCD7-GFP 
strain and the GCD7-GFP strain (Fig. 5E). No subunits of eIF2B were identified in the untagged ybr159wΔ 
control strain AL401. These results suggested that the composition of eIF2B is not dependent upon 
presence of YBR159W.  
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While the composition of eIF2B appeared to be independent of YBR159W, the consistently lower 
number of identified peptides for each eIF2B subunit from the mass spectrometry data for the GCD7-GFP, 
ybr159wΔ null strain compared to the GCD7-GFP strain suggested that the cellular abundance of eIF2B 
was lower in the ybr159wΔ null background (Fig. 5E). To determine if the cellular abundance of eIF2B is 
lower in a ybr159wΔ null strain, Western analysis was performed on the yeast strains used in the GCD7-
GFP affinity purification of eIF2B complexes. Lack of signal for YBR159W in the ybr159wΔ strains 
confirmed the expected null genotype (Fig. 5F). In concordance with the mass spectrometry results, the 
GFP7-YFP, ybr159wΔ strain had a lower abundance of eIF2B compared to GCD7-GFP strain (Fig. 5E). To 
validate this observation in untagged strains, Western analysis was also performed using the WT strain 
AL400 and the untagged ybr159wΔ null strain AL401. The ybr159wΔ null strain again showed lower 
abundance of eIF2B compared to the WT strain (Fig. 5F)  
We next tested whether eIF2B played a role in VLCFA synthesis. Previous studies had shown a 
ybr159wΔ null strain had an altered VLCFA lipid composition (Han et al. 2002). Since four of the five 
subunits of eIF2B are essential, we used a gcn3Δ strain AL424 to test for VLCFA defects. WT strain 
AL400, ybr159wΔ strain AL401, ybr159wΔ rescue strain AL402, sur4Δ strain AL414, and lip1Δ strain 
RH5994 were used as positive and negative controls. To profile the VLCFAs, lipids were extracted from 
yeast cells and directly infused into an ESI-LTQ-Orbitrap mass spectrometer while scanning at high 
resolution in negative ion mode. Several inositolphosphoceramides (IPC), a class of VLCFA-containing 
sphingolipid, were identified using previously published m/z values at 10 ppm mass accuracy (Ejsing et al. 
2009; Sud et al. 2007). We validated the identification of the IPC species using either previously observed 
fragmentation spectrum or expected m/z values for the IPC’s  [ceramide phosphate – H2O]
-
 and [ceramide 
phosphate]
-
 fragment ions (Fig. 6) (Ejsing et al. 2006). The IPC 44:0;4 and IPC 46:0;4 sphingolipids 
contain full-length VLCFAs and are the most abundant yeast sphingolipid species (Dickson et al. 2006). 
Compared to WT, the gcn3Δ, ybr159wΔ, and other VLCFA and ceramide synthase mutant strains all 
showed a reduction in the IPC 44:0;4 and IPC 46:0;4 sphingolipids containing full-length VLCFAs (Fig. 
7A). The IPC sphingolipid species IPC 38:0;4, IPC 40:0;4, and IPC 42:0;4 contain shorter-chain fatty acids 
and are typically only detected in VLCFA biosynthesis mutant strains (Dickson et al. 2006). As previously 
observed, the sur4Δ strain had elevated shorter-chain fatty acid-containing IPC species 38:0;4, 40:0;4, and 
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42:0;4 (36). We observed IPC 38:0;4 and IPC 42:0;4 were also elevated in the ybr159wΔ strain. The gcn3Δ 
strain showed no significant changes in the shorter-chain fatty acid sphinglipid’s IPC 38:0;4, 40:0;4, and 
42:0;4 levels (Fig. 7B). The lip1Δ strain contained barely perceptible levels of any IPC, supporting its 
requirement for ceramide synthesis (Vallee and Riezman 2005).  
We next looked at cellular localization of eIF2B and YBR159W using strains with subunits of 
eIF2B endogenously tagged with GFP and the YBR159W-RFP expression plasmid YCp-YBR159W-
dsRed. To show the RFP-tagged YBR159W allele was functional, the plasmid YCp-YBR159W-dsRed 
complemented the ybr159wΔ null strain AL401 (data not shown). Confocal microscopy of the dual-
fluorescently-labeled strains was used to look for co-localization between eIF2B and YBR159W (Fig. 8). 
As observed in previous studies and Fig. 2, YBR159W localized to membranes corresponding to the 
endoplasmic reticulum (Fig. 8). Using strains with different eIF2B subunits tagged with GFP, we observed 
eIF2B localized as 1-2 large foci (Fig. 8). In addition, GFP-tagged eIF2B is seen dispersed throughout the 
cytoplasm (data not shown). Surprisingly, the confocal microscopy images did not convincingly show the 
majority of YBR159W signal co-localizing with eIF2B subunits. Because we observed that the 2B body 
localizing near the ER membrane-bound YBR159W, we performed a statistical analysis to test if eIF2B 
and YBR159W co-localize. We examined 221 individual 2B bodies from 140 dual labeled cells by pooling 
results from the YCp-YBR159W-dsRed transformed GCD1-GFP, GCD6-GFP, and GCD7-GFP strains 
(AL405, AL406, and AL407). We found 60.1% ±6.6% of 2B bodies examined showed partial co-
localization with a bright area of YBR159W signal. Based on the area of the cell taken up by bright areas of 
YBR159W signal, it would be expected that only 30.7% ±6.9% of 2B bodies would co-localize with 
YBR159W signal if the two signals were independent of each other. A Student’s t-test (P=2.9x10-8) shows 
this difference to be significant. 
To observe the effects of the ybr159wΔ deletion on eIF2B localization, we performed live cell 
imaging using epifluorescence microscopy on the yeast strains ybr159wΔ, GCD7-GFP  (AL403), GCD7-
GFP (AL429), and ybr159wΔ, GCD7-GFP, [YCp-YBR159W] (AL404) . Cells from the GCD7-GFP 
control strain were found to contain 1 to 2 large 2B bodies (Fig. 9A). In the ybr159wΔ strain AL403, eIF2B 
appeared as multiple foci (Fig. 9A). The ybr159wΔ phenotype of AL403 was rescued by expression of 
plasmid YCp-YBR159W in strain AL404 (Fig. 9A). Using these strains, we counted the number of cells 
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containing 1 to 2 large 2B bodies compared to the number of cells having the multiple eIF2B foci or diffuse 
cytoplasmic localization. We found that the majority of ybr159wΔ cells had multiple eIF2B foci phenotype 
(Table 4A). For the GCD7-GFP WT control strain, no cells had the multiple eIF2B foci phenotype and a 
majority of cells had either 1 or 2 2B bodies. The rescued ybr159wΔ, GCD7-GFP, [YCp-YBR159W] strain 
AL404 did not have multiple eIF2B foci (Table 4A). To show the 2B body phenotype was independent of 
the GFP-tagged alleles, we performed immunofluorescence microscopy on untagged yeast strains using 
polyclonal antibody against the eIF2B subunit GCD6 (Fig. 9B). We observed the 1 to 2 large 2B body foci 
phenotype for the majority of the WT control AL400 cells while the majority of the ybr159wΔ cells 
(AL401) displayed multiple eIF2B foci (Table 4B). The ybr159wΔ, [YCp-YBR159W] rescue strain AL402 
showed  a majority of cells had eIF2B present as either a single 2B foci or no detectable foci (Table 4B). 
The VLCFA and ceramide synthase mutants AL413 (fen1Δ), AL414 (sur4Δ), and RH5994 (lip1Δ) were all 
found to have the multiple eIF2B foci phenotype (Table 4B). 
Because eIF2B is thought to be a soluble cytoplasmic protein and YBR159W has been shown to 
be an integral membrane protein in the endoplasmic reticulum (Klein 1957), we performed membrane float 
experiments to determine if a population of eIF2B complexes physically interacted with lipid membranes. 
The lack of signal from the Western blot for the control yeast GAPDH analogs TDH1, 2, and 3 in the 
membrane fraction showed the fractionation was efficient at separating cytoplasmic proteins from 
membrane-associated proteins (Fig. 10A). A significant lipid membrane signal was seen for the ER 
proteins YBR159W and DPM1. A portion of the YBR159W and control ER membrane protein DPM1 
signals was still present in the soluble fraction indicating the membrane-associated proteins do not appear 
to completely separate from the soluble fraction. The membrane float experiments showed that in WT 
AL400 cells, a significant fraction of the eIF2B subunit GCD6 localized to the lipid membrane fractions 
(Fig. 10A). The Western blot profiles of the membrane and soluble fractions for GCD6 showed the same 
pattern as the known ER membrane proteins YBR159W and DPM1 (Fig. 10A). Interestingly, the SUI2 
component of eIF2 also showed a similar membrane association pattern. The data indicates a fraction of 
eIF2 complexes are associated with membranes in yeast cells. 
To validate our observation that eIF2B is membrane-associated, we used whole cell extracts 
prepared from TAP-tagged eIF2B and control strains and the membrane float separation experiment to 
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collect fractions from the membrane-associated and soluble protein region of the density gradients. Next, 
we performed a modified TAP purification on each fraction and analyzed the affinity purified complexes 
using LC-MS/MS. Our data showed that the interaction between eIF2B and YBR159W was still present in 
both the membrane-associated and soluble protein fractions (Fig. 10B). Because of the incomplete 
separation of membrane proteins in the assay, it is not known if both soluble and membrane-associated 
eIF2B interact with YBR159W or if only membrane-associated eIF2B interacts with YBR159W. To see if 
YBR159W was required for eIF2B’s membrane association, we performed the membrane floatation assay 
and Western blots using the ybr159wΔ strain AL401. We found that eIF2B associated with the membrane 
fraction in the ybr159wΔ strain at similar levels as seen in the control strain (Fig. 10C). Overall, the 
membrane float experiments showed a fraction of yeast eIF2B is associated with membranes but the 
interaction is independent of YBR159W. 
To determine if the membrane association seen for eIF2B is possibly mediated by rough ER-
bound ribosomes, we performed a sub-cellular fractionation experiment to isolate smooth membranes. Cell 
lysates from WT strain AL400 were treated with either elevated levels of EDTA or the ribosome releasing 
antibiotic puromycin (Adelman et al. 1973). Following fractionation and Western blotting, ribosomal 
protein signal in the insoluble membrane fraction was significantly reduced in both the EDTA and 
puromycin treated cell extracts compared to untreated control extracts. However, the eIF2B signal in the 
rough or smooth membrane fraction did not noticeably change (Fig. 10D). The data indicates that the 
eIF2B-membrane association is independent of ribosomes. 
 
DISCUSSION 
Previous large-scale yeast interactions studies failed to show eIF2B interacting with the VLCFA 
pathway (Gavin et al. 2002; Krogan et al. 2006; Miller et al. 2005). We show using TAP-tagged and GFP-
tagged affinity purifications as well as yeast-2-hybrid that the VLCFA keto-reductase YBR159W interacts 
with the translation initiation factor complex eIF2B. Because our unpublished proteomic screen of 
translation factor interactions identified YBR159W interacting with eIF2B, we named the S. cerevisiae 
locus Initiation Factor Associated protein of 38 kD or IPA38 (Link et al., unpublished). Affinity 
purification and LC-MS/MS experiments show that YBR159W co-purifies with all five subunits of eIF2B 
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and not in controls. No other member of the VLCFA pathway co-purifies in the eIF2B affinity 
purifications. Interestingly, the TAP-tagged members of the VLCFA pathway do not seem to strongly 
interact with each other. Our Y2H data suggest the eIF2B subunits GCD6 and GCD7 physically interact 
with YBR159W.  
The interaction between the VLCFA synthesis pathway and the eIF2B translation initiation 
pathway presents a number of possibilities. Is one pathway regulating the other or vice versa?  It can be 
hypothesized that the cell might need to regulate VLCFA synthesis if translation is disrupted. Alternatively, 
it might be advantageous to reduce translational activity if VLCFAs are being down regulated. Finally, the 
YBR159W-eIF2B complex could be involved in a novel function. A link between a translation initiation 
factor and lipid membranes is not totally unique. Experiments in human cells have shown an interaction 
between the translation initiation factor eIF4E and the Golgi apparatus (Willett et al. 2011). 
To test the hypothesis that YBR159W and VLCFA synthesis play a role in translation, we used 
35
S-methionine incorporation and polysome profiling to assay translation activity in mutant strains. Both 
experiments show a reduction in the translation rate for the ybr159wΔ strain. However, a similar phenotype 
is seen for the slow growing lip1Δ strain. The VLFCA mutant fen1Δ and sur4Δ strains have wild type 
growth rates and do not share a translation defect with the slower growing members of the pathway. It is 
not known if the cause of the translation defect seen in the ybr159wΔ strain is directly related to its 
interaction with eIF2B or is an indirect consequence of slow growth or a VLCFA defect.  
When GCN4 expression is examined using the GCN4-LacZ assay, the ybr159wΔ strain has WT 
levels of GCN4 induction. The GCN4-LacZ assay was normalized to protein concentration so the slow 
growth rate of ybr159wΔ should not affect the results. The data indicates that the ybr159wΔ strain does not 
have a defect in the GCN4 pathway. We cannot rule out the possibility that the slow growth of ybr159wΔ 
may be masking a subtle defect in eIF2B’s GEF activity unrelated to the GCN4 pathway. Our affinity 
purification experiments of eIF2B in a ybr159wΔ deletion background showed that the eIF2B complex is 
intact. A Western blot of ybr159wΔ strains showed that the overall abundance of eIF2B was lower in the 
deletion background compared to WT. It is not clear if the lower level of eIF2B is caused by the slow 
growth phenotype of the ybr159wΔ null background or some other factor. 
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To test the hypothesis that eIF2B plays a role in VLCFA synthesis, several limitations arose that 
made answering the question problematic. Of the 5 yeast eIF2B subunits, only GCN3 is nonessential. The 
gcn3Δ strain did not show a defect in VLCFA production or utilization. While the gcn3Δ strain showed a 
reduction in the sphingolipid species IPC 44:0;4 and IPC 46:0;4, it did not show a concomitant rise in 
shorter-chain fatty acid-containing IPC species indicative of a defect in VLCFA production. The presence 
of shorter-chain sphingolipids would indicate the cell is trying to compensate for a lack of VLCFAs. 
Therefore, we postulate the lower levels of IPC 44:0;4 and IPC 46:0;4 seen in the gcn3Δ strain are 
unrelated to a defect in VLCFA production. The VLCFA defect in ybr159wΔ is modest; with only a small 
rise in the shorter-chain fatty acid-containing sphingolipids. The loss of IPC 46:0;4 is the strain’s most 
striking characteristic. Previous work suggests that Ayr1p is able to perform 3-ketoacyl activity in the 
absence of YBR159W (Han et al. 2002). The same study showed ayr1 and ybr159w are synthetically lethal 
(Han et al. 2002).  
A gcn3 null strain is unable to fully derepress GCN4 expression during amino acid starvation 
(Hannig and Hinnebusch 1988). GCN4 is a transcription factor involved in the expression of several 
hundred genes during a wide variety of cellular stresses (Natarajan et al. 2001). Though growth conditions 
for the gcn3Δ strain should not have activated a stress response, we suspected analysis of the lipid content 
of the gcn3Δ strain could prove problematic if the VLCFA pathway was a downstream target of the GCN4 
transcription factor. We examined the effects of loss of GCN4 using expression data for gcn4Δ strains from 
the Gene Expression Omnibus (GEO) Database (Barrett et al. 2011). Two separate datasets showed no 
significant changes in the expression of various VLCFA genes (data not shown, GEO Accession 
GSE24057 (Fendt et al. 2010) and GSE25582). We concluded that under the conditions used for the 
analysis of sphingolipids, loss of GCN4 did not significantly alter VLCFA gene expression. We concluded 
our gcn3Δ strain was not experiencing alterations in VLCFA gene expression due to repression of GCN4. 
The lack of a direct translation defect in the ybr159wΔ strain and the lack of a VLCFA defect in the gcn3Δ 
strain suggest there is no significant cross-talk between the GEF and VLCFA pathways. 
Membrane floatation and subcellular fractionation assays show eIF2B interacts with lipid 
membranes. Our data and previous studies showed YBR159W is an integral membrane protein that co-
localizes with the ER membrane (Abraham et al. 1961; Klein 1957). We interpret these findings to mean 
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that the membranes eIF2B is interacting with are ER membranes. It is unknown if ER-associated eIF2B is 
actively engaged in guanine nucleotide exchange. A number of conclusions can be made about this ER 
membrane-interacting eIF2B. First, the eIF2B-membrane interaction is not mediated by rough ER-bound 
ribosomes. Treatment of cell extracts with EDTA or puromycin greatly reduces the amount of ribosomes 
that fractionate with lipid membranes but does not reduce the portion of eIF2B that fractionates with 
membranes. This fits the prevailing theory that eIF2B’s role in translation is independent of the ribosome 
(Merrick W. C.). Second, YBR159W is not required for the interaction. The ybr159wΔ null strain does not 
affect eIF2B’s interaction with the membrane showing that the interaction of eIF2B with ER membranes is 
YBR159W independent. This indicates that other factor(s) are possibly required. 
Confocal microscopy shows that the majority of 2B bodies are in close proximity to YBR159Wp 
and ER membranes, supporting the model that 2B bodies and the ER interact. This could be taken to 
indicate that the eIF2B shown to interact with ER membranes resides in 2B bodies. A possible conflicting 
interpretation of the data is that YBR159W-RFP is being overexpressed and its localization is an artifact. 
The co-localization experiment used a RFP-tagged YBR159W allele expressed from a GPD promoter on a 
centromeric plasmid. Global protein expression analysis shows that the GPD promoter’s target protein, 
TDH3, is expressed at roughly 4 times that of YBR159W (Ghaemmaghami et al. 2003). The fact that the 
RFP-tagged YBR159W localization agrees with endogenously expressed YBR159W-GFP localization 
leads us to believe that artifacts caused by the RFP tagged construct are not disrupting YBR159W’s 
localization. In addition, the RFP-tagged allele complements a ybr159wΔ null strain. How and why eIF2B 
might be interacting with the ER membrane is unknown. A population of membrane-interacting 2B bodies 
might possibly explain recent findings that 2B bodies can exist in a mobile or static state with mobile 2B 
bodies free in the cytoplasm and static 2B bodies being associated with membranes (Taylor et al. 2010). 
Further work is needed to prove this hypothesis.  
 The observation that the ybr159wΔ null strain leads to multiple eIF2B foci is intriguing. This 
phenotype is also seen in other VLCFA mutants. The fact that these mutants all display disrupted lipid 
membranes lends itself to the theory that properly formed membranes are required for the integrity of 2B 
bodies. An intriguing question is whether the membrane disruption prevents the 2B bodies from forming 
properly or whether the 2B bodies are unable to be maintained once formed?  For the first model, an as yet 
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unknown factor in membranes required for 2B body formation could be disrupted and cause 2B bodies to 
form throughout the cell. We speculate that this membrane-associated factor could serve as a nucleating 
site for the formation of 2B bodies. The second model would predict that membrane disruption is affecting 
a factor needed for 2B body stability. Loss of this factor leads to 2B bodies dissociating into multiple 
smaller foci. A previous study showed VLCFAs were important for lipid raft formation (Gaigg et al. 2006). 
It is possible that lipid raft disruption in the VLCFA mutants causes the multiple eIF2B foci phenotype. 
Translation assays using the ybr159wΔ strain suggested the disruption of 2B bodies into multiple foci does 
not affect translation. The translation activity of yeast cells does not appear to be affected by the change 
from a single 2B body to multiple eIF2B foci. 
 Our work sheds light on the recently discovered 2B body. The data show a relationship between 
eIF2B localization and an ER membrane bound protein. We discovered the membrane co-localization of 
eIF2B while examining its interaction with YBR159W. Our data show that YBR159W is not necessary for 
the co-localization of eIF2B with the membrane. The primary mediator of the membrane association of 
eIF2B is unknown. It remains to be determined if the translation defect seen in the ybr159wΔ strain is the 
cause of the slow growth of the strain or vice versa. Further experiments are required to determine the 
functional role of YBR159W interacting with eIF2B.  
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Table 1. Strains used in this study 
Strain Source Genotype 
AL400 This study MATa, ura3, leu2, HIS+ 
AL401 This study MATa, ura3, leu2, HIS+, YBR159W::KanR 
AL402 This study MATa, ura3, leu2, HIS+, YBR159W::KanR, [YCp-YBR159W] 
AL403 This study MATa, ura3, leu2, HIS+, YBR159W::KanR, GCD7-GFP 
AL404 This study MATa, ura3, leu2, HIS+, YBR159W::KanR, GCD7-GFP, [YCp-YBR159W] 
AL405 This study MATa, leu2, ura3, met15, GCD1-GFP, [YCp-YBR159W-dsRed] 
AL406 This study MATa, leu2, ura3, met15, GCD6-GFP, [YCp-YBR159W-dsRed] 
AL407 This study MATa, leu2, ura3, met15, GCD7-GFP, [YCp-YBR159W-dsRed] 
AL408 This study 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [YBR159W-GAL4DBD] 
AL409 This study 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD1-GAL4DBD] 
AL410 This study 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD2-GAL4DBD] 
AL411 This study 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD6-GAL4DBD] 
AL412 This study 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ, [GCD7-GAL4DBD] 
AL413 This study MATa, leu2, ura3, met15, HIS+, FEN1::KanR 
AL414 This study MATa, leu2, ura3, met15, HIS+, SUR4::KanR 
AL415 This study MATa, ura3, leu2, HIS+ [p180] 
AL416 This study MATa, ura3, leu2, HIS+, YBR159W::KanR, [p180] 
AL417 This study MATa, ura3, leu2, HIS+, YBR159W::KanR, [YCp-YBR159W], [p180] 
AL418 This study MATa, leu2, ura3, met15, FEN1::KanR, [p180] 
AL419 This study MATa, leu2, ura3, met15, SUR4::KanR, [p180] 
AL420 This study MATalpha, ura3-52, gcd1-101, [p180] 
AL421 This study MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+, gcn2Δ, [p180] 
AL422 This study MATa, leu2, ura3, met15, FEN1-GFP, [YCp-YBR159W-dsRed] 
AL423 This study MATa, leu2, ura3, met15, DPM1-GFP, [YCp-YBR159W-dsRed] 
AL424 Deletion library MATa, leu2, ura3, met15, his3, GCN3::KanR 
AL425 GFP library MATa, leu2, ura3, met15, YBR159W-GFP 
AL426 GFP library MATa, leu2, ura3, met15, FEN1-GFP 
AL427 GFP library MATa, leu2, ura3, met15, GCD1-GFP 
AL428 GFP library MATa, leu2, ura3, met15, GCD6-GFP 
AL429 GFP library MATa, leu2, ura3, met15, GCD7-GFP 
AL430 TAP library MATa, leu2, ura3, met15, GCD2-TAP 
AL431 TAP library MATa, leu2, ura3, met15, GCD7-TAP 
AL432 TAP library MATa, leu2, ura3, met15, YBR159W-TAP 
AL433 TAP library MATa, leu2, ura3, met15, FEN1-TAP 
AL434 TAP library MATa, leu2, ura3, met15, SUR4-TAP 
AL435 TAP library MATa, leu2, ura3, met15, TSC13-TAP 
AL436 Deletion library MATa, leu2, ura3, met15, his3, FEN1::KanR 
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AL436 GFP library MATa, leu2, ura3, met15, DPM1-GFP 
AL437 Deletion library MATa, leu2, ura3, met15, his3, SUR4::KanR 
F98 A. Hinnebusch MATalpha, ura3-52, gcd1-101 
H1511 A. Hinnebusch MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+ 
H2557 A. Hinnebusch MATalpha, ura3-52, trp1-63, leu2-3, leu2-112, GAL2+, gcn2Δ 
pAD(GCD7) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [GCD7-AD] 
PJ69-4a 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ 
PJ69-4alpha 
Yeast Resource 
Center 
MATalpha, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-
HIS3, GAL2-ADE2, met2::GAL7-lacZ 
pOAD(GCD1) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [GCD1-AD] 
pOAD(GCD2) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [GCD2-AD] 
pOAD(GCD6) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [GCD6-AD] 
pOAD(GCN3) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [GCN3-AD] 
pOAD(SUI2) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [SUI2-AD] 
pOAD(TDH1) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [TDH1-AD] 
pOAD(YBR159W) 
Yeast Resource 
Center 
MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, 
GAL2-ADE2, met2::GAL7-lacZ, [YBR159W-AD] 
RH5994 H. Riezman MATalpha, leu2, ura3, trp1, bar1, LIP1::HIS3 
 
  
133 
 
Table 2. Plasmids used in this study. 
Name backbone Source Notes 
pOBD2 pOBD2 Yeast Resource Center 
ampR, TRP1, CEN4 ORI, GAL4-
DBD 
YCp-YBR159W pAG415GAL-ccdB This study 
ampR, LEU2, CEN ORI, 
YBR159W 5' UTR-YBR159W 
YCp-YBR159W-dsRed pAG415GPD-ccdB-dsRed This study 
ampR, LEU2, CEN ORI, PGPD-
YBR159W-dsRed 
p180 YCp50 A. Hinnebusch 
ampR, URA3, CEN ORI, GCN4 5' 
UTR-LacZ 
pFa6a-kanmx6 pFa6a-kanmx6 Addgene ampR, KanR2 
pENTR pENTR Invitrogen KanR 
pENTR-YBR159W 5' 
UTR-YBR159W pENTR this study 
KanR, YBR159W 5' UTR-
YBR159W 
pENTR-YBR159W pENTR this study KanR, YBR159W 
pAG415GAL-ccdB pAG415GAL-ccdB Addgene ampR, LEU2, CEN ORI ccdB 
pAG415GPD-ccdB-dsRed pAG415GPD-ccdB-dsRed Addgene 
ampR, LEU2, CEN ORI ccdB-
dsRed 
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Table 3. Primers used in this study. 
Genomic 
YBR159W 
Deletion 
primers 
 
Primer Sequence (5’-3’) 
for del primer 
 
CGTACGCTGCAGGTCGAC 
rev del primer 
 
ATCGATGAATTCGAGCTCG 
for 5' extension 
 
CGGATTTGGAAGTCCTTTATAG 
rev 5' extension 
 
GTCGACCTGCAGCGTACGCATTTCTTAAGCTGCACCG 
for 3' extension 
 
CGAGCTCGAATTCATCGATTAGAATTATCGTTCTCG 
rev 3' extension 
 
GGACTTGGTCCTTCCACC 
Yeast 2-Hybrid 
primers 
 
  
for common 
primer 
 
CTATCTATTCGATGATGAAGATACCCCACCAAACCCAAAAAAAGAGATCGAATT 
CCAGCTGACCACCATG 
rev common 
primer 
 
GTACCGTTAAGGGCCCCTAGGCAGCTGGACGTCTCTAGATACTTAGCATCTATGA 
CTTTTTGGGGCGTTC 
for YBR159W 
 
AATTCCAGCTGACCACCATGACTTTTATGCAACAGCTTCAAGAGGCTGG 
rev YBR159W 
 
GATCCCCGGGAATTGCCATGCTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGG 
for GCD1 
 
AATTCCAGCTGACCACCATGTCAATTCAGGCTTTTGTCTTTTGCGGTAAAGG 
rev GCD1 
 
GATCCCCGGGAATTGCCATGTTAACGCTCAAATAATCCGTCATCTTCGTACTCGTAC 
for GCD2 
 
AATTCCAGCTGACCACCATGAGCGAATCGGAAGCCAAATCTAGGTCG 
rev GCD2 
 
GATCCCCGGGAATTGCCATGTTATGCGGAACCTTTGTACTCTCTTAAAATAACAGGGAC 
for GCD6 
 
AATTCCAGCTGACCACCATGGCTGGAAAAAAGGGACAAAAGAAAAGTGGACTAG 
rev GCD6 
 
GATCCCCGGGAATTGCCATGTTATTCCTCTTCTGAGGAAGATTCTTCGTCAGCATTC 
for GCD7 
 
AATTCCAGCTGACCACCATGTCCTCTCAAGCATTCACTTCAGTACATCCG 
rev GCD7 
 
GATCCCCGGGAATTGCCATGTCACGCCTTATTTTTATCCAAATGCACATCAATTTGC 
YBR159W 
ORF + 600 bp 
upstream 
primers 
 
  
for primer 
 
CACCATGGTTTTTGTGACTTTACCTATAAATAGTACACAAC 
rev primer 
 
CTATTCCTTTTTAACCTGTCTTGCGGCTTTTTTTAAGGC 
prom remove 1 
 
GGGAGCTCCATACTGATTAGTACACTAGTGG 
prom remove 2 
 
CCACTAGTGTACTAATCAGTATGGAGCTCCC 
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Figure 1. eIF2B and the VLCFA functional pathways. (A) Diagram showing the GEF 
pathway of eIF2B that is required for recharging eIF2 with GTP to begin a new round of 
translation initiation. (B) Diagram showing the cyclical VLCFA elongase pathway and the 
genes required for the catalytic steps. Also depicted is the pathway utilizing VLCFAs by the 
ceramide synthase complex LAC1/LAG1 and LIP1 to make ceramide. Ceramide is later 
modified to generate various sphingolipids. 
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Figure 2. YBR159W’s interaction with eIF2B is unique among VLCFA genes. (A)  Mass 
spectrometry analysis of the affinity-purified TAP-GCD2, TAP-YBR159W, and other TAP-
tagged VLCFA protein complexes. Listed are unique peptide identifications with the percent 
coverage of identified peptides in the protein in parentheses. A “-“ indicates no peptides were 
detected for the gene. (B)  Yeast 2-hybrid (Y2H) analysis of interactions between YBR159W 
and eIF2B subunits GCD6 and GCD7. Shown is both the assay plate used for scoring the Y2H 
interactions and a table of the interactions tested at each spot. Shading on the table corresponds 
to a positive interaction on the plate. 
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Figure 3. Cellular analysis of YBR159W. (A)  Live cell epifluorescence imaging of 
endogenously tagged YBR159W-GFP indicates YBR159W localizes mainly to the 
ER membrane. (B)  Live cell confocal microscopy showing the co-localization of 
YBR159W with the VLCFA pathway enzyme FEN1 and ER membrane protein 
DPM1. YBR159W is expressed on a low-copy plasmid and tagged with dsRed. FEN1 
and DPM1 are endogenously expressed and tagged with GFP. (C)  Deletion of 
YBR159W results in a very slow growth rate.  
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Figure 4. Null mutations of genes in the VLCFA pathway disrupt lipid 
membranes. The lipophilic dye DiOC6(3) was used to label membranes in live yeast 
cells. Dye was applied to cells in suspension 10 min before plating on a microscope 
slide and imaging. Included are the VLCFA and ceramide synthase mutants fen1Δ, 
sur4Δ, and lip1Δ as controls. 100% of these mutants showed abnormal membranes 
(N=246) versus 1.1% for WT (N=89) and 9.7% for the rescue (N=93). 
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Figure 5. Translation assays on the ybr159wΔ strain. (A)  Translation efficiency as 
measured by 
35
S-methionine incorporation. Values are counts per minute per OD660 unit of 
cells. Results shown are from at least three replicates. (B)  Polysome profiling of 
ybr159wΔ and other VLCFA null strains. At least three replicates were performed for each 
strain. Though the example ybr159wΔ plot does not show a 40S ribosome peak, all other 
replicates of the strain showed a 40S peak similar to WT. (C)  Assay for GCN4 pathway 
competence by GCN4-LacZ induction. Results are LacZ expression per mg of protein per 
min normalized to the WT starvation condition. Starvation conditions were induced by 100 
mM 3-AT in synthetic complete minus histidine media for 4 h. The gcd1-100 strain has a 
constitutively derepressed GCN4 pathway and constant GCN4 protein translation while the 
gcn2Δ strain is incapable of derepression of GCN4 and cannot produce significant amounts 
of GCN4 protein. (D) Ratio of monosome:polysome peak areas for the polysome profiles. 
P values were generated using a Student’s t-test from at least 3 individual replicates. (E) 
GFP pull-down of eIF2B complexes in a ybr159wΔ background. Following pull-down LC-
MS/MS was performed to identify the proteins. An untagged ybr159wΔ strain and GCD7-
GFP tagged strain were used as controls. Displayed are unique peptide hits and percentage 
coverage as described in Figure 2A. (F) Western blot analysis of WT, ybr159wΔ, and GFP-
GCD7 strains. Yeast strains in Fig. 5D and WT strain AL400 were used. Equivalent 
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Figure 6. Validation and Identification of IPCs. (A) Mass spectrometry precursor and 
MS/MS fragmentation spectrum for IPC 44:0;4 from WT yeast. The observed precursor 
ion m/z 952.681 represents the expected ion IPC 44:0;4 (952.686). The observed m/z 
835.529 corresponds to the phosphotidyl inositols PI 16:0-18:1 and PI 16:1-18:0 used to 
normalize the relative abundance of each IPC species. In the lower MS/MS spectra of the 
952.681 precursor ion, the first and second most abundant peaks correspond to the 
expected IPC 44:0;4 fragment ions [Ceramide Phosphate – H2O]
-
, m/z 772.62 and 
[Ceramide Phosphate]
-
, m/z 790.63. (B) Theoretical fragmentation database for IPCs 
38:0;4, 40:0;4, 42:0;4, and 46:0;4. Shown are the theoretical m/z values for fragment ions 
[ceramide phosphate – H2O]
-
 and [ceramide phosphate]
-
 for IPCs 38:0;4, 40:0;4, 42:0;4, 
and 46:0;4. (C) MS/MS fragmentation spectra for IPCs 38:0;4, 40:0;4, 42:0;4, and 46:0;4. 
The observed precursor m/z values “Pre” of 868.586, 896.617, 924.648, and 980.712 
correspond to the expected m/z values of IPC 38:0;4 (868.592), IPC 40:0;4 (896.623), IPC 
42:0;4 (924.655), and IPC 46:0;4 (980.717) respectively. In the MS/MS spectra, the peaks 
corresponding to the expected theoretical IPC fragment ions [Ceramide Phosphate – 
H2O]
-
 and [Ceramide Phosphate]
-
 are mark with a “*”. In each case, the peak 
corresponding to the expected [Ceramide Phosphate – H2O]
-
 fragment ion was the most 
intense ion in the MS/MS spectrum. 
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Figure 7. Fatty Acid profiling of WT and mutant yeast strains. (A)  Longer-chain fatty 
acid-containing sphingolipid species. IPC species with 44 and 46 carbon-long acyl chains 
are shown. The VLCFA and ceramide synthase mutants sur4Δ and lip1Δ are included as 
controls. (B) Shorter-chain fatty acid-containing sphingolipid species. Three IPC species 
with 38, 40, and 42 carbon-containing acyl chains are shown. For both A and B, data 
represents percentage of signal of each lipid species normalized to the signal of the PI 16:0-
18:1 and PI 16:1-18:0 ion. 
142 
 
  
Figure 8. eIF2B and YBR159W localization in live cells. Confocal microscopy of 
live yeast cells showing localization of eIF2B subunits in relation to the localization 
of YBR159W. eIF2B subunits are endogenously tagged with GFP while YBR159W-
RFP is expressed on a centromeric plasmid. 
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Figure 9. eIF2B localization in the ybr159wΔ background. 
(A)  Live cell fluorescence microscopy of endogenously tagged 
eIF2B subunit GCD7-GFP. Brightfield (BF) images are included 
for clarity. (B) Immunofluorescence microscopy of 
formaldehyde fixed yeast cells. A polyclonal antibody against 
yeast eIF2B subunit GCD6 was used along with an Alexa Fluor 
488 tagged secondary. Nuclei are stained with DAPI for clarity. 
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Figure 7. Fatty Acid profiling of WT and mutant yeast strains. (A)  Longer-chain fatty acid-containing 
sphingolipid species. IPC species with 44 and 46 carbon-long acyl chains are shown. The VLCFA and ceramide 
synthase mutants sur4Δ and lip1Δ are included as controls. (B) Shorter-chain fatty acid-containing 
sphingolipid species. Three IPC species with 38, 40, and 42 carbon-containing acyl chains are shown. For 
both A and B, data represents percentage of signal of each lipid species normalized to the signal of the PI 
16:0-18:1 and PI 16:1-18:0 ion. 
Table 4. Statistics for eIF2B localization phenotypes. (A) 
Statistics of eIF2B localization phenotypes in live yeast cells. 
The strains are described in Fig 8A. (B) Statistics of eIF2B 
localization phenotypes via immunofluorescence of fixed 
yeast cells. The strains are described in Fig 8B. 
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Figure 10. eIF2B and YBR159W localization using membrane floatation assays. (A)  
Western blot of membrane floatation assay fractions using protein extracts from WT yeast 
showing the localization of the eIF2B subunit GCD6 and YBR159W. Controls include the 
eIF2 subunit SUI2, ER integral membrane protein DPM1, and the cytosolic protein 
GAPDH. TDH1-3 are the three GAPDH genes in yeast. The lanes represent 20% of 
fractions from the membrane floatation gradients. Labels show the location of the 
membrane-associated and soluble protein fractions. (B)  Mass spectrometry analysis of 
affinity purified TAP complexes from the membrane and soluble fractions of membrane 
floatation experiments. Unique peptides, percent coverage and “-” are described in Fig 
2A. (C)  Western blot of membrane floatation assay fractions comparing WT and 
ybr159wΔ strains. Conditions are the same as in “A”. (D) Western blot of crude 
fractionation following EDTA or puromycin treatment. Abbreviations are WCE = whole 
cell extract, Con = non-treated control, EDTA = EDTA treatment, Puro = puromycin 
treatment, S = supernatant, P = pellet. ASC1 is a component of the small ribosomal 
subunit and RPL32 is a large ribosomal subunit protein. Lanes represent 15 µL of WCE 
following fractionation, pellets were resuspended in starting volume. 
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